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ABSTRACT 
 
Guidelines for the management of asthma in the UK have been published (BMJ, 
1990, Thorax, 1993 and 1997) and embraced by many GP practices with 
improved outcome for patients. The study aims to observe and follow a cohort of 
adult asthma subjects from differing primary health care settings over a two-year 
period.  Also to assess a newly devised patient focused morbidity index (Q score) 
by comparison to an established asthma specific quality of life questionnaire 
(AQLQ, Juniper et al, 1993). 
 
One hundred and fourteen subjects from four GP Practices, two inner city and 
two suburban were studied. Morbidity was assessed by AQLQ and Q score 
(Rimington et al, 2001), psychological status by the hospital anxiety and 
depression (HAD) scale (Zigmond and Snaith, 1983).  Spirometry values (forced 
expiratory volume in one second, FEV1), peak expiratory flow (PEF) and details 
of current treatment as per BTS guidelines treatment step were recorded as 
markers of asthma severity. Subjects were assessed at baseline, twelve and 
twenty-four months. A random sub set of patients was asked to repeat certain 
elements of the study protocol at two weeks in order to assess the reliability of 
the Q score. 
 
The Q score correlated from baseline to two weeks (rs=0.61) as did AQLQ 
symptom score (rs=0.74) both p<0.01. At baseline AQLQ symptoms correlated 
with PEF (rs=0.40, p<0.001) and with BTS guidelines treatment step (rs=0.25, 
p=0.001) as did the Q score. Similar levels of correlation were reported for FEV1 
with symptoms. HAD scores also correlated to AQLQ and Q score, but there was 
little correlation with lung function. At one and two year follow up no significant 
differences were observed in subjective or objective markers of asthma. There 
was a significant increase (p<0.001) in the number of subjects in the higher BTS 
guidelines treatment steps from baseline to twelve and twenty-four months while 
psychological symptoms remained high for inner city patients. 
In conclusion the Q score yields similar results to the AQLQ and is quick and 
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easy to use in any busy clinic. The GP practice, at the forefront of asthma care 
should be offering appropriate therapy and regular review. The Q score used as a 
patient focused morbidity index can be a useful audit tool.  Altering medication 
can give the impression of treating asthma but with out short-term reassessment 
the same levels of morbidity can persist. 
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CHAPTER 1 
 
 
 
 
 
INTRODUCTION 
 
 2
1.1 Study Background 
 
1.1.1 Outcome Measures 
 
Health outcomes may be thought of as changes that can occur in  
a subjects’ health or health related status or risk factors that can 
affect their health (Pearson & Bucknall, 1999).  In asthma 
changes that occur can be related to the amount or type of therapy 
prescribed or taken, or the natural progress of the disease.  
 
Outcome measures used to determine the success (or failure) in 
the treatment of asthma vary widely. For the individual patient an 
improved outcome may well be a reduction in symptoms enabling 
them to carry out unhindered activities associated with daily 
living. An individual may seek a reduction in medication along 
with stabilisation of symptoms as an improved outcome. In order 
to achieve either an asthmatic patient would require individual 
assessment and review in order to monitor for a successful 
outcome. This is time consuming for the health professional but 
essential if a successful outcome is to be achieved for the 
individual patient. 
 
Health professionals do not always monitor the change of the 
individual patient often preferring to look at outcome measures 
for a cohort of subjects with the same disease. Positive outcome 
indicators for asthma have previously been recorded as a 
reduction in the days lost from work or school, or a decrease in 
the number of a patients admitted to hospital for acute 
exacerbation of their asthma (Lahdensuo et al, 1998). While these 
may indicate to the practitioner an overall improvement in care 
for the asthmatic cohort the needs of the individual patient may 
not be realised. 
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Current medical management for chronic respiratory disease 
involves the use of inhaled medication to reduce symptoms (BMJ, 
1990). Previous studies have investigated the long-term use of 
inhaled medication (bronchodilators and steroids) in Chronic 
Obstructive Pulmonary Disease (COPD) (Rimington, 1994). This 
study used a hospital-based cohort of COPD patients.  Part of the 
study looked at the use of inhaled medication in the long-term 
management of COPD. Subjects with the best outcome (as 
measured by lung function and survival rate) were those who had 
a positive response to oral corticosteroids trial and regularly used 
inhaled steroids as part of their management (Rimington et al, 
1993a and b). What the Rimington (1994) study did not 
investigate was how to monitor patient’s response to alterations in 
therapy. 
 
The majority of patients with chronic respiratory disease are 
managed in primary care (the GP practice) (Neville et al, 1999). It 
is therefore appropriate for the cohort presented in this thesis to 
be recruited from primary as opposed to secondary care. Previous 
research reports have tended to use objective markers of care as 
outcome measures, eg, improved lung function, fewer days absent 
from school or work or a decrease in the number of acute 
admissions to hospital. In the past studies have not used 
subjective markers as outcome measure. Such markers are 
important to patients eg, any reduction in dyspnoea for the 
breathless patient can be seen as a positive outcome. The study 
presented in this thesis intends to use subjective markers of 
asthma eg, quality of life (QoL), morbidity and psychological 
status and objective markers of asthma eg, spirometry, lung 
function and severity of disease as outcome measures over a two-
year period. This will be the first two-year follow up study 
observing asthma management in primary care. 
1.1.2 Basis of the Study 
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Asthma is one of the common chronic respiratory conditions with 
up to 4% of adults and 6% of children reporting symptoms at 
present (Department of Health, (DOH) 1995). Currently asthma 
affects more than three million people in the UK with this number 
growing daily. The estimated cost to the National Health Service 
(NHS) for treatment of asthma was some £511 million in 1995/6 
(Office of Health Economics, 1997). The number of prescriptions 
issued for asthma medication has risen by 75% in the past decade. 
While some 76% of the asthma population reported days lost from 
work or school due to their respiratory disease (National Asthma 
Campaign, 1995). 
 
The provision of a high quality, cost-effective asthma service for 
the general public would seem to be of prime importance in order 
to reduce the financial burden on the NHS and to improve QoL 
for asthma patients. The key to success lies with the patient and 
GP at the primary care interface. Quick and accurate assessment 
of patients’ asthma status could lead to a responsive tool for 
management and improved outcome. The aim of this study was to 
observe the management of a cohort of adult asthma subjects in 
primary care and to evaluate a new patient focused morbidity 
index (Q score). A further aim of this study was to establish if the 
Q score reflects current individual status of subjects within the GP 
Practice as a whole. 
 
1.2 Asthma – Definition, Diagnosis and Problems 
 
1.2.1 Current Definition 
 
Dr Henry Slater, a physician at Charring Cross Hospital, London 
in his 1868 treatise described asthma as “paroxysmal dyspnoea of 
a peculiar character generally periodic with healthy respiration 
between attacks (Slater, 1868). This observation of airway 
obstruction and reversibility stemmed from his own personal 
 
 5
experience as an asthma sufferer and the observation of the few 
cases within London available for scrutiny at that time. Some one 
hundred years later a CIBA Foundation Guest Symposium was 
convened in an attempt to define asthma, the symposium ended 
without a definition being agreed upon. (CIBA, 1959).  Still 
controversy remains, though in recent years within the UK the 
British Thoracic Society (BTS) has gone to some lengths to give 
health professionals a working definition for asthma though it is 
by no means universally accepted. The BTS contained within its 
'Guidelines for the Management of Asthma' their definition of the 
disease, (Thorax, 1993) 
  
"A common and chronic inflammatory condition of the 
airways whose cause is not completely understood. As a 
result of inflammation the airways are hyper responsive and 
they narrow easily in response to a wide range of stimuli. 
This may result in coughing, wheezing, chest tightness and 
shortage of breath and these symptoms are often worse at 
night. Narrowing of the airway is usually reversible, but in 
some patients with chronic asthma the inflammation may 
lead to irreversible airflow obstruction". 
 
Asthma remains a prominent source of morbidity and cause of 
mortality within the UK.  It is the commonest respiratory disease 
that affects young and old alike in England (National Asthma 
Campaign, 1995).  Steven and Montgomery (1999) estimated 
there were approximately 3.4 million people with asthma in the 
UK (an estimated 6% of the population) with up to 2,000 deaths 
per year attributed to asthma (Keating et al, 1984, Burney, 1986, 
Partridge, 1986, Cochrane, 1993).  Asthma remains the only cause 
of preventable death with a mortality rate that actually rose at one 
point in time (ratio higher in 1987 than in 1979) despite an 
increase in the medication available to adequately improve 
respiratory function (Harrison and Partridge, 1991). 
1.2.2 The Diagnosis of Asthma 
 
In its loosest terms the diagnosis of asthma can be based upon the 
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patient recounting sporadic periods of wheeze associated with 
breathlessness (Clark et al, 1992). Causes for symptoms produced 
are many and various, what would seem to be important for the 
patient is the correct diagnosis and management of their 
symptoms. The diagnosis for asthma is usually based upon the 
patient’s symptoms and a record of their Peak Expiratory Flow 
(PEF). PEF is the greatest flow that can be sustained for 10 
milliseconds on forced expiration when starting from full 
inspiration (Cotes, 1993). Symptoms, which would indicate 
asthma would include intermittent wheezing associated with 
breathlessness, a cough often occurring at night or first thing in 
the morning, a wheeze related to exercise or respiratory 
symptoms, disturbed sleep especially in the early hours of the 
morning.  For a more accurate diagnosis PEF readings should be 
taken over a two-week period, four times per day (first thing in 
the morning, at lunch, tea and bedtime).  If the values recorded 
are below 70% of the predicted value (for the same age, height 
and gender) vary by 25% and the lowest scores are first thing in 
the morning - a diagnosis of asthma can be confirmed. Many 
subjects taking part in this study will have had their asthma 
confirmed by the former tool for diagnosis. 
 
For many patients either of the above criteria can be successfully 
used to obtain a positive diagnosis of asthma.  Using a 
combination of the above a diagnosis of asthma can be given to a 
patient with assurance.  Failure to diagnose asthma correctly and 
quickly can lead to inappropriate and ineffective treatment 
(Pearson, 1986). 
 
 
1.2.3 Problems with Asthma Management 
 
A patient diagnosed with asthma today would have received a 
very different treatment and management programme some thirty 
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years ago. Since the 1960's there have been many advances in the 
development of anti-asthma medication, accompanying this 
progress has been a change in the management of asthma by 
health care professionals. Indeed the asthma sufferer of thirty 
years ago would greatly appreciate these advances (Christie, 
1994). 
 
The inflammatory process occurring in asthma used to be dealt 
with by the use of oral or injected corticosteroids available from 
the mid 1950s. Side effects associated with the use of oral steroids 
are well documented (increased appetite, Cushing's syndrome, 
osteoporosis, peptic ulceration, etc) patients and doctors alike 
were concerned about such side effects. Inhaled steroids 
revolutionised the management of asthma in the 1970s. The new 
inhaled route allowed smaller doses of corticosteroids to be used 
and delivered to the sites of the inflammatory activity thus 
reducing systemic side effects.  Subsequently inhalation therapy 
became available for much of the medication used in asthma 
treatment both bronchodilators and agents other than 
corticosteroids which reduced inflammation. The means of 
delivery for all medication altered dramatically in the 1970s. The 
archaic atomiser sprays used to deliver isoprenaline were replaced 
by new metered dose inhalers and nebulisers (Christie, 1994). 
 
Hartley et al reported in the journal Nature for 1968 on a "new 
class of selective stimulants of adrenergic receptors". This 
medication relaxed the smooth muscle of the bronchial tree 
without greatly disturbing the function of the heart.  Salbutamol 
was released in 1969 followed quickly by terbutaline, these were 
the new adrenergic drugs.  Since their development in the late 
1960's other agonists have been developed to give longer acting 
relief of symptoms (Christie, 1994). 
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In essence the drug therapy for the management of asthma over 
the past thirty years has consisted of five groups of medication - 
the cromones, antihistamines, agonists, theophyllines, and more 
recently corticosteroids. Treatment has also been improved over 
the years by the dissemination and implementation of guidelines 
for the management of the disease. Guidelines have emphasised 
the increasingly important role of inhaled corticosteroids. The 
most recently published guidelines were in 1997 (Thorax, 1997). 
Their advice is probably already outdated with the emerging role 
of new therapy (leukotriene agonists). The 1997 guidelines 
comment on the antileukotrienes thus “more studies are needed to 
provide comparative data before any recommendations can be 
made”. 
 
The publication of national guidelines has lead asthma 
management to concentrate on the importance of preventative 
medication (Lipworth, 1999). Inhaled corticosteroids are a 
powerful anti-inflammatory agent when used in the treatment of 
asthma. Corticosteroids delivered directly to the airways in 
relatively small doses (<800 g/day) can successfully alleviate 
asthma symptoms (Barnes et al, 1998). Cromones also may also 
be used as preventative medication but are not as effective as 
corticosteroids. Their use is mainly beneficial to the atopic patient 
or to the exercise-induced asthmatic. Antihistamines also have a 
limited role to play being most useful in the management of 
patients with known allergic trigger factors e.g. fur or pollen. 
Symptom relief can be alleviated by the use of bronchodilators 
most commonly agonists but oral theophyllines may still be of use 
with some patients although their capacity for reversibility is 
somewhat weak. The anti-inflammatory potential of low dose 
theophyllines has of late been re-evaluated as a back up to 
corticsteroids. The slow release preparations can give long acting 
relief of symptoms for some patients and they remain a useful 
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adjunct to the management portfolio. However, the main 
bronchodilator remains the short acting agonist.  This drug is a 
most effective relaxant of airway smooth muscle. More recently 
long acting versions have become available. Use of a long acting 
agonist can allow the asthma patient to use a lower dose of 
inhaled cortico steroid producing comparable control to therapy 
when compared to use of a higher dose of inhaled corticsteroids 
alone (Pauwels et al, 1997). 
 
What may eventually alter guidelines is the effect the newly 
developed leukotriene agents can have on airway smooth muscle. 
These agents are effective over a wide spectrum of disease 
severity and display bronchodilator and anti-inflammatory 
activity.  Unlike other therapy leukotriene agonists can be taken 
orally which for the non-compliant inhaler patient can be an 
advantage. Responsiveness does however, vary and as yet there 
are no definitive recommendations for their inclusion in national 
guidelines (Lipworth, 1999).   
 
Despite an increase in the variety of medication currently 
available for the management of asthma and its mode of delivery 
the control of morbidity and mortality has remained a long-
standing problem for the asthma sufferer. 
 
 
 
 
 
1.3 Managing Asthma Today 
 
1.3.1 Mortality and Asthma –The Basis for the Development of 
Guidelines 
 
Mortality rates for asthma were stable during the first half of the 
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twentieth century. At the start of the 1960’s an increase in 
recorded mortality was noted in England, Ireland, Scotland, 
Wales, Australia, New Zealand and Norway (Greenberg, 1965). 
At the time the increase was thought to be associated with the 
excessive use of medication delivered by aerosol for the 
management of asthma. However, Alderson, (1987) noted many 
reports had since been published suggesting that the increase in 
mortality was related to an increase in prevalence of the disease, 
an increase in the severity of the disease, or an increase in the 
number of episodes reported by patients. At the same time 
Alderson refuted the link between environmental factors and 
increased prevalence of asthma. Following Alderson’s rebuttal 
Burney in 1993 restated support for the link between 
environmental factors contributing to increased prevalence even 
when taking into account genetic influences over the disease. 
Opinions constantly change as to the catalyst for the increase in 
the mortality rates of the 1960’s but there remained a significantly 
raised death rate. 
 
Despite the sudden increase in reported asthma deaths in the 
1960’s Dirks and Kinsman (1982) stated that asthma mortality 
remained an infrequent and isolated phenomenon. Janson-Bjerklie 
et al (1992) commented on the under recognition of asthma 
severity by patient and physician alike as a critical factor in 
asthma mortality. Acknowledging increased asthma symptoms 
can be difficult for some patients.  They may not wish to visit 
their GP or present themselves to the Accident and Emergency 
Department as symptoms increase preferring to manage unaided 
until such a time as their asthma deteriorates significantly. This is 
seen as a common phenomenon. Confidential enquiries into 
asthma mortality have brought to the forefront issues such as 
those raised by Janson-Bjerklie and others.  Many of the reports 
published over the past thirty years conclude that the majority of 
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asthma fatalities are preventable citing the less than optimal use 
of inhaled cortico steroids as a prime cause, (MacDonald et al, 
1976a, MacDonald et al, 1976b, Ormerod and Stableforth, 1980, 
BTA, 1982, Burney, 1988, Wareham et al, 1993, Matsuse et al, 
1995, Sommerville et al, 1995). 
 
The BTS published reports in 1982 and 1984 commenting on the 
high mortality rates for asthma for two regions from 1979. As 
opposed to an increase in the use of aerosol therapy the BTS 
attributed the rise in mortality to be the under use of inhaled 
corticosteroids (Thorax, 1982, 1984). Sommerville et al, (1995) 
some years later reported findings similar to previous studies.  
Asthma mortality is preventable and often the result of less than 
optimal treatment. Sommerville and co-workers concluded that 
resources should be directed towards primary care, patients, 
families and the health care professional. 
 
Asthma may be considered as one of the major public health 
problems in developed countries. Not only is it one of the most 
common chronic respiratory diseases but prevalence and severity 
appear to be increasing despite the availability of effective drug 
therapy. Where asthma mortality rates have been considered 
unacceptable, national guidelines have been produced and 
disseminated to health care professionals in primary and 
secondary care. The following authors have published asthma 
specific guidelines as a direct result of unacceptably high 
mortality rates, Woolcock et al, 1989, from Australia and New 
Zealand, Hargreaves et al, 1990 from Canada, BTS, 1997 from 
UK and the National Asthma Education Programme (NAEP), 
1997 for USA. 
 
1.3.2 The Development of Guidelines for Asthma Management - British 
Thoracic Society Guidelines for the Management of Asthma, 
(BMJ 1990, Thorax, 1993 and 1997) 
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The BTS guidelines were issued in direct response to the 
unacceptably high asthma mortality rates (BMJ, 1990). These 
guidelines were reviewed in 1993 and 1995 (Thorax, 1993 and 
1997).  Despite the increase in medication available both 
mortality and morbidity remained high (Pearson, 1986).  
Following their investigations, the BTS concluded there 
continued to be over reliance by patients and clinicians on the use 
of bronchodilator therapy and an under use of both inhaled and 
oral corticosteroid therapy. Too few objective measurements 
existed, there was inadequate monitoring of the disease by the 
health care professions and poor awareness of their severity of 
asthma by patients (Partridge, 1993). 
 
The guidelines gave a step by step approach to the management of 
asthma for both adults and children and set the standard for 
optimal care (Partridge, 1993). The guidelines were also to be 
used as a basis for patient education in order to establish 
continuity of care and information. Treatment was based on four 
components:- 
 
i) objective measurement of airways calibre in order to 
assess for the correct course of  medication and the 
severity of the patients disease; 
ii) optimal use of pharmacology, in order to give the patient 
genuine relief from their associated symptoms; 
 
 
iii) environmental control, if trigger factors exist for patients 
then they are to be isolated and patients advised to avoid 
the known factor; 
iv) patient education. 
 
The emphasis was based upon continuous monitoring by the 
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health care team of the patients PEF with the minimum of 
medication required for the maximum relief of symptoms. The 
forefront for the implementation of the guidelines has been within 
the primary health care setting. The responsibility for delivery of 
care lies with the GP and the primary care team. Recent reforms 
within the NHS have been directed towards chronic disease 
management in primary care. The majority of GP practices within 
the UK participate in the chronic disease management programme 
which now requires GP’s to annually review all asthmatic patients 
(Charlton et al, 1991). 
 
In order to comply with the chronic disease management 
programme asthma clinics have been established within general 
practice in order to offer patients structured and well-monitored 
care (Charlton et al, 1992).  To many GP practices and their 
health care team, the concept of an asthma clinic has been a 
radical method of managing patient and condition (Charlton, 
1989).  The emphasis of care is a partnership between practice 
and patient. The asthma clinic itself requires little in the way of 
resources save time and the enthusiasm of a member of the health 
care team (usually the practice nurse).  Patients attending the 
asthma clinic can expect to be given a self-management plan, this 
includes how to recognise deterioration in their asthma and when 
to adjust their medication (Hayward and Levy, 1990). This is 
normally conducted with the use of peak flow meter and asthma 
diary cards. 
 
 
The establishing of asthma clinics created a new role for GP and 
practice nurse (Charlton, 1989).  Rather than prescribe treatment 
for the patient on a self-referral basis the GP or more commonly 
practice nurse empowers the patient to take control of their 
disease. This giving of information by health care professional in 
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the treatment and management of asthma was a departure from 
old practices.  This alteration in the role of the patient is said to 
lead to a better outcome (Wilson, 1993) as measured by morbidity 
and days lost from work or school. This study intends to observe 
this process of care in the primary care setting. 
 
The publication and promotion of guidelines within the UK has 
improved the management of asthma in primary care but there 
would appear to be a discrepancy between the recommendations 
for management and compliance by clinicians (Neville et al, 
1997, Legorreta et al, 1998, Picken et al, 1998). 
 
1.4 Assessing Asthma  
 
Success in the management of asthma is often viewed by the clinician in 
relation to spirometry and PEF. The closer the patient’s recorded readings 
of FEV1 and PEF are to ‘normal’, the more control the patient has 
achieved by the use of medication over symptoms. The diagnosis of 
asthma relates to PEF values as stated in 1.2.2, which can be considered 
as an objective marker of asthma severity. What may not always be 
considered by the clinician is the patient’s response to other factors 
associated with their disease process. Juniper et al (1998) noted that 
physicians have come to appreciate the importance of evaluating 
functional impairment associated with the disease process when assessing 
patients, although asthma specific QoL scores are known to correlate 
poorly to objective markers. Juniper and colleagues also commented on 
the differences observed in QoL scores (emotional, environmental, 
activity and symptom related values) for subjects with identical objective 
markers of asthma severity. Subjects with good, near normal lung 
function may report what they consider to be increased symptoms 
associated with poor QoL while others will report little interference with 
QoL. QoL may be viewed as a subjective marker of asthma but for the 
patient it may be a more relevant indicator of asthma control. 
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1.4.1 Health Related Quality of Life (HRQL) 
 
The concept of HRQL has in medical terms a brief history.  
Quality of life was only considered by the World Health 
Organisation (WHO) in 1947 to be a health component. The 
WHO viewed QoL in relation to physical, mental and social well 
being along side other health measures. Quality of life may be 
considered as a “final health outcome” focusing on the person, not 
the disease and how that person intrinsically feels despite what 
objective clinical evidence may be present. HRQL includes the 
functional status of the patient, assessing their ability to perform 
activities of daily living of a physical, mental and social nature. 
The terms “functional status” and “health status” are often used 
interchangeably with HRQL, and while acknowledging a precise 
definition does not exist MacKeigan and Pathak, (1992) have 
proposed a hierarchical structure for these concepts.  On the 
lowest level is “functional status”, incorporating physical, 
psychological and social status. Pashkow (1996) suggested 
physical function includes self-care, mobility, physical activity 
and communication; that psychological function encompasses 
personal relationships, thoughts of the future and feelings about 
critical life events; and that perceptions of work, social 
performance, family support and material welfare are important 
aspects of social functioning. Above “functional status” is “health 
status”, which includes physiological status and patient well 
being. Above this lies HRQL, encompassing the previous two 
categories and general life satisfaction. 
Others considered HRQL to include physical, psychological and 
social domains with or without specific consideration for 
symptoms, perception of general health, role function, cognition 
or economic factors (Oldridge, 1997). However, Jenkins et al 
(1990) suggested there is a general consensus that HRQL is a 
multidimensional construct.  Jette and Downing, (1994) support 
Jenkins view but would also suggest that any patient’s goal when 
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complying with therapy is for an improvement in HRQL. 
 
Patient’s QoL can be severely affected by their asthma symptoms, 
emotional state, or exposure to environmental triggers. The 
impact of asthma on patients QoL varies considerably from a 
nuisance to life threatening (Steven and Montgomery, 1999). 
Many asthmatic subjects are concerned about their asthma status 
according to the National Asthma Campaign Helpline. Patient 
concerns include their medication and associated side effects, 
inconsistent advice from their GP and other health professionals 
and a failure to implement self-management plans. Also a 
perceived lack of specialist asthma knowledge in some cases, 
delays and incorrect diagnosis, as well as concerns about the 
avoidance of trigger factors, symptom control, asthma death and 
the cost of prescribed medication. Any combination of the above 
can lead to a deterioration in health related QoL for the asthma 
patient. There can also be an impact on the family of the 
asthmatic. Steven and Montgomery (1999) reported that the 
burden of asthma can be reflected towards other family members 
and cohabitees of asthma patients who most commonly complain 
of sleep disturbance. 
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According to Schmier et al, 1998 studies into the relationship of 
asthma to QoL are recent phenomena; most published work dates 
from the 1990’s.  Much of the current understanding of the impact 
of asthma on QoL originates from work carried out to develop 
asthma specific QoL tools. Preparation for the development of 
asthma specific QoL questionnaires was based mainly on clinical 
observational studies, noting that patients with asthma 
experienced a wide variety of problems in physical, psychological 
and social aspects of life.  In work carried out by Juniper and 
colleagues (1992), Juniper commented that asthma patients 
regardless of severity were concerned with symptoms, exposure 
to environmental irritants, levels of activity of daily living and 
emotional problems.  Similarly when Marks et al, (1992) were 
developing their asthma specific QoL questionnaire in Australia, 
they found that patients were concerned about emotional 
functioning, symptoms, activity restrictions, social interactions 
and disease control.  Hyland et al, had already noted earlier 
(1991) that HRQL was an important issue for asthmatic subjects. 
 
Juniper (1998) stated that HRQL “has emerged as an important 
component of health care”. The QoL of an asthmatic subject can 
be influenced by clinical intervention, patients seek advice from 
health professionals if they consider their function to be impaired. 
Yet clinicians do not include assessment of elements of QoL in 
routine care.  At present there are a number of validated QoL 
instruments available but many are too long and cumbersome to 
be used in routine clinical practice. 
 
There are two types of instruments for measuring QoL, the 
generic QoL questionnaire and the disease specific QoL 
questionnaire. The generic instrument can be used to assess 
different diseases with each other and reflect the burden of illness 
across a variety of conditions. Such generic QoL tools include the 
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Short Form 36 (SF-36) (Stewart et al, 1988), the Nottingham 
Health Profile (Hunt et al, 1980) and the Sickness Impact Profile 
(SIP) (Berger et al, 1981). Such generic tools are by their nature 
none specific to the problems associated with any one disease and 
may therefore not highlight patients perceived problems or small 
but important changes in their QoL.  Disease specific tools look at 
problems and limitations those patients with a particular disease 
experience on a daily basis. Such tools are normally developed by 
asking the patient what do they perceive as major impairments 
linked to their disease (Juniper et al, 1998). The St George’s 
Respiratory Questionnaire (Jones et al, 1991) is a tool used for 
measuring QoL in subjects with airways disease as is the Chronic 
Respiratory Questionnaire (CRQ) (Guyatt et al, 1987). Asthma 
specific QoL measures have also been developed eg, Living with 
Asthma Questionnaire (LWAQ) (Hyland et al, 1991) and the 
Marks et al, AQLQ  (1992). 
 
Juniper and co-workers (1992) developed the Asthma Quality of 
Life Questionnaire (AQLQ) by asking patients to “identify 
problems that were most troublesome in their day-to-day lives”. 
The AQLQ as previously stated has four domains and the asthma 
patient considers problem areas, which subsequently may affect 
their lives on a daily basis: symptoms, emotions, environmental 
stimuli and activity limitations. Patients using the AQLQ are 
asked to respond to each of thirty-two items using a seven-point 
scale (range, 1 totally limited – 7 no limitation). Rutten-van 
Mlken et al (1995) compared asthma specific and generic QoL 
tools when assessing the effects of medication on asthma QoL. 
Rutten-van Mlken concluded that the AQLQ responded well to 
improvements in QoL as noted by subjects receiving treatment. 
Ware et al (1998) also commented that when comparing disease 
specific and general QoL measures, the disease specific tools 
proved more valid than their generic counter parts. The AQLQ 
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has been evaluated extensively, showing excellent reliability and 
responsiveness with strong cross-sectional and longitudinal 
validity (Juniper et al, 1998). The current study presented in this 
thesis used the AQLQ as a means of assessing QoL in asthma 
subjects over a two year period and used the symptom domain 
specifically to evaluate a newly devised morbidity index. 
 
1.4.2 Morbidity Indices 
 
The development of asthma specific QoL assessment tools 
usually uses subjects with that disease and/or health professionals 
familiar with the condition as the initial contact. This mixed 
group is then required to generate items that they consider 
bothersome or impairs in some way their activities of daily living. 
Developed asthma specific QoL instruments contain items 
relating to symptoms of the disease eg, wheeze, breathlessness, 
sleep disturbance. The increase in morbidity is perceived by 
asthma subjects to be detrimental to their daily lives, indeed, 
increased morbidity can often be the precursor to seeking help 
from the clinician. While developing the AQLQ, Juniper and 
colleagues noted asthma morbidity proved to be an area of 
concern for subjects. When devising the symptom domain, 
symptoms relating to asthma had the highest impact factors with 
no score less than 2.01 (range 5 extremely important – 1 not 
important) in comparison to other domains featured in the score 
(emotional, environmental and activity domains) (Juniper et al, 
1997). Morbidity indices have been developed in parallel to QoL 
questionnaires and have been used as an assessment tool in their 
own right (Jones et al, 1992b). 
 
Jones (1991) and Jones et al, (1992a) responded to the reported 
increase in mortality rates by devising the Jones Morbidity Index, 
that has subsequently been revised (Jones et al, 1999).  Noting 
that the majority of asthma subjects were treated in the 
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community, Jones targeted these subjects. The Jones Morbidity 
Index was developed using the symptom of wheeze (during day 
and night) and interference with daily activity by asthma. Jones 
and co-workers concentrated on the development of a short 
morbidity index for use in routine clinical interventions, which 
was useful as an outcome measure when monitoring health care. 
Jones and co-workers acknowledged that morbidity indices are 
useful tools but are not as accurate as QoL instruments that 
examine the subject more fully. However, Jones stated that 
morbidity indices used at every scheduled visit to clinic could 
highlight at risk asthma subjects subsequently improving asthma 
care. 
 
Steen et al, (1994) also recognised the importance of symptom 
based outcome measures as a tool for monitoring health care in 
general practice. Steen and colleagues developed a ten-item 
morbidity index that could be used in primary or secondary care 
and could monitor symptom reduction over time. The 
development of the ten-item index again used asthma patients and 
health professionals with a specific interest in asthma to develop 
the tool in which wheeze and breathlessness were reported as 
symptoms creating bother for subjects. Steen and colleagues 
concluded that the ten-item questionnaire may perform as well if 
reduced to five items and the outcome of a five-item morbidity 
index was to be trailed at a later date. 
 
The DOH had in 1995 commissioned a panel of experts to 
examine what outcome measures were currently available for 
asthma and to recommend what might be useful for future 
development. The Q score used within this thesis was developed 
in response to the need for a patient focused morbidity index that 
was quick and easy to administer in any busy clinical setting.  The 
Q score was devised as described above using health professional 
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with specialist knowledge of asthma and piloted by members of 
the original working party. Items, which were deemed to impinge 
on activities of daily living were similar to those, reported by the 
Jones team. Nocturnal disturbance, wheeze, breathlessness and 
interference with activities of daily living proved to be common 
items raised by the Q score team. Patients using the Q score are 
asked to estimate disturbance over a one-week period. Recall is 
said to be more accurate over a shorter period of time. Questions 
pertaining to recall over short period are thought to have greater 
reliability than recall over a longer period though up to a month 
has been suggested as an acceptable time frame (Pearson & 
Bucknall, 1999). Steen et al, (1994) argued that by choosing too 
small a recall time span there may be problems with patients not 
being bothered by symptoms chosen for the morbidity index. The 
Q score team highlighted wheeze and breathlessness as two of the 
commonest features of asthma and a week is considered a 
reasonable time frame for recall and symptom identification. The 
scoring system is simple to calculate and record and gives an 
indication of symptom control. The Q score also included a 
question relating to increase use of medication associated with 
morbidity, increased usage would indicate poor morbidity control 
(Pearson & Bucknall, 1999). 
 
Recommendations from the Clinical Effectiveness Unit of the 
Royal College of Physicians (RCP) (Pearson & Bucknall, 1999) 
were that a suitable outcome indicator for monitoring asthma 
should contain a minimum of three questions. Questions should 
relate to nocturnal disturbance, daytime symptoms (including 
wheeze) and interference with activities of daily living. The Q 
score contains these three basic questions, although it also 
contains a fourth. In this thesis it is proposed to assess the Q score 
over a two-year period using adult (age 16 – 60 years) asthmatic 
patients and applying the score to subjects regardless of the 
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severity of the disease process, thus fulfilling further suggestions 
contained within the RCP report. 
 
1.4.3 Psychological Status 
 
Psychological status is not a routine assessment tool for the adult 
asthmatic subject and moreover the influence of psychological 
factors on outcome in asthma would appear to receive little 
attention at present (Harrison, 1998). It has previously been 
reported that psychological status can influence exacerbation of 
the disease and anxiety and depression are thought by many to be 
a common feature of asthma (Yellowness and Kalucy, 1990, 
Michel, 1994, Moran, 1994). Little published work has been 
presented examining the relationship of psychological status to 
asthma regardless of severity. Dales et al (1989) assessed the 
psychological status of subjects with respiratory disease in a 
Canadian epidemiological study.  Dales concluded that there was 
an association between symptoms of respiratory disease and 
psychological status. Janson et al, (1994) in a European 
epidemiological study came to the same conclusions as Dales and 
co-workers. Many studies have reported the association between 
near fatal asthma and increased psychological state (Yellowness 
and Ruffin, 1989, Campbell et al, 1995, Harrison, 1998) none 
have reported the relationship of psychological status regardless 
of severity. 
 
Anxiety, “the fear of impending adverse events” can be a feature 
of chronic illness and may indeed contribute to an exacerbation 
(Morgan, 1994).  Some asthma subjects may well have a tendency 
to sustained states of anxiety, fear of attack further increasing 
their anxiety state. It has been suggested that such a raised anxiety 
state may lead to over prescribing of medication (Dahlem et al, 
1977, Janson et al, 1994). High anxiety state patients have been 
thought to complain of small increases in symptoms more so than 
 
 23
less anxious subjects. Conversely some authors comment on none 
compliance associated with the denial of asthma symptoms and 
depressed subjects may well suffer more near fatal attacks of 
asthma due to their psychological status (Bosley et al, 1995). 
Some clinicians do advocate assessing psychological status, 
especially for the non-compliant patient, when planning treatment 
programmes (Bosley et al, 1996, Vamos and Kolbe, 1999, 
Centanni et al, 2000). Bosley and colleagues (1995) used the 
HAD scale to examine psychological status in their asthma cohort 
when assessing compliance with inhaled medication. They 
reported a high incidence of anxiety and depression in subjects 
who were none compliant with their asthma medication. 
Psychological status can influence how patients react to their 
asthma, the way in which they cope with asthma and the way in 
which health professionals respond to them as patients and may 
therefore affect how they are managed. If patients are noted to 
have increased psychological status, attention should be given to 
treatment plans and compliance with this group. Indeed, the 
relationship between asthma and psychological status remains 
complex. (Bosley, Corden and Cochrane, 1996). 
 
Zigmond and Snaith, (1983) developed the Hospital Anxiety and 
Depression Scale (HAD scale) arguing that emotional disorders 
can be the result of stresses and strains associated with long term 
disability. Some manifestations of physical disease, which lead 
the patient seeking a consultation with the clinician, may well be 
the result of a heightened psychological state and not due to the 
associated disease process. Conversely, psychological status may 
be so heightened that small alterations in symptoms can lead to 
increased distress and a patient who responds poorly to treatment.  
Although emotional factors are known to influence outcome in 
asthma the psychological status of the asthma patient cannot 
always be considered by the clinician in routine clinical practice. 
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The HAD scale was developed for clinical use to screen patients 
for any psychiatric disorder. The scale is quick to complete and 
designed to be self-administered and concentrates on the two most 
common neuroses, anxiety and depression. The HAD scale 
contains seven items pertaining to anxiety and seven for 
depression although Zigmond and Snaith concede that a smaller 
scale with fewer items may not affect outcome. When totalled, the 
score is reflective of the subject’s current mood and uses three 
bands grading depression and anxiety. Previous asthma studies 
have chosen the HAD scale to measure psychological status, 
Janson et al, 1994, Bosley et al, 1995, Vamos and Kolbe, 1999. 
Many asthmatic patients suffer from long term respiratory disease 
and the study presented in this thesis uses the HAD scale to assess 
the psychological status of subjects over a two year period. 
  
1.5 The Primary Care Setting 
 
1.5.1 Development and Organisation of Asthma Care 
 
The primary care setting may be considered as the GP practice, 
contact with the GP or primary care health professional such as 
the practice nurse or asthma nurse.  It has been established that 
the majority of asthmatic subjects (approximately 85%) are 
routinely managed in the primary care setting (Neville et al, 1999, 
van Schayck, 2001).  In 1990, new contracts were negotiated with 
GPs in England and Wales by the Department of Health and were 
followed by further government reforms introducing the Chronic 
Disease Management initiative (CDM) in 1992. Indeed, Jones 
(1989) advocated monitoring of objective markers of asthma, 
patient education and assessment of therapy by the health care 
team but comments that without adequate training and support, 
few objectives for improvement in care would be achieved. 
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The CDM initiative required GPs to annually review amongst 
others, all asthmatic patients (Neville et al, 1996). GP practices 
were required to assess the process of care by creating a register 
of all asthmatic subjects recording their therapy, monitoring 
objective markers of asthma (PEF) and noting the number of days 
admitted to hospital due to disease exacerbation.  As early as 
1985 Barnes proposed nurse run asthma clinics to improve patient 
asthma education thus targeting morbidity.  In the early 1990’s 
computer access in primary care was limited and it is only since 
the nation wide introduction of computerised registration for 
patient and prescription monitoring that practices (and funding 
bodies) are able to assess the organisation and delivery of asthma 
care. Despite computerisation, the instigation of the asthma 
register and the proliferation of nurse run asthma clinics some 
studies suggest that patients are reluctant to attend for annual 
review. With less that half the expected number of subjects 
attending nurse run asthma clinics (Dickinson et al, 1997, 
Gruffydd-Jones et al, 1999). 
 
1.5.2 Nurse Run Asthma Clinics in Primary Care  
 
Since the introduction of the 1990 new GP contracts and the 
CDM initiative, the role of the nurse in primary care has altered 
considerably and especially in the management of the asthma 
patient. Nurse-run asthma clinics are now widespread throughout 
the UK (Robertson et al, 1997). In the late 1980’s asthma 
education was considered an important part of care but despite 
this input morbidity remained unaltered (White et al, 1989). 
 
 
Since the early 1990’s, numerous studies have reported the 
outcome of the nurse run asthma clinic. Charlton et al (1991) was 
one of the first to report on such clinics. The Charlton group 
commented on the outcome for patients following the 
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introduction of patient self-management plans, PEF monitoring 
and the correct use of inhaled medication in nurse run asthma 
clinics. Self-management plans for asthma usually involve the 
patient making decisions regarding their asthma therapy on a 
daily basis.  Patients share the responsibility of disease 
management with the health care professional.  Many self-
management plans are based on key stages for the subject 
pertaining to their normal PEF value. How far below the normal 
PEF value they fall determines the treatment they should 
instigate. The implementation of self-management plans by 
patients are usually carried out following intensive training in the 
use of inhaled medication (Neville, 1998). Charlton’s work 
concluded that nurse run asthma clinics reduced morbidity, GP 
consultations and time off from work or school. By adhering to 
published guidelines these clinics increased inhaled steroid 
therapy and reduced oral steroid and agonist use. Charlton 
advocated the use of nurse run asthma clinics as an effective tool 
for better asthma care.  Other groups also published studies 
advocating the benefits of nurse run asthma clinics (Pearson, 
1986, Hoskins et al, 1996) but comment that such positive results 
may be due to “enthusiasm bias”. 
 
More recently Dickinson et al, (1998) assessed outcomes for 
asthma patients following a twelve-month intervention of nurse 
run asthma clinics. Attendance at nurse run asthma clinics was 
associated with significant alterations in inhaled therapy and 
subsequently reduced morbidity. Clinics followed BTS guideline 
resulting in a shift in therapy reducing bronchodilators and 
increasing inhaled corticosteroids. Dickinson and colleagues 
endorse the conclusions of Charlton et al (1991) concluding the 
benefits of nurse run asthma clinics in reduced patient morbidity 
outweigh increased cost in medication or staffing. 
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However, not all studies report improvements in care, Jones and 
Mullee (1995) commented on the proliferation of nurse run 
asthma clinics throughout the UK.  Jones and Mullee’s study used 
two GP practices, one with a nurse run asthma clinic and one 
without. As with Charlton’s 1991 study, outcomes included PEF 
monitoring and the correct use of inhaled medication. Jones and 
Mullee also included self-reported morbidity and subjects’ 
attitudes to asthma. Their study drew attention to the increased 
cost incurred by the GP practice by increased use of inhaled 
corticosteroid and staffing expenditure but with no significant 
difference for outcomes between the patients attending the nurse 
run asthma clinic and those that simply attended their GP 
practice.  However, Jones and Mullee did acknowledge the 
difficulties associated with clinically based research. Their study 
argued the case for nurse run asthma clinics remaining unproven, 
however, they accept large scale random control trials of asthma 
clinics would prove impossible to conduct. Long term 
observational studies, such as the work presented in this thesis 
could assess proactive asthma care and its effect upon the patient. 
 
Care of asthma patients in the community requires a major input 
by health care professionals. The quality of that care can be 
dependent upon the interpretation and implementation of 
published guidelines. With the majority of asthma patients 
managed in the primary care setting, providing nurse run asthma 
clinics could serve as a mechanism for monitoring care.  
According to Neville and Higgins, (1999) what needs to be 
established is the means for all asthma patients to receive 
excellence in their asthma management. 
 
1.5.3 Published Asthma Guidelines in Primary Care  
 
Published guidelines in the UK were developed by specialist 
groups with an interest in asthma (BMJ, 1990, Thorax, 1993, 
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Thorax, 1997). However most patients with asthma are treated by 
non specialists in respiratory care and both the GP and the health 
care professional involved in asthma management within the 
primary care setting, usually deal with many other diseases. As 
non-specialists in respiratory medicine this may in part account 
for some deficiencies of care (as previously reported by the 
National Asthma Campaign see 1.4.1).  Indeed, the majority of 
hospital asthma admissions and mortalities are preventable 
(Horne and Cochrane, 1989).  Problems remain at the primary 
care interface with patient and health care professional alike. 
Many asthma patients do not recognise the severity of their 
symptoms, presenting difficulties for management by the 
clinician. Some clinicians are also unaware of the severity of 
patient symptoms resulting in under treatment. In both scenarios 
hospital admission can result and also death in a few cases (van 
Schayck, 2001). Published guidelines alone may not be able to 
alter the practice of the patient or the clinician.  Van Schayck 
(2001) cites Smeele et als, 1999 study where a group of health 
professionals providing monitoring and feed back of care resulted 
in a significant improvement in outcome for their asthma patients. 
The intervention given to patients by the monitoring and feedback 
group of health professionals included regular opportunity for 
patient review and recall, feedback on their PEF, comment on 
their smoking habit and monitoring of medication. This group 
was supported by a specialist in asthma care. Van Schayck 
concluded that successful implementation of guidelines can 
succeed but required support in terms of feedback, especially for 
patients difficult to treat, if primary care clinicians are to improve 
care for patients. 
 
Problems associated with the implementation of guidelines in 
primary care have been acknowledged (Partridge et al, 1998). 
Although Partridge relates a significant improvement in the 
 
 29
management of asthma patients in primary care by following 
published guidelines, he also noted the need for vigilance and 
adequate education. Van Schayck (2001) later commented that for 
the successful implementation of guidelines adequate educational 
activities designed to increase health professionals’ knowledge 
and understanding of the recommendations are required, if 
guidelines are to improve outcome for patients. Primary care 
clinicians can improve their asthma management if education, 
feedback and support are offered by clinicians with specialist 
knowledge (Feder et al, 1995). 
 
1.5.4 Proactive Asthma Care 
 
Published guidelines have been embraced by many in the primary 
care sector with some health professionals becoming proactive in 
the implementation of good quality care and management. Several 
primary care health professionals and academics have taken part 
in assessing the implementation of asthma guidelines but have 
also developed and piloted their own extended care packages. 
 
The Grampian asthma study of integrated care (GRASSIC) group 
have published several papers (GRASSIC, 1994, Osman et al, 
1994, Osman et al, 1996) that describe their programme for 
integrated care between the GP practice and the hospital specialist  
 
in conjunction with the introduction of national asthma 
guidelines.  Asthma patients were initially randomised to receive 
a mixture of care at their GP practice or an integrated care 
programme by GP and hospital specialist and possibly including 
regular PEF monitoring and an enhanced education programme. 
Patients on the integrated care package received detailed 
questionnaires regarding their asthma care, as did their GP. Prior 
to consultation GPs received feed back for each patient and 
suggestions to improve asthma management. Osman and co 
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workers argued that the shared care initiated by their programme 
has lead to improved clinical effectiveness in asthma 
management. 
 
Again in Scotland, a Dundee based group of hospital, university 
and GP clinicians has developed a proactive programme of care 
similar to GRASSIC (Hoskins et al, 1998). The Tayside asthma 
management initiative offers GP practices the opportunity to 
improve their knowledge in relation to asthma management. 
Asthma workshops and programmes offer approved postgraduate 
education for all primary care health professionals involved in 
asthma care.  Difficult to treat patients were targeted in each GP 
practice with the clinician receiving feedback and suggestions for 
improved patient management. This group used a slightly 
different approach to the GRASSIC series of studies as clinical 
education was achieved by distance learning and computerisation. 
The Tayside group also advocated shared care as a successful 
means of achieving improved asthma management (Hoskins et al, 
2000). 
 
Other groups have used different methods to enhance their asthma 
programmes. The St George’s team based in London has used 
telephone contact to assess patient morbidity and compliance with 
inhaled medication as a means of improving outcome for patients 
(Anie et al, 1996). Anie et al advocated the use of telephone 
interviews as a means of successfully monitoring the health status 
of asthma patients in the community. 
 
 
The above groups have recognised that successful outcomes for 
patient care can be achieved but requires considerable effort, the 
publication of guidelines alone cannot lead to improved care. 
Specialist have been available to give expert advice in problem 
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cases and GP and other health care staff have availed themselves 
of postgraduate education to increase their asthma knowledge 
thus providing optimal care. Health professionals need to 
communicate their improved knowledge effectively to their 
patients. Patient education requires simple and repeated 
information over time and each consultation with any member of 
the health care team should contain an element of education. 
Asthma patients themselves have also been actively encouraged 
to participate in such programmes, patient education and the use 
of self-management plans can lead to improved care.  The patient 
and clinician need to work together if a better outcome for the 
asthmatic is to be obtained, while the GP and primary health care 
worker require access to specialist support in the community 
(Partridge, 1995). 
 
1.5.5 Reporting from Differing Primary Health Care Settings 
 
As the majority of adult asthma subjects are managed in primary 
care it is therefore appropriate for the study presented in this 
thesis to recruit subjects from that setting (Neville et al, 1999).  A 
hospital-based population would include more severe patients that 
require greater monitoring and care by the clinician and would 
skew the study population. Asthma is a respiratory disease that 
can affect any member of society and the present investigation 
chose to recruit from two differing primary health care settings, 
inner city and suburban situated practices. This should ensure a 
suitable cross section of society is recruited. The study intends to 
recruit subjects that are representative of many GP practices 
throughout the UK. 
 
Many studies carried out in primary care or use hospital based 
populations are sponsored by large-scale research bodies or drug 
companies who may wish to influence the research agenda. The 
study presented here uses unsponsored research staff with GP 
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practices and subjects who have been recruited without 
inducement. Randomised control trials are considered by many to 
be the “gold standard” research tool (Black, 1996). Yet such 
studies can be prescriptive in nature, recruiting only subjects that 
clinicians consider may respond suitably to the intervention 
giving the desired outcome for the trial. Inclusion criteria may be 
so exclusive that subjects participating (especially in drug trials) 
are highly selected and compliant giving rise to a positive 
outcome for the trial. It is proposed to maintain a wide and 
inclusive inclusion criteria for the study presented from a cross 
section of society. It is also proposed to observe clinical practice 
in its natural setting. Observation is said to be the appropriate 
technique for reflecting on “real life” in the “real world” (Robson, 
1994). This observational study intends to explore the 
effectiveness of asthma care in the primary health care setting. 
 
 
1.6 Aims, Objectives, Hypotheses 
 
1.6.1 Study Aims 
 
The aims of this study are:- 
 
i) to observe and follow up a cohort of adult asthmatic 
patients from differing primary health care settings over a 
two-year period. 
 
ii) to assess a newly devised patient focused morbidity index 
(Q score) for validity, reliability, sensitivity and 
specificity by comparison to an established asthma-based 
quality of a life questionnaire (AQLQ) (Juniper et al, 
1993). 
1.6.2 Study Objectives 
 
The objectives of this two-year follow up study of a number of 
asthmatic patients:- 
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  Assess patient asthma management over the two-year period by:-  
 
i) Assessing if subjects from different socio-economic 
groups (inner city versus suburban) report differing levels 
of asthma morbidity (Q score and AQLQ symptom score), 
severity (BTS Guidelines treatment step) or psychological 
status (HAD score) when compared to objective markers 
of asthma (Spirometry and PEF). 
ii) Assessing if asthma morbidity (as measured by Q score 
and AQLQ) responds to changes in asthma status (as 
measured by BTS Guidelines treatment step). 
iii) Examining the changes in asthma morbidity (as measures 
by Q score and AQLQ) to psychological status (using the 
HAD score). 
iv) Assessing if alteration in medication as recommended by 
BTS Guidelines reduces reported levels of morbidity (as 
measures by Q score and AQLQ). 
 
1.6.3  Hypotheses 
 
The Q score, designed to be a simple patient focused index of 
morbidity is as reliable as the AQLQ symptom score (Juniper et 
al, 1993) when used to monitor asthma management in a primary 
health care setting. 
 
The Q score is comparable to the AQLQ score when used to 
assess for asthma severity (as measured by BTS guidelines 
treatment step) in a primary health care setting. 
 
 
Patients in suburban areas have better outcomes (as measured by 
AQLQ, Q score, HAD score and levels of severity) following 
treatment intervention than their inner city counter parts. 
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1.7 Summary 
 
The lack of decline in morbidity and mortality related to asthma is well 
documented (Keating et al, 1984, Partridge, 1986, BTS, 1990, Cochrane, 
1993) the response of the BTS was to assess the then current management 
of asthma in the primary health care setting and to subsequently publish 
their asthma guidelines (BMJ, 1990, Thorax, 1993 and 1997).  The 
response of the NHS to the rising morbidity and mortality rates associated 
with asthma was the encouragement to establish asthma clinics within the 
primary health care setting. The impact of asthma clinics is reported to be 
one of reduced symptoms of morbidity, reduced consultation with the 
asthma clinic and improvement in days lost from work or school (White 
et al, 1989, Charlton et al, 1991, Charlton et al, 1992, Wilson, 1993, 
D'Souza et al, 1994). 
 
Information is not currently available for outcomes (as assessed by 
symptoms of morbidity, reduced consultation with the asthma clinic and 
improvement in days lost from work or school and QoL) in the primary 
health care setting where asthma clinics are not a feature of general 
practice and BTS guidelines are not adhered to thus possibly giving rise 
to poor asthma care.  Many GPs do not identify asthma patients quickly, 
monitor their patients, share information and prescribe appropriate 
treatment (Keeley, 1993). The aim of this study is to assess patient 
outcomes for their asthma using a cohort from GP practices in the inner 
city and suburbs comparing differing socio-economic groups. 
 
Many studies have used outcome measures related to QoL (Marks et al, 
1992, Juniper et al, 1993), morbidity and attitudes (Charlton et al, 1992, 
Steen et al, 1994) as their assessment tool for the patient as an individual. 
Such studies reflect the important indicators the researcher considers to 
be necessary to demonstrate an improved outcome for the asthmatic 
patient. 
 
A comprehensive indicator as to the patients’ QoL may include:- 
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* symptoms of morbidity; 
* restriction of activities of daily living which may trigger an 
attack; 
* any side effects of medication used to control asthma; 
* need to carry medication and awareness for self-management 
plan; 
* patient anxiety, fear of attack, stigmatisation; 
* number of hospitalisations per year; 
* days missed from work or school. 
 
At present many questionnaires used to assess outcome measures in 
clinical practice are long and/or cumbersome (QoL questionnaires eg, 
Marks et al, 1992, Juniper et al, 1993 and morbidity index questionnaires 
eg, Charlton et al, 1992, Steen et al, 1994).  Busy GP practices, 
regardless of the provision for asthma care require a uncomplicated, yet 
quick and accurate assessment tool for patient response to treatment. This 
study will assess if a short symptom related questionnaire can be as 
successful in monitoring patient outcome as compared to an established, 
reliable and validated questionnaire (Juniper et al, 1993). The short 
questionnaire (Q score) is a rudimentary patient focused index of 
morbidity that can be used to interpret and monitor the success of 
treatment.  This questionnaire is short and has been specifically designed 
to be easy and simple to administer. 
 
Outcome measures should be able to detect any change in a patient’s 
health over time (Steen et al, 1994).  More importantly they should be 
used to assess patients desired outcomes.  According to Steen et al, 
(1994) morbidity-based outcome measures are more likely to accurately 
reflect any change in a patient’s asthma than an assessment related to 
general health status. It is therefore vital that the patient fully 
comprehends the importance of asthma as a symptom related respiratory 
disease if they are to successfully monitor their own disease process. 
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Poor or non compliance by a patient with their treatment regimen has 
been thought to be the result of poor understanding of the disease process 
and the mode of action of prescribed therapy. With this lack of 
knowledge the patient perceives no benefit in carrying out medical 
instructions. 
 
Patient compliance may be defined as "the extent to which patient's 
behaviour coincides with medical advice" (Cochrane, 1993). With the 
increased awareness of the importance of self-management for the asthma 
patient (BMJ, 1990, Thorax, 1993 and 1997) the variety of information 
(printed matter, audiocassette and videotape) available for the patient has 
greatly increased. Despite this knowledge being readily available for the 
patient, compliance remains a problem for the health care team.  The 
problem of non compliance must not rest with the patient alone, the 
health care team are capable of undermining patient confidence (Keeley, 
1993) but compliance can be effectively measured by quantifying patient 
prescribed medication. 
 
Criteria for an adequate treatment outcome study should include:-  
 
* unbiased subject selection;  
* standard treatments;  
* clear outcome measures;  
* long follow ups;  
* large numbers of subjects;  
* confirmation of asthma as a diagnosis;  
* control of severity of the disease;  
* control of use of medication (Hyland, 1994).  
 
With the present media interest in asthma, hardly a day passes by without 
asthma being brought into the public domain. The continuously high rates 
in asthma morbidity and mortality are a constant reminder to patient and 
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health care professional alike that instability still exists within the asthma 
population.  Factors which predispose to high incidence of morbidity and 
mortality include the lack of patient and health care professional 
compliance with published guidelines (Thorax, 1993). 
 
This study will attempt to examine patient outcomes from differing socio-
economic area areas as measured by community wide social deprivation 
(Jarman, 1983).  Do patients who have a better standard of living fare 
better than those living with poorer facilities? The importance of 
appropriate interpretation of published guidelines, as a measure of good 
practice and its outcome for patients is an important area for review.  If 
the use of guidelines can be associated with patient compliance and a 
reduction in symptoms of morbidity (and mortality rates) then the 
advantages of such practice can be used to illustrate good models of care. 
Using outcome measures as part of an audit tool is at present a common 
means of evaluation in clinical practice.  Outcome measures assessing 
asthma care are dominated by symptoms of morbidity.  What have not 
been scrutinised are the effects other parameters may exert on the patients 
desired outcome in relation to QoL. For the clinician, desired outcome 
may well include reduced symptoms but for the patient there may be 
other indices.  There would seem little point in pursuing certain treatment 
modalities if this did not give the patient the required end point - a 
possible reason for non-compliance.  It is intended to assess the patient’s 
feelings of anxiety and depression with regard to their asthma and to 
assess patient’s desired outcomes.  This may well influence how patients 
perceive their asthma, the effect asthma has on their activities of daily 
living, their ability to cope with an asthma attack and their concern at any 
side effects associated with their current medication. 
 
The best outcome for patients with asthma can be achieved by good 
communication between patient and health professional. The blame for a 
poor outcome must be divided between patient and the health care 
professional (Keeley, 1993).  Patients with poorly controlled asthma can 
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be found within GP practices of good asthma care.  It remains easy for the 
asthma patient to 'slip through the net'.  The patient can so often be asked 
blanket questions that do not probe their current symptoms (Keeley, 
1993).  By developing a suitable short answer questionnaire this study 
hopes to establish a framework of questions that can be related to a 
simple morbidity index relevant to patients and health care professionals 
as an acceptable outcome measure.  It is hoped the Q score will prove to 
be a quick, reliable and objective assessment tool suitable to be promoted 
as a means of raising the standard of care for patients. 
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CHAPTER 2 
 
 
 
 
 
METHODS 
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2.1 Design 
 
This study was planned as a two-year observational study following a 
cohort of known adult asthma patients based in the community.  All 
subjects were assessed at outset and were invited to attend for 
reassessment at twelve and twenty-four months.  A random subset of 
subjects were asked to repeat certain elements of the study two weeks 
after the initial data set had been collected in order to assess the reliability 
of a newly devised patient focused asthma morbidity score (Q score). 
 
Subjects observed in this study were assessed at their own GP practice or 
place of residence if more convenient.  Baseline data was collected over 
Winter 1996/Spring 1997, final data collection took place over Winter 
1998/Spring 1999.  Some 114 subjects were recruited (42 males) from the 
four GP Practices. 
 
2.2 Subjects 
 
2.2.1 Recruitment of Primary Health Care Centres (GP Practices) 
 
Subjects were recruited from four GP Practices situated in close 
proximity to Aintree Chest Centre in north Merseyside.  A 
number of local GP practices were contacted, four agreed to assist 
in the study.  No incentives apart from individual reports at the 
end of the study were offered as inducements.  Each of the four 
practices regularly referred patients to the local University 
Teaching Hospital where Aintree Chest Centre is situated and had 
previously taken part in activities linked to the acute hospital site. 
 
A visit by the researcher was made to each GP practice. The aims 
and objectives (see section 1.6) of the study were explained and 
discussed with practice members (usually the GP with an interest 
in asthma, practice manager, practice or asthma nurse and records 
manager). 
The facilities required by the researcher to be available over the 
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two-year period (see Appendix I) were also discussed at this time. 
If the practice management deemed such facilities would be 
available the practice was entered into the study.  All four GP 
practices that offered to take part in the study agreed to provide 
the requirements of the Practice Agreement. 
 
2.2.2 Subject Selection 
 
Participating GP practices were asked to supply the researcher 
with a complete computer listing of all asthma patients (Reade 
code [five characters] H33).  The practice was asked to exclude 
from that list all known substance abusers and patients with 
mental illness who would not be able to co-operate fully with the 
researcher or where it would be unsafe for the researcher to enter 
the subjects abode unaccompanied.  The practice was also asked 
to exclude all subjects under 16 years of age and over 60 years of 
age on the date of agreement to take part in the study.  Selected 
practices had up to 450 subjects with an asthma coding.  It was 
proposed to select approximately forty adult asthma patients from 
each GP practice for observation. 
 
2.2.3 Subject Exclusion Criteria 
 
Subjects on the GP asthma register under sixteen years of age 
were considered as children and therefore excluded from the 
study.  Subjects were also excluded if they were over sixty years 
of age and/or if the had a smoking history greater than twenty 
pack years. This was felt necessary in order to exclude any 
potential diagnostic confusion with COPD. Increased age and a 
long term smoking history are established risk factors associated 
with COPD.  Subjects were further excluded if they had existing 
Bronchiectasis, other lung pathology or cardiac disease. 
 
Subjects were free to exclude themselves from the study at any 
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time (see Appendix II). 
 
2.2.4 Subject Inclusion Criteria 
 
Subjects were included in the selection process for the study if 
they were between sixteen and sixty years of age and if they had 
been receiving treatment for their asthma from their GP for the 
previous six months. Such treatment could include any 
prophylactic inhaler or two or more prescriptions for a β agonist 
inhaler. Each subject was diagnosed by their GP and subsequently 
placed on the practice asthma register. Each practice had 
confirmed at interview that they managed all their asthma patients 
following BTS published guidelines (Thorax, 1997) (see 
Appendix III). Thus each subject had had their diagnosis for 
asthma confirmed by criteria drawn from the current BTS 
guidelines.  This included a record of both the patient's symptoms 
and their PEFR over a two-week period.  Symptoms indicating 
asthma included intermittent wheezing associated with 
breathlessness, a cough often occurring at night or first thing in 
the morning, a wheeze related to exercise and respiratory 
symptoms disturbing sleep especially in the early hours of the 
morning. PEFR readings were recorded over a two-week period, 
twice per day (first thing in the morning and last thing at night).  
Subsequently a record of PEF variability over a two-week period 
was attempted as part of the data collection (see section 2.4.1). 
 
2.2.5 Subject Selection and Recruitment 
 
The patient list used in this research for recruitment and selection 
to the study excluded all subjects under sixteen and over sixty and 
any asthma subject with lung or heart pathology. 
 
 
At each GP practice, every eighth patient on the asthma register 
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was selected, in order to exclude members of the same family 
(systematic sampling technique).  The eighth patient on the 
asthma register had to fulfil all elements of the inclusion criteria. 
Subjects who had received asthma treatment in the previous six 
months were selected for telephone contact.  Before telephoning, 
practice records were used in order to exclude those with 
bronchiectasis or other pulmonary or cardiac disease, substance 
abusers and patients with mental illness. If the selected person 
was ruled out or if on phoning reported a smoking history of 
greater than twenty pack years, or refused to take part, or were 
unavailable, the next patient (ie, ninth) was contacted. An attempt 
was made to recruit forty subjects from each of the four GP 
practices. Initial recruitment was low and a second attempt at 
recruiting subjects was sought. The list secured from the GP 
asthma register was used a second time contacting every eighth 
patient but from bottom up.  Again, if the eighth patient was not 
available or willing to participate the next patient (ninth) was 
contacted; the next eighth patient from the last successful contact 
was then contacted.  It was anticipated forty subjects from each 
GP practice would be entered into the study. 
 
Prospective subjects were informed that the research was being 
conducted by a local university and  subjects would be contacted 
by a researcher from their GP's practice with their GP's 
permission. Subjects were informed of the observational nature of 
the study and the two-year follow up, the use of questionnaires 
and spirometry.  Subjects were not offered any inducement to 
participate in the study. 
 
Almost half the subjects contacted and invited to participate in the 
study did not.  Subjects who refused to enter the study, cited work 
commitments, inability to attend GP practice in working hours, 
home or family commitments and an unwillingness to participate 
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in home visits.  Many subjects worked full time and simply were 
not available for contact during GP practice hours (9.00 am – 6.00 
pm in all cases).  Other subjects declined to take part for non-
specific reasons. Some subjects who agreed to participate had 
smoking histories in excess of 20 pack years and therefore 
excluded themselves.  Subjects who were not contactable by 
telephone were also not entered into the study due to time 
constraints. No information on subjects who refused to participate 
was collected. 
 
It proved extremely difficult to recruit forty subjects from each of 
the four practices subsequently the numbers recruited were as 
follows:- 
 
 Practice W recruited 30 subjects from 229 patients on 
their asthma register aged 16-60  
 Practice Y recruited 20 subjects from 203 subjects 
 Practice S recruited 19 subjects from 189 subjects 
 Practice R recruited 45 subjects from 285 patients 
 Practices S and Y were situated in the suburbs. 
 
After obtaining informed consent, a total of one hundred and 
fourteen adult asthma patients agreed to participate in the study. 
 
2.3 Equipment and Materials 
 
Equipment and materials used in the study consisted of four Micro 
Medical hand held spirometers, a patient data sheet (see Appendix IV), 
two previously validated questionnaires the AQLQ (see Appendices VI) 
and HAD score (see Appendices VII) and the newly devised Q score 
contained in Appendix IV. 
 
2.3.1 Micro Medical Hand Held Spirometer 
 
Four hand held spirometers were purchased one for each practice 
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to be used over the two-year period (Micro Medical Ltd, 
Rochester, Kent).  The spirometers measured PEF, FEV1 and 
FVC by means of a turbine volume transducer.  The turbine 
drives a low inertia vane, when forced expiration initiates 
rotations of the vane. Movements of the vane are detected by a 
closed source of infra red light. This light source reflects onto a 
sensor that generates electrical pulses, which are computerised 
into the readings obtained from the spirometer. All spirometers 
were calibrated by Micro Medical prior to purchase.  On delivery 
each spirometer was allocated to a single practice to be used for 
data collection relating only to the study.  Prior to each set of data 
collection, at baseline, twelve and twenty-four month’s 
calibration was checked by use of a three-litre syringe. The 
syringe was attached to the mouthpiece of each spirometer the 
plunger was withdrawn and the content of the syringe was 
emptied via the mouthpiece. This activity was repeated three 
times on each spirometer, readings were taken following each use 
of the syringe. Readings taken remained unchanged throughout 
the study period The three litre syringe represented a patients 
forced vital capacity (FVC) the accuracy was within two percent 
as suggested by Chowienczy and Lawson, 1982. 
 
The hand held spirometers were used to collect subject's 
spirometry (PEF, FEV1 and FVC) at outset, twelve months and 
twenty-four months. 
 
 Figure 1 Micro Medical hand held Spirometer 
 
 
2.3.2 The Patient Data Set 
 
As much information for the patient data set was recorded from 
the GP computer files as was possible prior to the initial patient 
contact. All information recorded was checked for accuracy with 
each subjects at the initial contact. The patient data set included 
information regarding the subject's name, address and telephone 
number for contact purposes (see Appendix IV).  The subject's GP 
practice with computer file number was also recorded. This 
number was used to identify subjects on the research database (to 
avoid entering subject’s names) and subsequently on GP 
computer files. Date of birth was also recorded in order to 
establish predicted vales for spirometry measurements. 
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Subject's smoking habit was recorded, as was their smoking 
history. Allergy status was entered for each subject and their 
occupation was noted though this information was not used in the 
analysis of this study.  Patient's asthma medication was obtained 
from the computer files as was medication dosage and delivery 
system.  With this information the BTS Treatment Step was 
calculated (Steps 1-5). The number of hospital admissions for 
asthma in excess of twenty-four hours was entered as was the 
number of exacerbations for asthma, which required a visit to the 
GP or Asthma Nurse. The initial data set registered the number of 
prescriptions issued for oral steroids, inhaled steroids and 
agonists in the preceding six months (this formed part of the 
inclusion criteria). The subjects height was recorded in order to 
cite predicted spirometric values. This was followed by recording 
subject's spirometry (PEF, FEV1 and FVC) using a Micro Medical 
hand held spirometer.  Finally the expected outcome for the last 
GP visit due to asthma exacerbation was recorded (this 
information could only be acquired at face to face interview). 
 
At twelve and twenty four months the patient data set was 
repeated including any change in asthma medication since the 
previous review.  The numbers of repeat prescriptions for oral and 
inhaled steroids and agonists were recorded from the patient 
computer files (see Appendix IV). 
 
2.3.3 The Asthma Quality of Life Questionnaire - AQLQ (Juniper et al, 
1993) 
 
A copy of the AQLQ, response options and score sheet as used in 
this study is shown in Appendix VI.  The AQLQ was devised in 
Canada and as such the list of activities which gives rise to 
breathlessness included shovelling snow.  This was omitted in the 
version used in this study due to the poor snowfall record in the 
Merseyside area. 
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Juniper et al (1993) noted, asthma outcomes in the main have 
consisted of monitoring patients PEF and noting the change in 
morbidity to medication prescribed and such outcomes do not 
take into account the influence morbidity exerts on patients 
activities of daily living.  Activities of daily living could well be 
linked to outcomes the asthmatic patient realistically requires for 
themselves. 
 
The AQLQ covers four areas of importance for the patient. The 
four domains cover the degree to which asthma limited the patient 
in the previous two weeks. 
 
These are:- 
 
 activities that are limited by their asthma, (11 items) 
 symptoms of their asthma, (12 items) 
 emotional aspects related to their disease, (5 items) 
 environmental stimuli, (4 items). 
 
The patient responses are on a seven point scale to the thirty-two 
questions, a low score (1) on the seven point system indicates 
little effect on health status thus indicating good QoL. The mean 
scores are calculated for each domain, the overall QoL score is 
obtained by the mean score from all thirty-two items listed. 
 
Juniper considers that data collected using the AQLQ meets the 
assumptions for parametric testing (Juniper et al, 1992). This 
study considered the AQLQ to yield ordinal level data thus non-
parametric testing was used. 
 
 
 
2.3.4 The Q Score 
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This questionnaire was designed to be short and simple to 
administer in the primary health care setting and consists of four 
questions relating to morbidity (an example of the Q score is 
shown in Appendix IV). 
 
During the past week:- 
 
 On how many days have you wheezed or been breathless? 
 On how many nights have you woken because of asthma? 
 On how many days has your asthma prevented you doing 
normal activities? 
 How many times are you using your reliever inhaler each 
day? 
 
The subject is asked to reflect upon the questions in relation to the 
past seven days.  Subjects are asked to circle one of three options, 
0-1, 2-4 or 5-7 (relating to days per week). The scores are 
calculated as ordinal data, 0-1 scores 0 which equals symptoms 
well controlled, 2-4 scores 1 which equals reasonable control of 
symptoms, 5-7 scores 2 which equals poor control of asthma 
morbidity. 
 
2.3.5 The Hospital Anxiety and Depression Scale - HAD (Zigmond and 
Snaith, 1983) 
 
The HAD scale is a fourteen point self-assessment scale suitable 
for administration in any outpatient clinical situation.  It is a 
useful tool for screening for clinically significant anxiety or 
depression and is a reflection of the patients feelings at that 
particular intervention. The HAD scale consists of seven 
questions relating to anxiety and seven to depression. 
 
Participating subjects are asked to underline one of the option 
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responses under each question.  This can be totalled to give a 
depression score and an anxiety score.  Zigmond and Snaith,  
(1982) further qualify scores by banding subjects into those with 
no or moderate or definite symptoms.  The scoring system for the 
HAD ranges from 0-7, for little to no disorder, 8-10 is borderline 
and 11 and over shows significant depression or anxiety. 
Information may therefore be considered as ordinal data.  A copy 
of the HAD scale is shown in Appendix VII. 
 
2.4 Patient Contact 
 
All assessments took place at the GP practice or in the subjects own 
home. The researcher was given access to clinic rooms with computer 
facilities in order to access subject files. GP practices are busy areas and 
room occupancy was at a premium, this caused severe limitation to times 
and duration available to the researcher.  All GP practices were open on a 
Monday to Friday 9.00 am to 6.00 pm basis only, evening and weekend 
sessions were not available. 
 
2.4.1 Initial Contact - Collecting the Baseline Data 
 
Prior to the initial contact each subject was sent a letter with an 
appointment to attend the GP practice (see Appendix VIII).  If a 
home visit was requested a letter confirming date and time was 
sent to the subject. Subjects were reminded to take their asthma 
medication as normal on the day of the initial and subsequent 
assessments. The subject was telephoned on the day prior to the 
appointment to remind them of their agreement to attend for 
assessment. 
 
At the initial appointment subjects were greeted, the aims of the 
project were repeated and informed consent (see Appendix II) 
was obtained.  Personal details collected from the computer files 
were checked for accuracy (address, telephone number, and age). 
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One subject was older than her recorded age, being sixty-one 
years and was subsequently withdrawn from the study. All other 
information from the patient data sheet previously recorded from 
the GP computer files was also checked and verified with the 
subject.  Cross checking highlighted inaccuracies in the smoking 
histories of some subjects.  Verification of subjects smoking 
history had been obtained initially from GP computer files (this 
had been reviewed at telephone interview but was reviewed again 
at the initial contact), if at this stage the subject admitted to a 
smoking history greater that twenty pack years they were 
withdrawn from the study. This occurred in 15 subjects with 
smoking histories ranging from twenty two to eighty seven pack 
years.  These subjects were withdrawn from the study. 
 
Subjects Spirometry 
Spirometry was measured at each session (PEF, FEV1 and FVC). 
All measurements were taken using a Micro Medical hand held 
spirometer with all subjects placed in a sitting position to perform 
the manoeuvre.  Subjects were asked to inhale to total lung 
capacity (TLC), then to place their mouth around the mouthpiece 
of the spirometer and to exhale fully as fast as they could and for 
as long as possible.  Each measurement was taken following a 
questionnaire (regardless of the order in which the questionnaires 
were randomised) in order not to create undue bronchospasm by 
asking for three attempts at spirometry at once.  The best of the 
three values was recorded on the subject data sheet (Quanjer et al, 
1993). All operators unfamiliar with procedures for measuring 
and recording spirometry and PEF received training in the 
Pulmonary Function Laboratory of the same large teaching 
hospital prior to data collection. 
 Figure 2 Subject using Micro Medical hand held 
Spirometer 
 
 
Order of Administration of Questionnaires 
Subjects were then invited to draw one of three cards, then one of 
two, leaving a single card.  Each card had a number on the 
reverse; one, represented patient data sheet and Q score, two, 
represented AQLQ and three, represented HAD questionnaire. 
The sequence in which a patient drew the cards represented the 
administrative order used for the questionnaires at that session. 
 
The Patient Data Set 
Subjects were asked what asthma medication they were currently 
receiving, dose and delivery mechanism and if they were using 
oral steroids on a regular basis.  Subjects were asked how many  
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repeat prescriptions they had received in the preceding six months 
for each type of medication. Subjects’ answers were confirmed 
against computer records of prescription and uptake. If the 
subjects’ response differed from the prescribed medication the 
computer files were taken as accurate. All GP practices agreed 
they adhered to BTS Guidelines (Thorax, 1997) this includes 
patient self-management plans. 
 
Subjects were asked if they had a personal management plan  (see 
section 1.3.2) and their response was recorded. Subjects BTS 
Guidelines treatment step was allocated following confirmation of 
their asthma medication by computer records. 
 
Stability of asthma status was assessed by admission to hospital 
(in excess of 24 hours) and the number of visits to GP or Asthma 
nurse for asthma related symptoms in the preceding six months to 
the study.  Subjects were also asked following their previous visit 
to their GP practice what was their expectation for that visit.  (See 
section 2.3.2 for details of other information obtained from patient 
data set.) 
 
Completing the Q Score 
The newly devised Q score was contained within the patient data 
set. Subjects were shown a copy of the score and where asked to 
“read this score sheet, think about how “your asthma” has been 
over the past week, then circle the number of days on the right 
hand side of the page in answer to the four questions”. 
 
Completing the AQLQ 
When subjects were given the AQLQ to score they were 
reminded of the first three lines on the score sheet, that the list of 
activities following was merely suggestive, that they may have 
other activities that they as asthmatics know are limited by their 
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asthma and they were free to list these instead. Subjects were 
given the four colour coded cards and again were reminded that 
each was for a specific question and to ensure they used the 
correct coloured card for each question. Subjects were left to 
complete the AQLQ unassisted.  If subjects asked for clarity of 
any question assistance was given. 
 
Completing the HAD Scale 
Subjects were also given the HAD scale to score. Subjects were 
asked to read the opening paragraphs of the HAD score and then 
to proceed as directed.  If subjects asked for clarity of any 
question assistance was given. 
 
If at any point subjects had difficulty reading questionnaires the 
researcher read out the content of the questionnaires verbatim. 
 
End of Assessment 
At the end of the initial contact subjects were asked if they had 
been prescribed a Peak Flow Meter (PFM). Subjects who had a 
PFM were asked to keep a daily record of their PF over the next 
two weeks.  They were instructed to record the best of three 
attempts on the score sheet (see Appendix 5) first thing in the 
morning and before retiring in the evening.  All subjects who 
agreed to record PF were issued with a stamp addressed envelope 
to return their peak flow diaries to the researcher. 
 
Each subject was informed that a random subset of subjects 
would be selected in two weeks, in order to assess the 
repeatability of the Q score.   If selected these subjects would 
receive the Q score and the AQLQ to complete again and would 
be asked to return the questionnaires in a stamp addressed 
envelope (see Appendix 8 for contact letter) to the researcher. 
 
2.4.2 Initial Data Set for Each Subject   
 
 
 55
 record/case sheet number 
 address, phone number 
 date of birth 
 gender 
 GP Practice 
 current smoking habit plus pack years 
 patient allergy status 
 asthma medication and prescribing plan 
 operation of patient self management treatment plan 
 occupation 
 number of hospital admissions in past 6 months 
 number of exacerbations of asthma in past 6 months 
(requiring visit to GP) 
 number of oral steroid prescriptions in past 6 months 
 number of inhaled steroid prescriptions in past 6 months 
 number of inhaled bronchodilator prescriptions in past 6 
months 
 BTS Guidelines treatment step (steps 1-2 or 3-5) 
 predicted spirometry (PEF, FEV1 and FVC) 
 measured spirometry (PEF, FEV1 and FVC) 
 patients expectation for last visit to GP 
 Q score 
 AQLQ 
 HAD 
 
 
 
 
2.4.3 Assessing Q Score Reliability at Two Weeks 
 
In order to assess the reliability and repeatability of the newly 
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devised Q score against a reliable and validated questionnaire, at 
two weeks following the baseline assessment a random sub set of 
subjects was chosen from the initial database.  At each GP 
practice the second subject on the data file was allocated to the 
sub-group followed by each alternate subject. Seventy subjects 
were subsequently contacted at home by sending Q scores and 
AQLQ questionnaires for completion.  Subjects were asked to 
complete the enclosed questionnaires and return them as soon as 
completed to the researcher in a stamp addressed envelope. 
 
2.4.4 Data Collection at Twelve Months 
 
After twelve months each GP practice was contacted and an 
appointment was made in order to access the GP computer files. 
All subjects recruited at the start of the project had their computer 
files rechecked in order to establish if they were still alive (one 
subject deceased at twelve months, cause of death was not related 
to asthma) and were still at the same address.  If they had 
remained with the GP practice they were considered for review. 
Prior to contact the GP's computer files on each subject were 
accessed in order to assess if medication of any subject had 
altered.  Any change was recorded along with the subject's 
respiratory medication prescription (dose and delivery system), 
and uptake of prescription recorded. 
 
One hundred and thirteen subjects seen at the start of the project 
were contacted and invited to attend their GP practice for review. 
Subjects were contacted by telephone in the first instance and 
were offered an appointment at their GP practice or home if 
attendance proved difficult. A letter was sent confirming the 
appointment time and subjects received a telephone call the day 
before their appointment reminding them of the arrangements.  If 
the subjects did not attend the first appointment, they were 
contacted again and offered another appointment at their GP 
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practice or at their own home.  If subjects did not attend for a 
second appointment they were contacted for a third and final time. 
Subjects who did not attend for a third appointment were sent 
copies of the three questionnaires (Q score, AQLQ and HAD) 
with a covering letter asking them to complete the enclosed 
questionnaires, return them in the stamp addressed envelope and 
complete the tear off slip (see Appendix X ). The tear off slip 
asked the subject if the wished to withdraw from the study or 
would consider a home visit for collection of spirometry and PEF 
data. Ninety-five subjects attended, seven withdrew from the 
study at twelve months, eleven refused to attend, were unavailable 
or did not attend despite repeated contact. 
 
Subjects who attended for the twelve-month review were assessed 
using the same procedures for the initial collection of the patient 
data set (see section 2.4.1).  A copy of the twelve-month patient 
data set can be found in Appendix V. 
 
2.4.5 Data Collection at Twenty Four Months 
 
At 24 months the same procedures for contacting the GP practices 
and reviewing subjects were repeated as indicated in section 2.4.1 
and 2.4.4. 
 
One hundred and six subjects seen at the start of the study were 
contacted and invited to attend their GP practice for review (from 
the original cohort of 114 subjects 106 subject were left in the 
study, one died and seven withdrew at twelve months). Ninety 
subjects attended for review at twenty-four months (seventy-nine 
of the ninety had also been seen at twelve months) sixteen 
subjects withdrew or were unavailable. Only one subject had 
moved away from the area over the two-year follow up period. 
 
In summary the number of patients starting and progressing 
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through the study were as follows:- 
 
One hundred and fourteen subjects had been reviewed initially 
with ninety-five subjects presenting for review at twelve months 
and ninety subjects presenting for review at twenty-four months. 
Seventy-nine subjects were assessed at both twelve and twenty-
four months.  One subjects died within the first twelve months 
and one moved from the locality. 
 
Each subject was thanked for their contribution to the study and 
letters of thanks were sent to each GP practice informing them 
that the study was complete and a report of their individual 
practice would be available to them upon request. 
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 Figure 3 Flow Chart of Subject Assessment 
 
   
Baseline         114 subjects recruited to study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 deceased 
 
7 withdrew 
 
 
At 12 Months 
 
           106 subjects in study  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
95 reviewed 11 did not attend (DNA) 
/unable to attend (UTA) 
 
 
 
 
 
 
 
 
 
 
At 24 Months 
 
106 subjects in study 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
1 left 
area 
 
90 reviewed 
 
15 DNA/UTA 
 
 
 
NB: 79 subjects were seen at 12 and 24 months 
 (see Appendix XIII for data) 
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2.5 Data Analysis 
 
All subject data was transferred from paper data files to SPSS for 
Windows v 10.  To facilitate data analysis five distinct files were 
created:- 
 
a) baseline data file for 114 subjects 
b) twelve months data file for 95 subjects  
c) twenty-four month data file for 90 subjects  
d) 24 subjects from the baseline data file who withdrew from the 
study (see Appendix XII) 
e) file for 79 subjects with data recorded at baseline, twelve and 
twenty four months (see Appendix XIII). 
 
Descriptive statistics were used throughout the thesis. 
 
Objective measures of asthma (spirometry and PEF), health status 
(AQLQ and Q score) psychological status (HAD score) prescribed 
asthma medication and asthma severity (BTS Guidelines treatment step) 
were collected throughout the study period  (baseline, twelve and twenty-
four months).  Data were examined for relationships, (correlation design) 
using Spearman rank order correlation coefficient for non-parametric 
data. Non-parametric test were used for analysis with the AQLQ, Q score, 
HAD score and BTS treatment step as scales recorded ordinal level data.  
 
Data were examined for difference, (quasi-experimental design) from 
baseline to twelve months and baseline to twenty-four months using 
paired t test or Wilcoxon sign ranks for all subjects or using unpaired t 
tests or Mann-Whitney U tests for sub-groups. 
 
The level of significance was acceptable at 5% (p<0.05). 
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2.5.1 Sub Division of Analysis 
 
Data from the cohort was subdivided and explored at each stage 
by the following four sub-groups using experimental analysis. 
 
Inner City versus Suburban Subjects 
Subjects were divided by their place of residence and locality of 
GP practice. Two practices were situated in inner city areas with 
high Jarman (1983) deprivation scores (+18.7 and +13.45), two 
practices were situated in suburban areas having low scores for 
deprivation (-19.58 and –18.27). Differences between these two 
groups in relation to their spirometry and PEF, health status, 
psychological status and severity were explored by unpaired t test 
for parametric data or Mann-Whitney U tests for non-parametric 
data. 
 
Severity - BTS Guidelines Treatment Step 1-2 versus 3-5 
Severity of asthma was used to further sub divide subjects within 
the cohort as a whole.  Subjects in low BTS treatment step (1 and 
2) indicating mild to moderate asthma morbidity were assessed 
against subjects in the higher treatment steps (3-5) such subjects 
have less control over their morbidity and require increased 
medication in order to keep symptoms to a minimum (see 
Appendix III).  Differences between these two groups in relation 
to their spirometry and PEF, health status, psychological status 
and place of residence were explored by unpaired t test for 
parametric data or Mann-Whitney U tests for non-parametric data. 
 
Depression and Anxiety - Depressed Subjects versus Non-
Depressed Subjects 
 
Zigmond and Snaith, (1983) used three ranges of scores for 
depression and anxiety.  Their scoring system comprised the 
following scores 0-7, for little to no disorder, 8-10 borderline and 
11 plus significant depression or anxiety.  In this study the cohort 
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was subdivided as 0-7 no depression or anxiety, 8 or above, 
possible depression or anxiety. Differences between these two 
groups in relation to their spirometry and PEF, health status, 
severity and place of residence were explored by unpaired t test 
for parametric data or Mann-Whitney U tests for non-parametric 
data.  
 
Medication Changed - Inhaled Steroids Increased versus Inhaled 
Steroids Reduced/No change 
 
Subjects’ prescription for asthma medication was reviewed at 
twelve and twenty-four months from baseline. The cohort was sub 
divided by subjects who had their inhaled steroid prescription 
increased at the time of the twelve month assessment (twenty-four 
month assessment) when compared to baseline prescription and 
subjects with inhaled steroid prescription remaining as at baseline 
or reduced from baseline. Differences between these two groups 
in relation to their spirometry and PEF, health status, 
psychological status, severity and place of residence were 
explored by unpaired t test for parametric data or Mann-Whitney 
U tests for non-parametric data.  
 
2.5.2 Cross Sectional Data  
 
Baseline Data 
Spearman rank order correlation coefficient was used to explore 
the relationship of subjective measures of asthma such as health 
status (as measured by Q score to AQLQ) and psychological 
status (as measured by HAD scale), to spirometry, PEF, severity 
(as measures by BTS guidelines treatment step) Binary logistic 
regression analysis was used to identify the variable most strongly 
linked to morbidity from spirometry, PEF, psychological status 
and severity. 
Reproducibility of the Q Score 
The reproducibility of the Q score and its' relationship to the 
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symptom domain of the AQLQ was examined by comparing 
baseline scores and scores collected from the random sub set of 
subjects at two weeks using Spearman rank order correlation co-
efficient. Q score and AQLQ symptom scores correlate at 
baseline and at two weeks. The internal consistency of the Q 
score was measured at baseline and within the sub groups using 
Cronbach Alpha. 
 
2.5.3 Longitudinal Data 
 
These data were collated at twelve-month intervals throughout the 
study period (ie, on two subsequent occasions following initial 
assessment). Differences in spirometry, PEF, health status, 
psychological status, severity and medication uptake from 
baseline to twelve and baseline to twenty four months were 
explored for the whole cohort by paired t test for parametric data 
or Wilcoxon signed-ranks test for non-parametric data. 
 
Longitudinal data was also explored by the sub-groups in 2.5.1. 
From baseline to twelve months and baseline to twenty-four 
months using unpaired t tests for parametric data and Mann-
Whitney U tests for non-parametric data. 
 
2.6 Ethical Approval 
 
Approval was sort and gained from the local ethics committee, see 
Appendix XI for copy of letter of approval. 
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CHAPTER 3 
 
 
 
Initial Assessment of One Hundred 
and Fourteen Adult Asthmatics 
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3.1 The Data 
 
This chapter describes the baseline data collected from 114 subjects 
recruited for the study.  This baseline information includes the initial 
patient data set, the AQLQ, Q score and HAD scale.  The data is 
subdivided as stated in section 2.5.1 by inner city versus suburban 
subjects, severity as measured by BTS Guidelines treatment step and 
depression scores.  Relationships between established objective measures 
of assessing asthma (spirometry and PEF) are explored against health and 
psychological status and severity. The relationship of the Q score to the 
AQLQ symptom score is also examined at baseline and at two weeks 
noting the reproducibility of the Q score.  All results are discussed within 
this chapter. 
 
At the initial contact the patient data set was completed for all subjects, as 
was the AQLQ, Q score and HAD scale, (see sections 2.4.1 and 2.4.2). 
Spirometry and PEF were also recorded at this stage.  At two weeks a 
random sub set of subjects were asked to repeat the AQLQ and Q scores 
(see section 2.4.3 and 3.4 where the results are presented).  
 
3.2 Exploring the Baseline Data 
 
The baseline data for the population is reported initially for the whole 
cohort and then to examine relationships within the data set, the cohorts 
are sub divided as described in 2.5.1.  Differences between groups are 
discussed. 
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Table 1: Baseline Values for 114 Asthma Subjects 
 
Variable N=114 % Mean (SD) 
Age (Years)   42 (12) 
Gender (Males) 42 37  
Subjects living in Inner city   74 65  
Current Smoking 31 27  
Current smokers pack years   3.3 (6.4) 
Currently using  agonist 106 93  
Currently using inhaled steroid 95 83  
Currently using oral steroids 8 7  
BTS Guidelines Treatment Step (3-5) 34 30  
PEF   353L/min (126) 
Predicted PEF   463L/min (89) 
FEV1   2.23L (0.89) 
Predicted FEV1   2.99L (0.62) 
FVC   2.90L (0.98) 
Predicted FVC   3.81L (0.72) 
 FEV1/FVC  76  
AQLQ score   4.7 (1.2) 
AQLQ symptom score   4.6 (1.4) 
Q score   2.7 (2.4) 
HAD Anxiety    8.3 (4.3) 
HAD Depression   5.1 (3.9) 
 
3.2.1 An Asthmatic Population 
Table 1 illustrates the initial baseline data for the 114 asthmatic 
subjects. There were more female subjects recruited than males 
(72/42) and more subjects were recruited from inner city GP 
practices than suburban (74/40).  Little over a quarter of subjects 
still smoked (31/114) their mean pack years remaining low (3.3 
6.4).   
 
BTS Guidelines Treatment Step 
Step 1 - Inhaled agonists were used by 93% of the population 
with 18% (21/114) using this type of therapy alone. 
Step 2 - Inhaled steroids were used by the majority of subjects 
with 52% (59/114) of the population using low dose inhaled 
steroids. 
 
Steps 3-5 - Subjects in these treatment steps, 3-5 accounted for 
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30% of the population (34/114). There were 22/114 (20%) of 
subjects in step 3, these subjects required high dose inhaled 
steroids. With 6/114 (5%) of subjects each in treatment steps 4 
and 5. 
 
Few subjects used other prescribed medication for their asthma on 
a regular basis (theophylline, anticholinergics or sodium 
cromoglycate). 
 
The population was comprised of relatively stable asthmatics with 
only two subjects admitted to hospital in excess of 24 hours for 
their asthma in the preceding six months prior to the 
commencement of the study. Sixty percent (68/114) of the 
population did not experience an exacerbation of their asthma in 
the same period and of the subjects who did, 63% (29/46) 
received one or more courses of oral steroids for relief of 
symptoms. 
 
If subjects attended their GP practice for their asthma, subjects 
were asked what their expectations were for the visit.  Fifty 
percent of the population required better control of their asthma 
symptoms with 10% complaining specifically of sleep 
disturbance. 
 
The GP practice was also assessed at the outset of the study as to 
adherence to and awareness of current guidelines recommended 
for practice with asthma. All practices said they adhered to 
current guidelines eg, by prescribing peak flow meters for 
patients, issuing patients with self-management plans and advice 
on increasing medication.  No practice had a dedicated GP for 
asthma or an asthma nurse, though all practices had a GP with an 
interest in asthma management.  The practice nurse at each 
practice ran specific asthma clinics but only one practice ran 
clinics on a regular basis as recommended. 
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 Spirometry and PEF were recorded for all subjects and were 
compared to predicted values for age, height and gender (Cotes, 
1993).  Recorded values for spirometry and PEF were less 
(though not significantly so) than predicted with FEV1/FVC at 
76% of predicted. 
 
Mean values for health status scores as measured by AQLQ and 
the newly devised Q were 4.7 and 2.7 respectively.  The AQLQ 
score ranges from 1-7, the lower the score the greater the 
infringement on health status, the baseline score (4.7) indicates 
only moderate interference in QoL for the cohort. Q score ranges 
from 0-8, the higher score represents increased morbidity, mean 
value for the cohort was 2.7 mirroring the AQLQ score and 
indicating a relatively active population.  
 
Psychological status was assessed by the HAD scale. The mean 
depression value for the cohort was below the threshold of eight 
(5.13.9) indicating no depression while the mean anxiety score 
was recorded as (8.3 4.3) just over the threshold of eight points 
which would indicate slight anxiety. 
 
3.2.2 Relationship of Quality of Life Measures to Lung Function and 
Psychological Status 
 
Spearman's rank order correlation coefficients for relationships in 
the baseline data are illustrated in Table 2.  The newly devised Q 
score inversely correlates (p<0.01) to the established AQLQ 
symptom score and overall AQLQ (both p<0.01) reflecting the 
similar levels of patient health status (see Figures 4 and 5). 
 
 
 
 
 
 
Table 2: Spearman's Rank Order Correlation Coefficients for 
the Baseline Data 
 
 HAD Depression 
HAD 
Anxiety PEF FEV1 
PEF -.160* -0.095  .812** 
FEV1 NS -0.01 .812**  
AQLQ total  -.359** -.359** .310** .316** 
AQLQ symptom -.433** -.352** .396** .351** 
Q score -.371** 0.238** -.444** -.417** 
BTS  (3-5) -.240** NS NS NS 
HAD Depression  .602** -.160* NS 
HAD Anxiety .602**  NS NS 
 
 AQLQ Total 
AQLQ 
Symptom Q Score 
BTS 
(3-5) 
PEF .316** .396** -.444** NS 
FEV1 .316** -.417** -.417** NS 
AQLQ total   .898** -.678** .217* 
AQLQ symptom -.898**  -.762** .248** 
Q score -.678** -.762**  -.415** 
BTS  (3-5) .217* .248** .414**  
HAD Depression -.509** -.433** .371** -.240** 
HAD Anxiety -.359** -.352** .238** NS 
 
Key ** = p<0.01, * = p<0.05, NS = not significant. 
 
 Figure 4 - Scatterplot of the Q scores relationship to AQLQ 
symptom score (p<0.01). 
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Key: circle and each subsequent point on all scatterplots 
denotes one subject. 
 Figure 5 – Scatterplot of the Q scores relationship to AQLQ 
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score (p<0.01). 
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AQLQ total score and symptom score directly correlate 
significantly (all p<0.01) to worsening levels of PEF and FEV1. 
Subjects with reduced spirometry and PEF i.e. poor lung function 
due to poor control of the disease process and their associated 
morbidity have increased symptom scores indicating reduced 
health status. Figures 6, and 7 illustrate the relationship of 
morbidity as measured by AQLQ symptom score to PEF and 
FEV1. Figures 6a, and 7a illustrate the relationship of morbidity 
as measured by AQLQ symptom score to predicted PEF and 
FEV1. 
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 Figure 6 – Scatterplot of lung function (as measured by PEF) to 
morbidity (as measured by AQLQ symptom score) (p<0.01). 
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 Figure 6a - Scatter plot of baseline PEF as a percentage of 
predicted PEF to morbidity (as measured by AQLQ symptom 
score) (p<0.01) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 7 – Scatterplot of lung function (as measured by FEV1) to 
morbidity (as measured by AQLQ symptom score) (p<0.01) 
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 Figure 7a - Scatterplot of baseline FEV1 as a percentage of 
predicted FEV1 to morbidity (as measured by AQLQ symptom 
score) (p<0.01) 
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Health status as measured by AQLQ inversely correlated (p<0.05) 
with increased levels of treatment as measured by BTS Guidelines 
treatment step (Steps 3-5) indicating subjects with increased 
levels of treatment have reduced QoL.  Increased levels of 
morbidity (low AQLQ symptom score) inversely correlated with 
increased treatment step (p<0.01), (see Figures 8 and 9). 
 
Subjects requiring more medication to control symptoms 
registered higher scores on the morbidity indices used.  Although 
lung function (FEV1) and PEF correlated to the overall AQLQ 
and morbidity scores, they did not correlate to increased levels of 
treatment (not significant for both). 
 
 Figure 8 – Scatterplot of BTS Guidelines Treatment Step to 
AQLQ score (p<0.01) 
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 Figure 9 Scatterplot of BTS Guidelines Treatment Step to AQLQ 
symptom score (p<0.01) 
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The higher the AQLQ scores the fewer the symptoms of asthma 
and the greater the QoL. BTS treatment step 1-2 requires low 
dose medication to keep asthma symptoms to minimal, higher 
dose treatment steps 3-5 requires more medication to keep 
symptoms to minimum. 
 
Depression scores correlated with health status (AQLQ) and 
morbidity (inversely with AQLQ symptom score and directly 
with Q score) and severity of asthma (treatment steps 3-5) all 
p<0.01 but weakly correlated to levels of PEF (p<0.05).   
 
Figures 10 and 11 illustrate the relationship of subjects with 
increased symptom scores to higher depression scores (see also 
Figure 12, this illustrates mean HAD depression scores for 
patients with different Q scores and shows that subjects with more 
symptoms of asthma i.e., higher Q scores exhibit higher HAD 
depression scores).  Levels of anxiety as measured by the HAD 
score also correlate to QoL scores (all p<0.01) but not to levels of 
lung function or asthma severity. 
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  Figure 10 - HAD Depression score correlates directly to 
increased morbidity as measured by Q score (p<0.01). 
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 Figure 11 – HAD depression score correlates inversely to 
increased morbidity as measured by AQLQ symptom score 
(p<0.01). 
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 Figure 12 – Mean HAD depression scores for subjects with 
different Q scores. 
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Binary logistic regression analysis was used to determine the 
influence of psychological status on reported symptoms after 
controlling for lung function and BTS treatment step. Symptoms 
were measured by Q score ( 4 or > 4) and by AQLQ symptom 
score ( median of 4.9, > median). Whichever score was used to 
measure morbidity, after controlling for lung function and 
severity both anxiety and depression added significantly to the 
predictiveness of the model (Table 3 gives a summary of the 
relationship between HAD depression and morbidity after 
adjustment for PEF and severity). 
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Table 3: Summary statistics for symptoms (Q score and 
AQLQ symptom score) by PEF, BTS Guidelines treatment 
step and HAD depression 
 
   
Q Score AQLQ Symptom score 
PEF BTS 
Step 
HAD 
Depression 
%  4 Mean 
Score (SE)
%  
 median of 
4.9 
Mean 
score 
(SE) 
359 1-2  4 20% (4/20) 2.3 (0.4) 35% (7/20) 5.2 (0.2) 
  > 4 47% (8/17) 3.6 (0.7) 77%(13/17) 3.8 (0.4) 
 3-5 4 40% (2/5) 3.2 (0.8) 40% (2/5) 5.0 (0.6) 
  > 4 79%(11/14) 5.3 (0.7) 93% (13/17) 3.1 (0.3) 
359 1-2 4 14% (3/22) 1.3 (0.4) 27% (6/22) 5.4 (0.3) 
  > 4 6% (1/17) 1.5 (0.3) 53% (9/17) 5.0 (0.5) 
 3-5 4 43% (3/7) 3.3 (0.6) 29% (2/7) 5.3 (0.5) 
  > 4 50% (3/6) 4.3 (1.4) 67% (4/6) 4.0 (0.8) 
 
The higher the Q score, or the lower the AQLQ symptom score 
the greater the symptoms.  Also the higher the depression score 
the worse the depression.  
 
PEF is split by the overall median of 359. 
 
HAD Depression is split by over all median of 4. 
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3.2.3 The Population by Place of Residence 
 
Four GP Practices were recruited, two were situated in inner city 
areas and two in suburban areas, this reflects a differing socio-
economic subgroup based on Jarman scores (Jarman, 1983) for 
the wards the GP practices cover. The population was divided by 
their place of residence, inner city versus suburban.  Table 4a and 
b illustrate the baseline data for this sub division. Sixty-five 
percent (74/114) of the original cohort resided and attended GP 
practices within the inner city, while thirty-five percent (40/114) 
of the original cohort resided and attended GP practices within the 
suburbs. The internal consistency of the Q score within the sub-
groups was assessed by Cronbach Alpha (Alpha = 0.8367 for 
inner city subjects and 0.6283 for suburban subjects). Reliability 
of the Q score was below the accepted level of 0.75 for the 
suburban sub-group.  
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Table 4a: Baseline Data for Inner City Subjects 
 
Variable N=74 % Mean (SD) 
Age (Years)   41 (12) 
Gender (Male) 26 35  
Currently Smoking 27 37  
Currently using  agonist 68 92  
Currently using inhaled steroid 63 85  
Currently using oral steroids 4 5  
BTS Guidelines Treatment Step (3-5) 20 27  
PEF   348L/min (131) 
Predicted PEF   461L/min (86) 
FEV1   2.20L (0.94) 
Predicted FEV1   2.99L (0.61) 
AQLQ score   4.5 (1.3) 
AQLQ symptom score   4.3 (1.5) 
Q score   3.0 (2.6) 
HAD Anxiety   9.46 (4.1) 
HAD Depression   5.9 (4.2) 
 
 
Table 4b: Baseline Data for Suburban Subjects 
 
Variable N=40 % Mean (SD) 
Age (Years)   42 (12) 
Gender  (Male) 16 40  
Currently Smoking 4 10  
Currently using  agonist 38 95  
Currently using inhaled steroids 32 80  
Currently using oral steroids 4 10  
BTS Guidelines Treatment Step (3-5) 14 35  
PEF   363L/min (116) 
Predicted PEF   469L/min (95) 
FEV1   2.3L (0.89) 
Predicted FEV1   3.0L (0.64) 
AQLQ score   5.1 (0.94) 
AQLQ symptom score   5.1 (1.2) 
Q score   2.1 (1.7) 
HAD Anxiety   6.1 (3.8) 
HAD Depression   3.7 (2.7) 
 
Although there were more subjects recruited from the inner city 
(74/40) no significant differences were noted in levels of recorded 
spirometry, PEF, prescribed medication, severity, QoL or 
morbidity. At each level of treatment (steps 1-5) inner city 
patients recorded higher morbidity scores and depression scores 
(see Figures 13, 14 and 15). The inner city cohort was however 
significantly more anxious (p<0.001) more depressed (p<0.01) 
and consumed more cigarettes (p<0.01) than their suburban 
neighbours. 
 
 Figure 13 – Mean AQLQ symptom score plotted against BTS 
Guidelines treatment step for subjects from inner city and 
suburban areas. 
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 Figure 14 - Mean HAD Depression score plotted against BTS 
Guidelines treatment step for subjects from inner city and 
suburban areas 
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 Figure 15 – Mean Q score plotted against BTS Guidelines 
treatment step for subjects from inner city and suburban areas. 
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3.2.4 Psychological Status and the Asthmatic, Depressed versus Non-
pressed Subjects 
 
The psychological status of the cohort was assessed using the 
HAD scale, subjects were subdivided into two groups of non-
depressed subjects with scores of 7 or less and depressed with 
scores of 8 or more according to the HAD scale.  The HAD scale 
allows for borderline depression with scores of eight and above. 
Subjects with scores of eight or higher on the HAD scale were 
assigned to the depression group, 27% (30/113) subjects from the 
original cohort were regarded as depressed. Subjects with scores 
of seven or less on the HAD scale were assigned to the non-
depressed group, 73% (83/113) subjects from the original cohort 
were regarded as non-depressed. Data for the two groups is 
presented in Table 5a and b. The internal consistency of the Q 
score within the sub-groups was assessed by Cronbach Alpha 
(Alpha = 0.8293 for inner city subjects and 0.7598 for suburban 
subjects). Reliability of the Q score was greater in the depressed 
sub-group than the non-depressed although both were above the 
accepted level of 0.75.  
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Table 5a: Baseline Data for Depressed Subjects 
 
Variable N=30 % Mean (SD) 
Age (Years)   46 (10) 
Gender (Male) 11 37  
Currently Smoking 10 33  
Currently using  agonist 27 90  
Currently using inhaled steroids 25 83  
Currently using oral steroids 3 10  
BTS Guidelines Treatment Step (3-5) 12 40  
PEF   331/min (143) 
Predicted PEF   461L/min (92) 
FEV1   2.16L (0.92) 
Predicted FEV1   2.90L (0.65) 
AQLQ score   4.0 (1.35) 
AQLQ symptom score   4.0 (1.61) 
Q score   3.82 (1.61) 
HAD Anxiety   12.10 (4.11) 
HAD Depression   10.5(2.77) 
 
Table 5b: Baseline Data for Non-Depressed Subjects  
 
Variable N=83 % Mean (SD) 
Age (Years)   41 (12) 
Gender (Male) 31 37  
Currently Smoking 21 25  
Currently using  agonist 78 94  
Currently using inhaled steroids 69 83  
Currently using oral steroids 5 6  
BTS Guidelines Treatment Step (3-5) 21 25  
PEF   360L/min (119) 
Predicted PEF   466L/min (89) 
FEV1   2.25L (0.84) 
Predicted FEV1   3.04L (0.61) 
AQLQ score   5.02 (1.07) 
AQLQ symptom score   4.96 (1.32) 
Q score   2.24 (2.14) 
HAD Anxiety   6.92 (3.51) 
HAD Depression   3.24 (2.08) 
 
The majority of the cohort (73%, 83/113, one subject’s HAD 
scores were not recorded) were not depressed having a mean 
score of 3.24, this was significantly lower than the depressed 
group of 10.5 (p<0.001), as was their anxiety score of 6.92 
compared to 12.10 (p<0.001). This sub division revealed little 
difference in the observations between the two groups for 
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spirometry, PEF, prescribed medication, severity, QoL, and 
morbidity or smoking habit (all weakly significant, p>0.05). 
 
3.2.5 Severity of Asthma According to BTS Guidelines Treatment Step, 
Groups 1-2 versus 3-5 
 
Baseline data for subjects divided by BTS guidelines treatment 
step 1 to 2 and 3 to 5 is shown in tables 6a and 6b. Asthma 
subjects requiring minimal medication to reduce symptoms, BTS 
Guidelines Treatment Step 1-2 are shown in table 6a. Asthma 
subjects requiring moderate use of medication to minimise 
symptoms, BTS Guidelines Treatment Step 3 to5 are shown in 
table 6b. The internal consistency of the Q score within the sub-
groups was assessed by Cronbach Alpha (Alpha = 0.7416 for 
subjects in steps 1-2 and 0.7872 for subjects in steps 3-5). 
Reliability of the Q score was just below the accepted level of 
0.75 in steps 1-2.  
 
 
 84
Table 6a: Baseline Data for Subjects as per BTS Guidelines 
Treatment Step 1 and 2 
 
Variable N=80 % Mean (SD) 
Age (Years)   40 (12) 
Gender (Male) 27 34  
Currently Smoking 23 29  
Currently using  agonist 72 90  
Currently using inhaled steroids 61 76  
PEF   358L/min (117)
Predicted PEF   461L/min (89) 
FEV1   2.28L (0.80) 
Predicted FEV1   3.0L (0.61) 
AQLQ score (p<0.05)   4.9 (1.1) 
AQLQ symptom score (p<0.01)   4.9 (1.3) 
Q score (p<0.001)   2.0 (2.0) 
HAD Anxiety   8.2 (4.6) 
HAD Depression (p<0.05)   4.6 (4.0) 
 
 
Table 6b: Baseline Data for Subjects as per BTS Guidelines 
Treatment Steps 3 to 5 
 
Variable N=34 % Mean (SD) 
Age (Years)   46 (10) 
Gender (Male) 15 44  
Currently Smoking 8 24  
Currently using  agonist 34 100  
Currently using inhaled steroids 34 100  
Currently using oral steroids 6 18  
PEF   340L/min (145) 
Predicted PEF   471L/min (90) 
FEV1   2.10L (0.90) 
Predicted FEV1   2.95L (0.65) 
AQLQ score   4.2 (1.3) 
AQLQ symptom score   4.0 (1.5) 
Q score   4.3 (2.4) 
HAD Anxiety   8.5 (4.5) 
HAD Depression   6.3 (3.5) 
 
 
Table 6a and b illustrate that the majority of subjects (71%) are 
contained in BTS step 1-2, requiring the use of agonists alone or 
with low dose inhaled steroids.  Again little difference was 
exhibited in the observations between the two groups for 
spirometry, PEF, prescribed medication or smoking habit (all 
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p>0.05).  Symptom scores as measured by Q score (p<0.001) and 
AQLQ symptom score (p<0.01) were significantly different 
between the two groups as was the HAD depression score 
(p<0.05) but not anxiety.  Subjects who's asthma was more 
unstable (group 3-5) required more medication to minimise their 
symptoms and symptom scores recorded were higher for the Q 
score (4.3 versus 2.0) and AQLQ symptom score (4.9 versus 4.0). 
Subjects with poor symptom control were slightly more depressed 
(HAD depression, p<0.05).  
 
3.3 The Reliability of the Q score as a Simple Patient Focused Morbidity 
Index 
 
Reporting and symptoms monitoring play a key role in modern asthma 
management. The clinician should inquire regularly as to the patients’ 
current symptom status.  By regular monitoring an attempt can be made 
to reduce symptom levels to those acceptable to the patient when coping 
with activities of daily living. The problem remains that health 
professionals do not always ask the correct questions at an appropriate 
time (Keeley, 1993). Patients can present for repeat prescription without 
monitoring of symptoms or indeed attend the GP practice (seeing either 
nurse or doctor) without having their asthma symptoms checked or 
recorded. 
 
Although there are a number of respiratory and asthma specific 
questionnaires within the current literature that contain sections relating 
to morbidity many are too long to be of use in the busy clinic setting 
(Hyland et al, 1991, Juniper et al, 1992). The Q score asks those 
questions that the clinician should use in order to assess symptoms.  The 
Q score rather like the Jones’ score (Jones et al, 1992b) is quick and easy 
to administer in any routine clinical intervention.  In order to assess the 
validity of the Q score in the clinical setting it was administered at the 
same time as the AQLQ, a reliable and validated questionnaire. Internal 
consistency of the Q score was assessed at baseline for the whole cohort 
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(Alpha = 0.8006) indicating good internal consistency within the four 
questions. 
 
The Q score was developed following consultation with a variety of 
health professionals with a specific interest in asthma management. As 
stated by Steen et al, 1994 “the key problem with the estimation of 
validity is that there is no gold standard to act as criterion”. This study 
used an “expert panel” to select questions and an asthma specific tool to 
assess the newly devised Q score’s validity. 
 
3.3.1 The Relationship of the Q score to the AQLQ 
 
Section 3.2.2 (Figures 4 and 5) illustrates the relationship of the 
baseline Q score for the cohort of subjects to the AQLQ. The Q 
score correlates to the AQLQ symptom score (p<0.01) and the 
complete AQLQ that assesses the subjects HRQL (p<0.01). 
Subjects who have poor control of symptoms with the Q score 
also record increased symptoms when assessed by the AQLQ 
symptom domain and subjects with high Q scores recorded poorer 
QoL scores.  Symptoms of wheeze and breathlessness are 
common to both scores as well as disturbed sleep and interference 
in activities of daily living.  The Q score would seem to relate 
well to an already validated asthma specific questionnaire. 
 
The relationship of symptoms to PEF and severity was explored 
in section 3.2.2 using the AQLQ symptom score (see Figures 6 
and 7 and 8 and 9).  Morbidity when assessed by AQLQ symptom 
score correlated to severity and PEF (both p<0.01).  According to 
Jones and Mullee, (1995) when health related questionnaires are 
seeking validity, they should ensure scores are related to the 
severity of the disease itself.  When assessed by the Q score the 
relationship to PEF and severity is similar (see Figures 16 and 17, 
both p<0.01 and 18) to those of the AQLQ symptom score thus 
fulfilling Jones recommended requirements. Figures 16a and 17a 
show the relationship of the Q score at baseline to predicted lung 
function and spirometry. 
 
 Figure 16 – Scatterplot of Q score’s relationship to PEF at 
baseline (p<0.01). 
 
 
 
 B a s e lin e  P E F R
8 0 07 0 06 0 05 0 04 0 03 0 02 0 01 0 00
Ba
sl
ei
ne
 Q
0 R s q  =  0 . 2 0 8 5  
 s
co
re
8
6
4
2
 
 
 87
 
 
 
 
 
 
 
 
 
 Figure 16a - Scatterplot of baseline PEF as a percentage of 
predicted PEF to morbidity (as measured by Q score) (p<0.01) 
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 Figure 17 - Scatterplot of Q score’s relationship to lung function 
(FEV1) at baseline (p<0.01) 
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 Figure 17a - Scatterplot of baseline FEV1 as a percentage of 
predicted FEV1 to morbidity (as measured Q score) (p<0.01) 
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 Figure 18 – Scatterplot of relationship of baseline Q score to 
BTS Guidelines treatment steps 1 to 5 (p<0.01). 
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3.3.2 Test Re-test Reliability 
 
The reliability of the Q score was assessed by test re-test 
reliability (see section 2.4.3). Following the collection of baseline 
data a random sub set of subjects were selected (every alternate 
subject) and sent a copy of the Q score and AQLQ score at two 
weeks. Thirty-nine subjects (39/70) returned their questionnaires. 
The repeat Q score at two weeks correlated with initial 
determinations with a correlation coefficient of 0.61. In 25% 
(10/39) of repeat cases the Q score was exactly the same as first 
reported. In 54% (21/39) it agreed to within one unit and in 82% 
(32/39) it agreed to within two units.  However, it should be noted 
the Q score reflects upon symptoms in the past week while the 
AQLQ has a two week reflective period.  The AQLQ score runs 
from 1 to 7 and correlation was 0.67 with 67% (26/39) agreement 
to within one unit and 92% to within two units.  Allowing for the 
variable nature of asthma the Q score would appear to be almost 
as reliable as the AQLQ.  The Q score does not assume to be as 
sensitive a tool for assessing outcome as the longer AQLQ. It can  
however be considered as an indicator thus the proximity of the 
relationship to the AQLQ would appear to be satisfactory. 
Scatterplots in figures 19, 20 and 21 illustrate the relationship of 
Q score to AQLQ symptoms score at two weeks and baseline Q 
score to re test Q score and baseline AQLQ symptom score to re 
test AQLQ symptom score. 
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 Figure 19 - The relationship of Q score to AQLQ at two weeks 
(p<0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 20 - Scatterplot illustrates the relationship of baseline Q 
score to re test at two weeks (p<0.01) 
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 Figure 21 - Scatterplot illustrates the relationship of baseline 
AQLQ to re test at two weeks (p<0.01) 
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3.3.3 The Use of a Simple Patient Focused Morbidity Score – The Way 
Forward for the Q Score 
 
The AQLQ reflects morbidity and it can be seen that the Q score 
also reflects morbidity in the same way (see Figures 4 and 5). The 
Q score correlates to the AQLQ symptom score at baseline and at 
two weeks and reflects PEF and severity in a similar manner (see 
Figures 16, 17, 19, 20, and 21). The Q score is a simple 
questionnaire as it asks only four questions. It is patient focused, 
asks questions that are relevant to the patient and is specific to 
their asthma symptoms. The result gives the clinician and patient 
an indicator as to the patient’s control of asthma morbidity. The Q 
score is not a sensitive tool but does indicate whether the patient 
requires further assessment. 
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Asthma management as advised by current guidelines looks at 
symptom reduction as a positive outcome for patients.  If patients 
can understand the objectives of management sharing in the goals 
of treatment then patients are far more likely to comply with 
treatment plans.  Desired outcome by the clinician must also be 
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those desired by the patient if any success is to be achieved. 
Therefore, an outcome measure that asks questions the patient 
deems important is more likely to elicit an objective response 
from the patient. Questions must be relevant to asthma and the 
patient. Patients will often visit their GP only when symptoms 
become a problem that interferes or disturbs their activities of 
daily living. Sleep disturbance can be an important factor in the 
management of asthma morbidity.  In the study population 52% 
of subjects visited their GP because asthma symptoms prevented 
sleep.  The reduction of sleep disturbance must be considered as 
an important outcome measure for patients. 
 
The Q score is asthma specific and aims to indicate whether the 
patient has a satisfactory health outcome (few symptoms) or an 
unsatisfactory health outcome (increased symptoms) at a given 
point in time. The Q score is intentionally brief and three of the 
four questions have been identified in a recent publication by the 
Royal College of Physicians, Clinical Effectiveness Unit (Pearson 
and Bucknall, 1999) and are considered relevant to patient 
assessment.  
 
The Q score can be used as a crude assessment tool, indicating 
patient control of asthma symptoms. Scores greater than four can 
indicate poor control reflecting incorrect treatment step while 
scores below four can indicate good symptom control. Such 
assumptions could act as a filter eg, when patients’ contact GP 
practices by telephone requesting repeat prescriptions and any 
known asthma patient could be assessed by the Q score.  Positive 
(low) scores would allow repeat prescriptions while high scores 
could be used to advise patients to attend the practice for further 
assessment and review in order to reduce morbidity. 
Resulting scores could be collected on a regular basis thus 
creating an opportunity to monitor subjects and the practice over 
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long periods. The potential exists to not only monitor a single 
patient or practice but any patient who attends any GP practice, 
outpatient clinic. If collected on a national basis the Q score could 
be used as part of a larger more complex tool assessing overall 
quality of asthma management and the response to published 
national guidelines. The delivery of appropriate care and the 
development of  “good practice” (as found in published 
guidelines) in the primary care setting could be promoted if 
outcome measures such as the Q score were adopted for routine 
practice. This should be carried out in association with PEF 
monitoring although the problems associated with continuos 
monitoring have previously been noted. 
 
A simple straightforward measure for outcome is more likely to 
be accepted in routine practice by patient and health care 
professional (Keeley, 1999). The measure needs to accurately 
record the patients’ symptoms at that intervention. The 
information recorded must be simple in order to be correctly 
recorded and interpreted by all members of the health care team. 
The Q score is practicable to collect at every consultation and 
gives the professional worthwhile feedback with regard to the 
patient’s asthma status. It asks questions relevant to all asthmatic 
subjects and uses a time frame that is easily recognisable to 
patients. From initial testing the Q score is reliable and valid 
when compare to existing HRQL questionnaires. 
 
The Q score is not alone in its approach, indeed, it has a common 
theme evident in the work of Jones et al, (1992b), Jones et al, 
(1999), and the GRASSIC study (Osman et al, 1996).  Such 
systems emphasise their simplicity, commenting that other 
questionnaires are available but are too lengthy for use in 
everyday clinical practice (Rimington et al, 1997).  These tools 
also stress that they are specific to asthma, quick and easy to use, 
yet ask questions that are relevant to the patient as an outcome 
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measure. Their scoring system can be used to audit outcome for 
single patients or a GP practice.  At no time do such scores assess 
the process of care given, they simply reflect outcome. 
 
In a recently held Royal College of Physicians (RCP, London) 
seminar a variety of tools in use nationally for assessing asthma 
were examined (Pearson and Bucknall, 1999). The seminar 
presented a diversity of tools relating to patient focused morbidity 
including the Q score.  There was a consensus of agreement at the 
end of the seminar to which the Q score was able to concur. The 
main elements of a patient focused morbidity tool were 
summarised in the subsequent report following the RCP seminar. 
The Q score was able to concur with the following points raised:- 
 
 The tool should be useful for adult asthma patients (age 
16 and over) 
 The tool should be asthma specific 
 Is appropriate for all asthma patients irrespective of 
severity 
 Questions used within the tool are specific to asthma 
symptoms 
 The tool asks questions relating to night-time disturbance, 
daytime wheeze and affect on activities of daily living 
 The questions are asked at every visit to GP practice 
 The tool is capable of being recorded at any asthma 
intervention in primary or secondary care 
 
 
 
The Q score is applicable to adult asthma patients. The seminar 
discussed the inclusion of paediatric assessment but as the 
guidelines for management are different, an inclusive tool seemed 
inappropriate.  Questions included in the Q score are specifically 
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related to asthma patients and their symptoms. The Q score 
provides basic information that can indicate which patients may 
require further assessment and is envisaged as a simplistic 
outcome measure as opposed to a diagnostic tool. Questions 
relating to asthma symptoms are common to all patients 
regardless of their severity. Any asthma patient regardless of the 
severity of their disease and level of treatment step can experience 
wheeze, nights waking from sleep and disturbances in activities of 
daily living.  The comments from the seminar came out strongly 
in favour of recording information at every contact.  The 
information gathered from the Q score is quick and simple to 
obtain and record making it ideal to transfer to a simple computer 
based record system. 
 
The Q score did not fulfil all recommendations of the seminar. 
The RCP report did recommend the use of a minimum of three 
questions with the possibility of expansion if a positive response 
was initially given. While the yes/no response allows no room for 
error, it lacks sensitivity.  Jones et al, 1992a commented that 
when the morbidity index was piloted many centres concluded 
simple yes/no responses were as time consuming as could be 
allowed. Yet the Tayside Asthma Management Initiative report a 
simple scoring system expanded from the yes/no response is 
achievable and collectable and have reported their results 
(Hoskins et al, 1998). 
 
The Q score does not fulfil the recommendation for yes/no 
scoring as the scores achieved relate to days of the week and do 
not allow for expansion. However, the core three questions 
recommended in the RCP report are incorporated in the Q score 
despite the lack of opportunity for expansion.  Also included in 
the Q score is a question relating to the use of agonist inhalers, 
this was felt to be more accurately recorded if prescription files 
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were accessed rather than to rely on patient reporting. 
 
However, the core areas addressed by the RCP seminar were 
incorporated into the Q score. The Q score is asthma specific and 
gives an indication of outcome for the patient and would therefore 
seem to be a useful and worthwhile tool for further research.  
Jones et al, 1999 comment on the need for a simple asthma 
outcome measure which can be used in any clinical setting, 
“Patients will have better understanding of the goals of treatment 
if professionals agree on the on these and work towards achieving 
then in a coherent manner.” The Q score will be assessed in the 
primary health care setting over a two-year period. 
 
3.4 Discussion - The Characteristics of an Asthma Population 
 
The characteristics of the population used in this study and the 
relationships within the data are described in section 3.4.1.  The results 
reported and conclusions drawn are highly dependent on the population 
used.  The intention was to study a stable asthmatic population over the 
two-year period. It was therefore necessary to establish that the subjects 
presented are representative of a typical population which can be found in 
any primary health care setting. Section 3.4.2. sets out the argument to 
support this study cohort as representative of a typical primary care based 
asthma population. 
 
3.4.1 The Diagnosis of Asthma for the Study Population 
 
A protocol deliberately designed to study a typical group of adult 
asthmatics to be found in primary care was used (see section 2.2). 
Subjects selected for this study all came from the practice asthma 
register, a primary health care physician was in most cases 
responsible for the diagnosis of asthma thus the subject was 
placed on the practice register. The GP diagnosis for asthma was 
accepted, as all practices stated they adhered to BTS Guidelines 
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(Thorax, 1993) for the diagnosis and management of asthma. BTS 
Guidelines insist correct diagnosis is essential.  In addition a 
requirement that all subject participating in the study should in the 
preceding six months have collected two or more scripts for 
agonist or inhaled steroids was included. Thus the GP had 
diagnosed asthma and the patient had deemed it worthwhile to 
collect repeat scripts  (see 2.2.4). If subjects who do not have 
asthma are treated as such with an increasing variety of 
medications including systemic steroids they will be exposed to 
risk of steroid use with little gain.  Any presentation of asthma 
like symptoms requires close examination to ensure correct 
diagnosis. The diagnosis of asthma is commonly made by 
establishing the episodic nature of the disease with its associated 
variability in airways obstruction (NAEP, 1997). 
 
When assessing subjects a detailed history noted the following 
items:- 
 
 Presenting symptoms, which may include wheeze, cough, 
dyspnoea, chest tightness and disturbed sleep. 
 Past respiratory symptoms such as repeated upper and 
lower respiratory tract infections. 
 Trigger factors, including exposure to cold air, exercise, 
allergen or infection. 
 Pattern of symptoms, often nocturnal or episodic. 
 There may also be a familial history of asthma, eczema or 
hay fever. 
 
 
As asthma is an episodic condition, physical examination may 
appear normal when the subject is symptom free and symptoms 
vary from subject to subject.  It is a recommendation of guidelines 
that subjects who may have asthma have their PEF monitored to 
 
 98
ascertain any variation in PEF.  Guidelines state subjects should 
record the best of three attempts first thing in the morning and last 
thing at night noting these over a two-week period.  A variation in 
PEF of 15% or more is diagnostic of asthma.  At the initial 
assessment subjects were included into the study if they fulfilled 
the inclusion criteria. It was the intention of the study to review 
GP asthma diagnosis by asking all subjects with a PFM to record 
PF over a two-week period as per BTS guidelines thus ensuring 
the credibility of the population used. Despite 63% (72/114) of 
the population stating they had received a PFM as part of their 
self management plan in order to monitor their asthma, of the 
subjects asked to record PF readings only 17/72 subjects returned 
their monitoring forms. This additional diagnostic test for asthma 
was therefore abandoned at an early stage and the GP diagnosis of 
asthma was unchallenged unless there was clear evidence from 
their practice records that elements for exclusion existed. 
 
Many internationally published guidelines comment on the 
sporadic nature of symptoms associated with the diagnosis of 
asthma (Woolcock et al, (1989), from Australia and New 
Zealand, Hargreaves et al, (1990), from Canada, Thorax, (1997) 
for UK and NAEP, (1997) for the USA). All subjects were 
repeatedly asked to comment on their asthma morbidity in the 
AQLQ and Q score questionnaires at each intervention thus 
assessing their symptoms at that particular moment in time. It is 
accepted that responses will be dependant upon the subjects 
fluctuating asthma status but as this study took place over a two 
year period this should have assisted in avoiding problems 
associated with such short term exacerbation. 
If published guidelines were adhered to as stated by all GP 
practices then all subjects were correctly placed on the asthma 
register making them suitable for inclusion in the study. 
Following the implementation of the NAEP guidelines in the 
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USA, primary care physicians were asked to comment on their 
adherence to nationally published guidelines (Legorreta et al, 
1998, Picken et al, 1998).  Of the cohort surveyed by these 
authors a positive response to the guidelines was given but local 
interpretation ensured the minimum use of PF meters for the 
assessment of all asthma subjects. Picken and colleagues 
suggested this may be due to clinicians not feeling all guidelines 
are pertinent to their patients and practice. This may account for 
the lack of compliance with guidelines by some patients, a direct 
result of the influence exerted by some practitioners on their 
patients. 
 
When the dissemination of UK guidelines were assessed by 
Partridge et al, (1998) the number of GP and practice nurses 
responding positively to guidelines was high (82% and 79% 
respectively).  Many practitioners agreed guidelines affected their 
approach to asthma management but the adherence to guidelines 
and the recommendation for the use of PF meters to record the 
variable nature of asthma was not recorded.  It would seem that 
the cohort of asthma subjects in this study have been equipped 
with the tools to monitor their asthma (63% were supplied with 
PF meters) few (15%) complied with the use when requested.  
Observational studies such as this may therefore be useful in 
assessing the impact of national guidelines on local practice and 
more importantly the clinicians own interpretation and 
implementation. 
 
 
 
Published guidelines also acknowledge the problem of a 
definitive diagnosis for asthma as an obstructive but reversible 
disorder that excludes any confusion with COPD especially when 
associated with smoking.  (Thorax, 1997).  The exclusion criteria 
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used in this study, (age below 60 years, smoking history less than 
20 pack years), was an attempt to exclude all potential COPD 
subjects from the cohort thus ensuring a pure asthma population. 
 
3.4.2 The Study Population Make-up and Stability 
 
This study hoped to secure a stable asthmatic population that 
could easily be followed over the two-year period (see Table 1).  
Although subject selection used a stratified sampling method 
there were only (2/114) of subjects who required hospital 
admission in excess of 24 hours over the follow up period, with 
one death and one subject leaving the area. The population is 
reflective of many GP asthma populations found within the UK 
with the majority of subjects (70%) in BTS Guidelines treatment 
step groups 1-2 (Horn and Cochrane, 1989). Subjects requiring 
increased therapy as per steps 3-5 had significantly (p<0.001) 
higher morbidity scores and depression (p<0.05) scores than 
subjects requiring less medication (see Table 6a and b). This 
observation was also noted by Horn and Cochrane (1989) who 
saw an increase in morbidity in subjects in higher treatment steps 
in a community based study though their study was completed 
prior to the publication of national guidelines for the management 
of asthma. 
 
The cohort for this current study consisted of more females than 
males  (72/42). Most studies relating to adult asthma exhibit a 
female bias (Pearson et al, 1995). This anomaly may be due to the 
recruitment methods employed in this study. As many subjects as 
possible were encouraged to attend their GP practice for 
assessment and opening hours were restricted from 9.00 am to 
6.00 pm. Horne and Cochranes 1989 study did have access to 
evening appointments, which may have accounted for their almost 
equal gender population (157F: 155M).  Access to practice 
facilities for this study were restricted for days and times, as no 
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practice could give access 9.00 am to 6.00 pm Monday to Friday 
and no access was given for weekends. This study was therefore 
limited to sessions, morning or afternoon on a variety of days and 
for many subjects working full time this proved impossible. 
Those willing to participate but unable to attend the practice were 
offered a home visit though not all agreed to this. Such difficulties 
in recruiting subjects are well documented, Horne and Cochrane 
comment “it is impossible to obtain 100% sample”. Many 
published studies comment on asthma in general practice using 
small numbers eg, a cohort of 67 subjects being 0.5% of the total 
practice population. For this study a cohort of 114 subject from 
four practices would appear representative of such recruitment 
problems. 
 
3.4.3 Compliance in the Use of Asthma Medication within the 
Population 
 
In order to take part in the study all subjects had to have been 
using a prophylactic inhaler for six months prior to entry or in the 
past six months received two or more prescriptions for a agonist 
inhaler. All subjects complied with this requirement patient 
information was confirmed by computer prescription records.  
 
Compliance according to Sackett and Snow (1979) may be 
defined as the extent to which a person’s behaviour coincides 
with medical advice given (in the case of this study the ability of 
the subject to take inhaled medication as prescribed).  Subject 
lack of compliance with medication uptake is well documented 
(Horn et al, 1990, Rand et al, 1992, Apter et al, 1998) with failure 
to adhere to prescribed medication occurring in up to 50% of 
subjects (Rand et al, 1992). Good compliance with medication 
characteristically take over 80% of prescribed therapy. Those 
taking 80-70% are deemed adequate compliers while subjects 
taking 50% or less are termed poor compliers (Sackett and Snow, 
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1979).  Eighty three percent of the population in this study was 
prescribed inhaled steroids at the outset (see Table 1). At 
interview some subjects commented to the researcher a reluctance 
to comply with inhaled steroids. 
 
Such anecdotal evidence has previously been noted (Yeung et al, 
1994, van der Palen et al, 1997) and this cohort proved no 
exception in this case. When subjects were asked to confirm their 
prescription uptake many subjects freely commented on their 
personal reluctance to comply with recommended dose and 
frequency especially of inhaled corticosteroids. In general 
subjects preferred to use their agonist inhaler more than 
prescribed (this data was not recorded).  Anecdotal evidence was 
similar to that cited by Bosley et al, (1994) who demonstrated that 
many asthmatic subjects do not take their prescribed amount of 
inhaled medication. Subjects may not use their inhaled steroids 
regularly as they do not give immediate relief of symptoms or fear 
of associated side effects. Mayo et al, (1990) and Osman et al 
(1993) also reported their asthma subjects exhibited steroid 
“phobia”.  
 
Bosley and colleagues concluded that asthmatic subjects, no 
matter how distressing their symptoms, were no more likely to 
adhere to prescription regimens than subjects exhibiting little 
morbidity did. 
 
Supposed steroid “phobia” is not the only reported cause of non-
compliance.  If subjects are not informed of how, when and why 
to use their inhaled medication, non-compliance is inevitable 
(Cochrane, 1996). Subjects taking regular inhaled steroids may 
subsequently improve, their asthma symptoms may decrease and 
they therefore discontinue treatment. Knowledge of inhaled 
medication is an important element of the patient’s self-
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management plan. Non-compliance would appear from the 
literature to be well reported, therefore practitioners must be 
aware that many of their patients with poor symptom control may 
well be non-compliant but it may not be the only confounding 
factor.  Other elements affecting morbidity may well require due 
attention rather than simply altering asthma medication. 
 
Compliance was not formally monitored with inhaled medication, 
but by merely noting actual prescription uptake in comparison to 
expected uptake. It was not expected that behaviour in relation to 
the use of inhaled medication had been affected by participation 
in this study. The monitoring of subject compliance is notoriously 
fraught with difficulties and beyond the scope and resources of 
this study. It has been previously reported (Mahwhinney et al, 
1991, Rand et al, 1992, Yeung et al, 1994) when subjects are 
aware of compliance monitoring their behaviour with medication 
use can alter dramatically.  Subjects are known to empty canisters 
immediately prior to clinic appointments and to discharge 
canisters at irregular intervals in an attempt to feign compliance 
with prescription medication (Bosley et al, 1994). 
 
The anecdotal use of inhaled agonist as opposed to inhaled 
corticosteroid is not a new phenomenon as previous studies 
monitoring compliance have reported similar difficulties.  The use 
of quick acting agonist for short term relief of symptoms is 
highly effective, however, the safety and efficacy of short acting 
therapy for long term use has been reassessed (Taylor et al, 
1996). Long term regular use of quick acting agonists is 
currently thought to affect morbidity and in some cases mortality. 
 Subjects relying upon regular use of quick acting agonists can 
develop worsening lung function, which remains masked until 
challenged by allergens resulting in inflammatory changes. These 
subjects are unable to further bronchodilate their airways thus 
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they are unable to respond to further bronchodilator therapy. 
Taylor et al refers to this as “agonist addiction”. Long term abuse 
of agonists may result in tachyphylaxis (Taylor et al, 1996) 
although this subject remains highly debated. The need for 
bronchodilator therapy should be reduced and preferably used 
only as required (Dickinson et al, 1998).  BTS guidelines 
treatment step state that if subjects require quick acting agonists 
more than once daily (step 1) inhaled anti-inflammatory therapy 
should be added to their treatment regimen (step 2).  It would 
seem that despite published guidelines and the risks attached to 
agonist abuse, many of our cohort of asthma subjects would 
prefer this course of action to regular inhaled steroid therapy.  
This would appear reflective of a typical asthma population. 
 
3.4.4 The Use of Self-management Plans within the Population 
 
British asthma guidelines published in 1990 (BMJ, 1990) 
included in the recommendation “guided self-management plans”. 
This shift in emphasis had begun in an attempt to empower 
patients to take control of their asthma and such a strategy 
involved a new partnership of patient and physician/nurse. 
Recommendations included written information to be given to all 
patients notifying them of such symptoms that would indicate 
their asthma was worsening and what specific treatment regimen 
to adopt. The updated guidelines in 1993 (Thorax, 1993) noted 
the change from the original stating “there is now considerable 
evidence of the benefit from patient education and the issuing of 
self-management plans”.  The 1997 revision also advocated the 
use of PFM as part of a patients self management plan (Thorax, 
1997). 
Some of the subjects in this study were assessed prior to the 
publication (Feb 1997) of the revised guidelines.  All subjects 
were asked if they had a plan, given to them by their GP practice 
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to cope with worsening asthma symptoms and did they have a 
PFM. Sixty-three percent of subjects said they did have a self-
management plan. Further details of self-management plans were 
not requested from subjects participating in the present study. The 
introduction and advocacy of self-management plans for asthma 
patients was thought to improve knowledge and reduce morbidity 
and in some cases mortality, (Hilton et al, 1986, Cochrane, 1993, 
Hoskins et al, 1996).  Hoskins and co-workers did note that the 
adoption of self-management plans required an enthusiastic 
approach to care.  In more recent publications (Neville, 1998), the 
importance of asthma management plans improving patient 
knowledge and reducing morbidity is supported. Neville 
comments that all asthma patients may not need or require self-
management plans but patients who want to take an active part in 
their management would benefit from a structured approach to 
care. 
 
The use of PFM as part of a structured self management plan had 
been advised in guidelines but Neville (1998) and Turner et al, 
(1998) amongst others question the use of routine PFM as part of 
a plan for many asthmatics (though poor perceivers and brittle 
asthmatics should use PFM). It has been previously documented 
that few subjects who have been prescribed PFM actually use 
them as part of their own monitoring process (Garrett et al, 1994). 
Subjects in this study who were issued with PFM also stated they 
were in receipt of self-management plans. It must therefore 
remain speculative how many of the cohort who do not use their 
PFM did not adhere to their self management plans, a common 
problem in any asthma population. 
 
3.4.5 The Relationship of Morbidity to Subjective and Objective 
Markers of Asthma 
 
The physiological response to stimuli in asthma is one of 
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inflammation and bronchoconstriction resulting in expiratory 
wheeze, cough and dyspnoea all symptoms of asthma. According 
to Moxham and Costello (1997), bronchial ‘hyper-reactivity’ 
appears to be the key to the asthmatic reaction. Following 
exposure to a trigger the airways of the subject may (or may not) 
react immediately or over a period. This exposure can result in 
airways narrowing reducing normal levels of spirometry and PEF, 
such symptoms can be acute or occur over a short period and may 
eventually become a chronic feature of the disease. The extent to 
which the subject is affected will depend upon the exposure time 
and the extent of the response. It has been acknowledged for some 
time that subjects with asthma will have poorer lung function than 
non-asthmatic subjects when matched for age and gender (Peat et 
al, 1987).  Associated with airway narrowing are the symptoms of 
cough and wheeze due to the hyper-responsive nature of the 
disease and dyspnoea that is often worse at night.  Fletcher et al, 
(1976) in their classic publication noted the abnormal rate of 
decline in lung function in subjects with obstructive disease and 
this rate of decline is reflective of many asthma patients over their 
lifetime. The inter relationship between symptom reporting and 
objective measures of asthma (lung function and PEF) were 
explored along with subjective measures (psychological status 
and asthma severity) within the population (see section 3.2.2 and 
Table 2). 
 
Symptom reporting along with PEF monitoring forms part of 
asthma management as per BTS guidelines (Thorax, 1997). The Q 
score asks subjects to comment on their symptoms of asthma, 
wheeze, nights waking and the occurrence of symptoms that 
disturb daily routines.  The AQLQ symptom score similarly asks 
subjects’ the extent to which symptoms interfere with daily life 
and which symptoms are the most distressing. In this study 
subjects who reported increased symptoms as measured by Q 
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score or AQLQ symptom score also recorded poor lung function 
and reduced PEF (see Figures 6 and 7).  These subjects exhibit 
increased symptoms of asthma with consequentially poorer 
spirometry yet, they were receiving more treatment for their 
asthma symptoms (see Figures 8 and 9).  The relationship within 
the study population of worsening symptoms, poorer lung 
function and increased asthma severity (increased treatment step) 
provides some face validity and is in keeping with other work 
(Horn et al, 1990 and Rand et al, 1992). 
 
The relationship of poorer lung function to increased symptoms 
has previously been noted (Horn et al, 1990). This study 
attempted to study a cohort of subjects when they were relatively 
stable (ie, a GP based population as opposed to a hospital 
outpatient based population).  These patients had a mean FEV1 of 
74% predicted and PEF of 76% predicted which might be 
suggestive of an element of fixed airway obstruction or a lack of 
compliance with prescribed medication. The question remains as 
to whether the poor lung function exhibited in this cohort was due 
to chronic disease or was due to their airways no longer respond 
to therapy despite patient compliance. Were the subjects non-
compliant with their medication thus giving the impression of 
poor lung function as medication to improve airways calibre has 
simply not been administered?.   
 
Connolly et al, (1994) have shown that best lung function 
obtainable decreases with increased treatment step. The cohort in 
the present study may (as previously noted) already exhibit an 
element of obstruction associated with longstanding respiratory 
disease or may choose not to comply with their prescribed dose of 
medication (see section 3.4.3). This may have resulted in poor 
lung function with increased morbidity. 
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Current literature does acknowledge the influence of 
psychological status on asthma symptoms (Dales et al, 1989, 
Yellowness and Kalucy, 1990, Janson et al, 1994, Bosley et al, 
1995, Bosley et al, 1996).  In this cohort depression significantly 
correlated with symptom scores (both p<0.01) and with measures 
of asthma severity (p<0.05) (see Figures 10, 11 and 12). Binary 
logistic regression was used to assess the influence of 
psychological status on reported symptoms after controlling for 
lung function and asthma severity (see Table 3).  Whether 
symptoms were assessed by Q score or AQLQ symptom score 
depression was the best predictor of symptom level. While asthma 
remains high in media interest, can this be reflected towards the 
patient increasing their awareness for symptoms and thus raising 
their associated psychological status?  
 
On the other hand, in this current study are we simply seeing 
subjects with increased severity of asthma depressed due to long-
term illness? 
 
3.4.6 Socio-economic Influence on the Population 
 
The mortality and morbidity of a large number of diseases can be 
linked to poverty and social deprivation (Smith et al, 1994, 
Eachus et al, 1996).  Poor socio-economic status may contribute 
to the aetiology and subsequent management of asthma but in the 
UK asthma may not always be associated with reduced social 
status.  However, it has been documented that smoking, exposure 
to high pollution levels, obesity and large family size are 
characteristics that can be associated with poverty, an element of 
social deprivation (Rona, 2000).  According to Nsouli (1999), 
“poverty is the single most important risk factor for asthma 
hospitalisation” and in the West Midlands recent studies by 
Watson and co-workers have reported the association between 
increased admissions for asthma from areas with high deprivation 
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scores (Watson et al, 1995 and Watson and Lewis, 1995).  
 
The cohort for this study was recruited from four GP practices, 
two inner city practices and two suburban practices (see Table 4a 
and b). To assess the different socio-economic influences in the 
different settings, Jarman scores were used as an estimate of 
deprivation. Jarman scores estimate community wide deprivation, 
noting weighted values for elderly people living alone, single 
parent families, number of children under five, social class and 
numbers unemployed etc within the locality based on census 
information. Jarman scores for each practice were based on the 
last public census of 1991.  Poverty may be measured in several 
ways and although other scores are available that measure 
deprivation, the four practices used in this study was situated in 
differing Health Authorities and thus Jarman scores were the only 
deprivation score available for all practices. 
 
The two groups were in differing socio-economic states, the inner 
city cohort was drawn from an area with increased levels of 
deprivation (high Jarman scores +18.7 and +13.45) while our 
suburban cohort had lower Jarman scores, (-19.58 and –18.27). In 
the study group, 75% of the inner city subjects were not working 
or unskilled whereas only 30% of suburban subjects where in the 
same situation. The assessment of social class is linked to poverty 
and deprivation (Rona, 2000) as the Jarman scores illustrate by 
using lower social class as one of the markers associated with 
increased deprivation. 
Objective measures of asthma (spirometry and PEF) did not 
reveal any significant differences in the two social groups (see 
Table 4a and b). When looking at morbidity, despite the lack of 
significant differences between groups, inner city subjects always 
reported higher symptom scores at each treatment step than 
suburban subjects (see Figures 13, 14 and 15). Juniper (1998) 
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commented that symptom reporting was independent of objective 
measures of asthma. Such reporting can be linked to the subjects’ 
personal perception of their symptoms and may be reflective of 
their immediate environment and personal circumstances. Some 
of the inner city subjects increased morbidity may be as a direct 
result of poor housing and the area of habitation as well as their 
personal situation as opposed to deteriorating lung function. In the 
1995 Health Survey for England (Prescott-Clarke and Primatesta, 
1997) wheeze and breathless (known symptoms of asthma) were 
unrelated to social class but nights waking (a question contained 
within the Q score and AQLQ score) reporting was highest in 
unskilled subjects.  Although the 1995 survey did not differentiate 
between types of obstructive disease, in the present study nights 
waking was reported in 35% of inner city subjects as opposed to 
17% in suburban mirroring the association of higher nights 
waking noted by more unskilled subjects in the 1995 survey. 
 
Rona (2000) comments on the relationship of smoking to asthma 
noting increased smoking activity can be associated with poverty. 
The inner city subjects included in this study smoked significantly 
more (p<0.01) than their suburban counter parts. This could in 
some cases account for increased symptoms as inner city subjects 
reported increased symptoms for asthma at all levels of treatment 
step. 
 
 
Recent publications have begun to investigate the connection 
between social deprivation and asthma commenting upon 
morbidity and mortality.  Burr et al, (1997) looked at social 
deprivation and asthma using Townsend scores as a measure of 
deprivation.  From Burrs survey taken in South Wales they agreed 
with a West Midland based study (Watson et al, 1995 and Watson 
and Lewis, 1995) that there was a strong association between 
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deprivation and increased morbidity associated with hospital 
admissions for asthma.  Although Burrs et al surveyed children 
Watson (Watson et al, 1995 and Watson and Lewis, 1995) 
reviewed all age groups, illustrating the association can occur in 
all age groups.  The inner city cohort presented in this study 
would seem to reflect current published work linking deprivation 
to increased morbidity. 
 
Subjects residing in the inner city area are exposed to more 
pollutants. Not only is traffic in close proximity to many houses 
but some heavy industry remains close to the city centre where 
these subjects reside. Other areas of deprivation are situated near 
local industrial complexes situated close to motorway access 
routes. All must be considered as contributing to pollutants that 
this sub set of the population is exposed to on a daily basis. The 
reduced health status of such subjects may be connected to their 
increased smoking habit, exposure to increased pollution or poor 
housing which are all known factors allied to increased 
respiratory symptoms. This may go some way to account for the 
increase in morbidity reported by subjects in this study who reside 
in inner city areas.  
 
3.4.7 Psychological Status and its Affect upon the Population 
 
Psychological status was explored using the HAD scale noting 
anxiety and depression levels of all subjects at the start of the 
study. Although 73% of the cohort exhibited no significant 
psychological symptoms when assessed at outset, there were 
some subjects with significant anxiety and depression (see section 
3.2.4, Table 5a and b). Although asthma is not considered as a 
“psychological disease” the patients psyche can influence its 
outcome (Centanni et al, 2000). Subjects with anxiety and 
depressions scores over the threshold of eight on the HAD scale 
were said to exhibit signs of that phenomenon. Subject residing in 
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inner city areas exhibited significant depression (p<0.01) and 
anxiety (p<0.001).  Such psychological symptoms can heighten 
morbidity and increasing therapy may well be the clinicians 
response. However, increased therapy will go little way to solving 
the subjects psychological problems.  If a reduction in symptoms 
is not achieved the clinician might be wise to explore 
psychological influences as opposed to increasing medication 
further (Rimington et al, 2001) 
 
The relationship between psychological and respiratory symptoms 
has been previously documented (Dales et al, 1989, Yellowness 
and Kalucy, 1990, Janson et al, 1994, Bosley et al, 1995, Bosley 
et al, 1996). Subjects from the European Commission’s 
Respiratory Health Survey demonstrated an association between 
respiratory symptoms and psychological status although asthma 
subjects were no more anxious or depressed than any other 
subjects with respiratory symptoms (Jansen et al, 1994).  A large 
Canadian study surveying the general health  of a population 
noted that even healthy subjects were more likely to report 
respiratory symptoms such as cough, wheeze or dyspnoea if they 
also had an abnormal psychological status associated with 
increased anxiety, depression, anger or cognitive disturbances 
(Dales et al, 1989).  Dales and co-workers commented that an 
increased anxiety state might well lead to subjects being more 
aware of their respiratory symptoms or their anxiety state 
heightened such symptoms to the subject.  When assessing 
baseline data for the cohort as a whole (see section 3.2.2), anxiety 
and depression as measured by the HAD scale aligned to 
symptom scores more so than objective measures of asthma 
(spirometry and PEF) (see Figures 10.11 and 12). Subjects who 
were more anxious and/or depressed complained about their 
asthma symptoms (cough, wheeze and dyspnoea) more so than 
the subjects with reduced psychological status. 
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Yet Bosley et al, 1995 state that subjects with psychological 
problems can deny or disregard their asthma symptoms leading to 
difficulties in the management of their condition and the effective 
reduction of their morbidity.  These subjects may desire to be, “in 
control” of their asthma equating a visit to the GP surgery as 
“loosing control” and subsequently deny symptom severity 
(Janson-Bjerklie et al, 1992).  Bosley et al, (1995) also noted that 
psychological issues coexist with social problems. Subjects used 
in their study were recruited from four GP practices in inner city 
Southeast London.   
 
Yellowness and Kalucy, 1990 also note that increased levels of 
anxiety can lead to denial of respiratory symptoms. Both 
Yellowness and Kalucy (1990) and Bosley et al, (1996) suppose 
that reasons for increased levels of anxiety are often 
multifactorial. If a trigger is elicited that causes increased levels 
of anxiety, panic can result which in turn may lead to 
hyperventilation and subsequent asthma.  Subjects with increased 
panic and anxiety levels are also associated with increased uptake 
of care (Jansen et al, 1994).  This study cohort reflect these 
findings, inner city subjects were from areas with high 
deprivation scores and subjects from such areas were more 
anxious and depressed (p<0.001 and p<0.01 respectively) and 
also reported higher symptoms levels than their suburban counter 
parts.  These inner city subjects would not appear to be in denial 
of their symptoms but were reporting increased symptoms despite 
no significant reduction in objective measures of asthma. Thirty 
percent (22/74) of inner city subjects recorded HAD anxiety 
scores less than eight while 65% (48/74) had depression score less 
then eight whereas suburban subjects reported fewer 
psychological symptoms (anxiety scores lees than eight in 26/40, 
65% depression scores less than eight in 35/40, 88%).  The 
 
 114
increase in uptake of care in this study cohort as assessed by 
frequency of visits to the GP practice will be assessed over the 
two year follow up period. 
 
Psychological issues are important factors to consider in the 
management of asthma and do contribute to the patient’s overall 
experience of their disease affecting how they might cope with 
the variable nature of symptoms (Jansen et al, 1994). Published 
guidelines recommend patients receive self-management plans for 
the control of their asthma symptoms (Thorax, 1997), yet subjects 
with increased psychological symptoms may not comply with 
care plans (Bosley, et al 1995).  Such disregard by subjects to 
self-management plans is a common feature of chronic disease in 
general. This is not related solely to subjects with respiratory 
symptoms. It has been documented that information and 
education do not necessarily alter behaviour (Cochrane, 1996). 
Subjects in this current study all attend GP practices that manage 
patients according to published asthma guidelines. Subjects may 
very well be in receipt of self-management plans for their asthma 
but if they have poor psychological status may not feel able to 
comply with instructions or, may simply deny their asthma 
morbidity requires any alteration in their current management 
regimen. 
Indeed, as illustrated by this cohort no significant differences 
were found for spirometry, PEF or morbidity, yet 35% of the 
depressed subjects were receiving higher doses of treatment (as 
opposed to only 26% of non-depressed subjects) without an 
appropriate drop in symptom recording (see Tables 5a and b). 
Subjects with mild psychological problems such as anxiety and/or 
depression can therefore provide a challenge when their asthma 
management is being considered (Bosley et al, 1996). 
 
The now widespread use of asthma guidelines in day to day 
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management has lead to the empowerment of patients in the 
management of their disease process (see section 1.3.2).   Many 
subjects who exhibit psychological symptoms may feel increased 
levels of anxiety and stress associated with the added 
responsibility of implementing their self-management plans 
(Hyland et al, 1995). This increase in “bother” as termed by 
Hyland and colleagues may actually attribute to increased anxiety 
and depression in some asthma subjects that could add to the 
already heavy burden of these inner city subjects.  This may in 
some part account for the increase in symptom reporting by the 
depressed inner city subjects who cannot cope with the added 
stress imposed by self management plans. 
 
Awareness by the clinician of psychological factors and the 
influences that they can exert upon the asthma patient may play 
an important role in the management of asthma. When assessing 
patients, the reporting of their asthma symptoms is an important 
part of the consultation process.  Symptom reporting in terms of 
increased morbidity (as associated with the inner city subjects) or, 
in terms of denial (as reported by Bosley et al, 1995) may be in 
response to psychological factors more so than to asthma status 
itself and is therefore worthy of consideration. 
 
3.4.8 Asthma Severity as per BTS Guidelines Treatment Step 
 
Subjects in the study were divided into two sub-groups by their 
BTS Guidelines Treatment Step (Thorax, 1997) (see Tables 6a 
and b). Subjects requiring minimal medication were from steps 
one to two, these subjects had mild asthma symptoms while 
subjects requiring a variety of inhaled and oral medication were 
found in treatment steps three to five (moderate to severe asthma 
symptoms). Almost three-quarters of the cohort were found to be 
in treatment steps one to two.  In a primary care based cohort this 
was expected (Horne and Cockrane, 1989).  Subjects requiring 
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more medication were more depressed (p<0.05) than subjects in 
lower treatment groups and had significantly increased morbidity 
scores when assessed by Q score (p<0.001) and by AQLQ 
symptom score (p<0.01) but less so (see Table 6a and b). Subjects 
with long-standing disease are known to have increases 
psychological status more so than subjects with mild disease and 
the prospect of a life time consuming a variety of medication may 
well lead to increased stress (Yellowness and Kalucy 1990). The 
interaction between increasing medication for long standing 
asthma and psychological factors can result in differing outcomes. 
These subjects develop a variety of coping strategies for their 
level of disease severity (Moran 1994). 
 
Published guidelines followed on from a variety of reports 
recording asthma deaths, most noticeably following the report 
from the British Thoracic Association in 1982.  Prior to the 
publication of asthma guidelines many studies reported increased 
asthma deaths, guidelines sought to address this anomaly. 
Subsequent guidelines emphasised a structured approach to 
medical management relying in part upon symptom reporting by 
patients. With the publication and implementation of guidelines 
mortality rates in the UK are reported to have fallen (Bucknall et 
al, 1999).  Although mortality rates are said to have fallen 
subsequent audits concerning asthma deaths report a core of 
subjects for whom under reporting of symptoms resulting in under 
treatment may have been a contributory factor to death 
(Sommerville et al, 1995, Burr et al, 1999). 
 
The minimising of symptoms is a goal of asthma management and 
this relies to a certain extent on symptom reporting by patients. 
Published guidelines recommend a combination of therapy to 
ensure minimal or no symptoms (steps one to two).  As treatment 
steps increase, (three to five) the aim is to achieve least possible 
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symptoms with therapy. Studies examining asthma deaths 
comment repeatedly on the probability of under treatment of 
asthma symptoms as a contributory factor to asthma death 
(Wareham et al, 1993, Janson-Bjerklie et al, 1992).  It is thought 
some asthma patients may be poor perceivers of symptoms thus 
failing to recognise any deterioration in their asthma status 
(Bucknall et al, 1999, Burr et al, 1999, Sommerville et al, 1995, 
Wareham et al, 1993).  Several papers have already noted 
psychological factors either attributed to the patient or associated 
with their immediate family can lead to difficulties in the 
management of symptoms and in the symptom reporting by 
patients. The East Anglia study (Wareham et al 1993) 
demonstrated seventy one percent of their asthma deaths had 
associated psychological problems that were thought to influence 
the patients demise. 
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Thirty percent of this study cohort had increased markers of 
severity (BTS guidelines treatment step three to five). This sub-
group could therefore not be considered as poor perceivers of 
symptoms. Yet, within that sub-group, some subjects with mild 
depression may be being over prescribed asthma medication in 
response to reported symptom increase.  Although no significant 
differences in objective measures of lung function were evident 
between the two groups morbidity scores were significantly 
different (Q score p<0.001, AQLQ symptom score p<0.01).  
Subjects with increased markers of severity not only complained 
more about their symptoms but they were more depressed 
(p<0.05), though no more anxious than subjects with decreased 
markers.  Current literature would suggest that within the sub-
group with reduced markers of severity, there could exist some 
cohort members who could be poor perceivers of their morbidity. 
Indeed many patients find the burden of their own asthma 
management too stressful and choose simply to ignore it 
(Bucknall et al, 1999). 
 
BTS guidelines treatment step gives the clinician an indication as 
to the severity of asthma status.  The treatment step onto which 
the patient is placed and subsequently managed is dependent upon 
two variables, PEF and symptom reporting.  Although PEF 
monitoring is desirable it is not always made readily available by 
patients and it would seem that symptom reporting alone can be 
subject to many influences. The relationship of asthma severity, 
lung function, morbidity and psychological factors appears 
complex and it would seem for many of this study cohort 
inextricably linked. 
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3.4.9 Summary 
 
The aim of this study is to follow a cohort of known adult 
asthmatic subjects from differing primary health care settings 
over a two-year period.  An important issue at outset was to try to 
ensure a true diagnosis of asthma for subjects included in the 
study.  All GP Practices gave assurances that patients were 
assessed for asthma as per BTS Guidelines (BMJ, 1990, Thorax, 
1993 and 1997).  Diagnosis is based upon the variable nature of 
the airways as assessed by PEF monitoring. This study attempted 
to record PEF over an initial two-week period but the subject 
response rate was too poor to be of use to validate any previous 
diagnosis. The diagnosis of asthma by the GP was not challenged 
in this study. Subjects were excluded who may have had a 
diagnosis (give by GP) of COPD by disregarding smokers and 
any subject over sixty years of age. In doing this it was hoped to 
secure a pure asthma population to follow over the two-year 
period. 
 
The population would appear typical of that found in any primary 
health care setting with the majority of subjects requiring minimal 
medication.  Published guidelines for the management of asthma 
relies upon symptom reporting and PEF monitoring by the patient 
in order to keep symptoms to a minimum.  Many patients are 
given asthma self-management plans along with their prescribed 
medication; it would appear that this study cohort report the same 
problems associated with medication and self-management 
compliance as others have previously noted. The population in 
this study would therefore appear to be representative of any 
given asthma population within any inner city and suburban 
primary health care setting. 
 
 
 
This study set out to examine the relationship of symptoms, 
 
 120
(which may be considered as subjective markers of asthma) to 
objective markers such as spirometry and PEF. The investigation 
also wished to observe the inter relationship with the 
psychological status of the patient in their differing primary 
health care settings. Increased level of symptoms whether 
measured by AQLQ symptom score or Q score did correlate to 
poorer lung function and reduced PEF. Symptoms also correlated 
to BTS guidelines treatment step, thus subjects requiring more 
medication recorded higher levels of symptoms indicating poor 
control.  Increased HAD scores also correlated to levels of 
morbidity but not to spirometry or PEF.  It was interesting to note 
that logistic regression analysis revealed HAD scores were 
closely linked to symptom scores after allowing for lung function 
and severity.  Health status was poorer, while morbidity and 
psychological status were higher for inner city subjects compared 
with a suburban sub-group while little difference was observed in 
objective measures of asthma. 
 
The cohort presented in this investigation is representative of any 
given asthma population but this study found that morbidity can 
be more closely linked to psychological status rather than 
objective markers of asthma. 
 
Asthma guidelines suggest that changing levels of symptoms 
should be used to monitor the effectiveness of treatment along 
side PEF. The compliance of patients to PEF monitoring remains 
unreliable and not always available to the clinician. Hence, the 
prescribing clinician may be left with symptom reporting alone 
upon which to base treatment. The baseline data discussed would 
suggest that reported symptoms may be misleading and unreliable 
because they may reflect non-asthma factors that cannot be 
expected to respond to changes in asthma therapy. 
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CHAPTER 4 
 
 
 
 
Subjects reviewed at year one 
and year two recall 
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4.1 The Data 
 
The aim of this study was to observe and follow a cohort of adult asthma 
subjects managed within the primary health care setting over a two-year 
period. This chapter contains data collected from ninety-five subjects 
from the original cohort who agreed to attend for review at twelve months 
(see Table 7) and data collected from ninety subjects who attended for 
review at twenty-four months (see Table 13). There were twenty-four 
subjects who withdrew from the study, their baseline data can be found in 
Appendix XII. Seventy-nine subjects were assessed at baseline, twelve 
and twenty-four months and their data can be reviewed in Appendix XIII. 
 
The relationship of objective measures of asthma, health status, 
psychological status, prescribed asthma medication and asthma severity 
within the whole group were explored using the Spearman rank order 
correlation coefficient test for non-parametric data (see Table 8). These 
data were explored from baseline to twelve months and baseline to 
twenty-four months (as described in section 2.5). 
 
Data were examined for differences (quasi-experimental design) from 
baseline to twelve months and baseline to twenty-four months using 
paired t tests for parametric data or Wilcoxon sign ranks tests for non-
parametric data for the whole cohort (as described in section 2.5).  
 
Data from the sub-groups (inner city versus suburban subjects, low versus 
high asthma severity, depressed versus non-depressed subjects and 
medication altered or not, as stated in 2.5.1) were explored for differences 
using unpaired t tests for parametric data and Mann-Whitney U tests for 
non-parametric data.  
 
All data used within this chapter was collected using the patient data set 
contained within Appendix IV and V. All participating subjects were 
asked to complete the AQLQ, Q score and HAD scale (see sections 2.4.1 
and 2.4.2). Spirometry and PEF were also recorded. 
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All data collected at twelve months for the whole cohort and the sub-
groups are contained within section 4.2 and all data collected at twenty-
four months are contained within section 4.3. Twelve and twenty-four 
month data are discussed together in section 4.4.  
 
4.2 Changes and Relationships within the Cohort of Subjects at Twelve 
Months 
 
One hundred and thirteen subjects were contacted at twelve months, one 
subject died within the first twelve months of the study though not due to 
respiratory disease. Seven subjects withdrew at this stage and their 
baseline data is included in Appendix XII.  Eleven subjects refused 
appointments, were unable to attend for review or did not attend despite 
repeated contact. They remained within the study cohort and were 
contacted again at twenty-four months. 
 
4.2.1 Twelve Month Data for 95 Subjects 
 
Table 7 illustrates the baseline data set and the twelve months 
data set for ninety-five subjects who attended for review. Data is 
explored against baseline for difference in order to note any 
changes in values. The relationships between morbidity (as 
measured by AQLQ symptom score and Q score), psychological 
status, (as measured by HAD scores) FEV1 and PEF are explored 
in order to assess if relationships established at baseline persist at 
twelve months. 
 
 
 
 
 
 
 
 
 
 
 
Table 7: Data from 95 subjects at baseline and at twelve 
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months  
 
Variable 
Base 
Line 
N=95
% Mean (SD) 
12 
months 
N=95 
% Mean (SD) 
Age (Years)   43 (12)    
Gender (Male) 34 36     
Living in inner city 57 60     
Current Smokers 23 24     
Using ß agonist 88 93  84 88  
Using inhaled 
steroids 
80 84  80 84  
Using oral steroids 6 6  11 12  
Inhaled steroids 
increased at 12 
months 
   18 19  
BTS Guidelines 
treatment step (3-5) 
32 34  48 51  
PEF   344L/min(131)   327L/min(132) 
FEV1   2.18L (0.96)   2.12L (0.89) 
AQLQ   4.66 (1.23)   4.54 (1.18) 
AQLQ symptom 
score 
  4.55 (1.50)   4.50 (1.43) 
Q score   2.93 (2.47)   2.92 (2.53) 
HAD Anxiety   8.09 (4.50)   7.83 (4.54) 
HAD Depression     5.28 (3.83)   4.54 (3.46) 
 
As with the baseline cohort of one hundred and fourteen subjects, 
there were more women than men (61/95) attending for review at 
twelve months and just over half of the population (60%) were 
from the inner city area. 
 
There was a slight drop in the use of ßagonist (93% to 88%) over 
the first twelve months while the percentage of subjects using 
inhaled steroids remained unchanged at 80% but there was an 
increase in the use of oral steroids (6% to 19% respectively). This 
is reflected in the significant increase (p<0.001) in the number of 
subjects in higher treatment steps at twelve months (34% versus 
51%).  
 
 The population had remained stable over the twelve months with 
only 2% of subjects admitted to hospital for more than 24 hours 
for their asthma.  Seventy-five percent (71/95) of the population 
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did not visit their GP for an exacerbation of their asthma and of 
those who did, 54% (13/24) received one or more courses of oral 
steroids.  On their last visit to the GP practice prior to the twelve-
month assessment, subjects were asked to give the reason for that 
visit.  Forty-five percent reportedly did so because they required 
better control of their asthma morbidity, 22% wanted to check 
their medication whilst 14% complained specifically of sleep 
disturbance. 
 
There were no significant changes in spirometry, PEF, morbidity, 
anxiety or depression at twelve months. However, there was a 
significant increase in the number of subjects in BTS treatment 
steps 3-5 (p<0.001, McNemar test) at twelve months (as shown in 
Figure 22b). Subjects in higher treatment steps also complained of 
more symptoms of asthma than did subjects in lower treatment 
steps (as shown in Figures 23a and b). The observation of higher 
Q scores and lower AQLQ symptom scores exhibited at baseline 
was repeated at twelve months. 
 Figure 22a Subjects in BTS Guidelines treatment steps 1-2 and 3-
5 at baseline. 
 
 
Baseline BTS Guidelines Treatment Step
Steps 3-5Steps 1-2
0
90
80
70
60
50
40
30
20
10
0Pe
rc
en
t
10
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 22b Subjects in BTS Guidelines treatment steps 1-2 and 
3-5 at twelve month follow up (p<0.001). 
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 Figure 23a – Mean AQLQ symptom score plotted against BTS 
Guidelines treatment step 1-2 and 3-5 at twelve months 
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 Figure 23b – Mean Q score plotted against BTS Guidelines 
treatment step 1-2 and 3-5 at twelve months 
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The Relationship of Quality of Life Measures to Lung Function 
and Psychological Status at Twelve Months 
 
Data examining the relationship of QoL measures to lung function 
and psychological status at baseline can be seen in Table 2. This 
was repeated at twelve months, data is shown in Table 8. At 
baseline symptoms scores (AQLQ symptom score and Q score) 
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were used as a measure of QoL, subjects spirometry (FEV1) and 
PEF were also recorded as a test of lung function, anxiety and 
depression were noted to assess psychological status and BTS 
guidelines treatment step as a measure of severity.    
 
Cross sectional analysis of data collected at twelve months 
 
At twelve months symptoms of morbidity as measured by Q score 
and AQLQ symptom score correlate in a similar manner to 
baseline values (both p<0.01) (see Figure 24 and 25). Symptoms 
at twelve months also correlate to lung function (FEV1 and PEF) 
(both p<0.01) (see Figures 26a and c and 27a and c) anxiety and 
depression again correlate in a similar manner to baseline (all 
p<0.01). Figures 26b and d and 27b and d show relationship of 
lung function and spirometry (FEV1 and PEF) expressed as a 
percentage of predicted values to morbidity scores at twelve 
months. Anxiety weakly correlated to lung function (p<0.05) 
whereas the relationship with depression was stronger (p<0.01) at 
twelve months. At baseline the relationship of anxiety to FEV1 
and PEF was not significant while depression only had a weak 
relationship (p<0.05) with PEF. At baseline patients in higher 
treatment steps (BTS Guidelines steps 3-5) had increased 
depression and more symptoms. At twelve months these 
relationships were not significant. 
 
Table 8: Spearman's Rank Order Correlation Coefficients for 
95 subjects at twelve months 
 
 Q 
Score 
12 
months 
AQLQ 
symptoms score 
12 months 
HAD 
Anxiety 
12 months 
HAD 
Depression 
12 months 
FEV1 
12 
months 
PEF 
12 
months 
Q Score 12 months  -.825 .495 .526 -.538 .463 
AQLQ symptom score 12 
months -.825  -.527 -.646 .518 -.450 
HAD Anxiety 12 months .495 -.527  .645 -.252* -.262* 
HAD Depression 12 
months .526 -.646 .645  -.391 -.415 
All values were significant p<0.01 * significant p<0.05. 
 Figure 24 – Correlation of Q score at twelve months (p<0.01) 
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 Figure 25 – Correlation of AQLQ symptom score at twelve 
months (p<0.01) 
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 Figure 26a Correlation of PEF to morbidity as measured by 
AQLQ symptom score at twelve months (p<0.01). 
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 Figure 26b - Correlation of PEF at twelve months as a percentage 
of predicted PEF to morbidity as measured by AQLQ symptom 
score (p<0.01) 
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 Figure 26c Inverse correlation of PEF to morbidity as measured 
by Q score at twelve months (p<0.01). 
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 Figure 26d - correlation of PEF at twelve months as a percentage 
of predicted PEF to morbidity as measured by Q score (p<0.01) 
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 Figure 27a Correlation of FEV1 to morbidity as measured AQLQ 
symptom score at twelve months (p<0.01). 
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 Figure 27b - Correlation of FEV1 at twelve months as a 
percentage of predicted FEV1 to morbidity as measured by AQLQ 
symptom score (p<0.01) 
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 Figure 27c - Inverse correlation of FEV1 to morbidity as 
measured by Q score at twelve months (p<0.01). 
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 Figure 27d - Correlation of FEV1 at twelve months as a 
percentage of predicted FEV1 to morbidity as measured by Q 
Score (p<0.01) 
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4.2.2 Changes at twelve-months - the population sub divided by place 
of residence 
 
The population was subdivided by their place of residence at 
baseline. Sixty-five percent (70/114) of subjects resided within 
the inner city area (see Table 4a and b). Similar proportions of 
groups, inner city and suburban residents attended for review at 
twelve months. Sixty-five percent of subjects resided in the inner 
city at baseline (74/114) with 60% (57/95) at twelve months. 
Thirty-five percent resided in the suburbs (40/114) at baseline and 
40% (38/95) at twelve months. These data can be seen in Table 9a 
and b. 
 
Table 9a: Baseline Data and Twelve Months data for Inner 
City Subjects 
 
 
Variable Base Line 
N=57 
% Mean (SD) 
12 
months 
N=57 
% Mean (SD) 
Age (Years)   41(12)    
Gender (Male) 19 33     
Current smokers 19 33     
Using ß agonist 51 90  49 86  
Using inhaled steroids 51 90  50 88  
Using oral steroids 4 7  9 16  
Inhaled steroids 
increased at 12 months    12 21  
BTS Guidelines 
treatment step (3-5) 18 32  26 46  
PEF   336L/min(140)   315L/min(136) 
FEV1   2.13L(0.98)   2.02L(0.92) 
AQLQ   4.34(1.29)   4.37(1.18) 
AQLQ symptom score   4.13(1.52)   4.16(1.49) 
Q score   3.43(2.73)   3.64 (2.59) 
HAD Anxiety   9.44(4.36)   8.64(4.50) 
HAD Depression   6.28(4.16)   5.14(3.61) 
Attends GP >1       
In 6 months    7 12  
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Table 9b: Baseline Data and Twelve Months data for 
Suburban Subjects 
 
Variable 
Base 
Line 
N=38 
% Mean (SD) 
12 
months 
N=38 
% Mean (SD) 
Age (Years)   45 (12)    
Gender (Male) 15 40     
Current smokers 4 11     
Using ß agonist 37 97  35 92  
Using inhaled steroids 29 76  30 79  
Using oral steroids 2 5  2 5  
Inhaled steroids 
increased at 12 months    6 16  
BTS Guidelines 
treatment step (3-5) 14 37  22 58  
PEF   358L/min(117)   344L/min(126) 
FEV1   2.26L(0.77)   2.27L(0.82) 
AQLQ   5.14(1.25)   4.80(1.14) 
AQLQ symptom score   5.19(1.25)   5.01(1.17) 
Q score   2.18(1.79)   1.84(2.03) 
HAD Anxiety   6.10(3.95)   6.60(4.38) 
HAD Depression   3.81(2.74)   3.65(3.06) 
Attends GP >1       
In 6 months    4 11  
 
Fifty-seven (60%) subjects resided and attended GP practices 
within the inner city. Little increase occurred in the use of inhaled 
ßagonist or inhaled steroid but there was an increase in the use of 
oral steroids (7% versus 16%).  Although no significant increase 
occurred in the number of subjects using inhaled steroids at 
twelve months 21% of subjects did have their dosage increased. 
This increase is reflected in the number of subjects moving to the 
higher treatment step (step 3-5) represents an increase of 14% 
(p<0.01). 
 
Thirty-eight (40%) subjects resided and attended GP practices 
within the suburbs. Inhaled medication used by suburban subjects 
remained almost the same at twelve months although 16% of 
subjects did have their inhaled steroids increased.  This increase is 
reflected in the number of subjects moving to the higher treatment 
step (step 3-5) an increase of 21% (p<0.01).  
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At baseline there were no significant differences between groups 
for spirometry, PEF, morbidity or severity. Inner city subjects 
were however significantly more anxious (p<0.001) and 
depressed (p<0.01).  
 
At twelve months the same relationship between groups for 
spirometry and PEF was maintained. Inner city subjects remained 
more depressed (p<0.05) but the relationship was weaker than at 
baseline and they were no longer more anxious than their 
suburban counter parts. Morbidity scores were however 
significantly higher in inner city subjects at twelve months (Q 
score, p<0.001 and AQLQ symptom score, p<0.01). Levels of 
treatment for inner city subjects at twelve months did increase 
more so than suburban with inner city subjects receiving more 
oral steroids (16% versus 5% and 21% versus 16% had inhaled 
steroid therapy increased).  
 
Figures 28a and b illustrate inner city subjects were more 
depressed and reported more symptoms than suburban subjects. 
Increased Q scores are associated with increased depression 
scores while increased AQLQ symptom scores (improved QoL) 
were associated with reduced depression scores. 
 Figure 28a Bar chart of mean morbidity score as measured by 
AQLQ symptom score to HAD Depression for Inner City and 
Suburban subjects at twelve months. 
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 Figure 28b Bar chart of mean morbidity score as measured by Q 
score to HAD Depression score for Inner City and Suburban 
subjects at twelve months. 
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severity (BTS Guidelines treatment step 1-2 versus 3-5) 
 
Subject were sub-divided at baseline into two groups according to 
their asthma severity, BTS Guidelines treatment steps 1-2 and 
subjects who had more severe asthma requiring more therapy as 
found in BTS Guidelines treatment steps 3-5 (see Table 5a and b). 
At baseline 71% (80/114) of subjects were in BTS Guidelines 
treatment step 1-2 requiring low dose medication to control 
asthma morbidity. At twelve months sixty three subjects (63/80, 
79%) from steps 1-2 attended for reassessment, 75% (47/63) of 
subjects remained in steps 1-2. There were 32/34 (94%) of the 
subjects in the higher treatment step attending for review at 
twelve months 31/34 (91%) remaining in steps 3-5. There were 
80/114 (70%) subjects at baseline in BTS Guidelines treatment 
step 1-2, 63/80 (79%) attended for review at twelve months. 
There were 34/114 subjects at baseline in BTS Guidelines 
treatment step 3-5, 32/34 attended for review at twelve months. 
The data are shown in Table 10a and b. 
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Table 10a: Baseline Data and Twelve months Data for 
subjects in BTS Guidelines treatment step 1-2 
 
Variable 
Base 
Line 
N=63 
% Mean (SD) 
12 
months 
N=63 
% Mean (SD) 
Age   41 (12)    
Gender (male) 20 32     
Current smokers 16 25     
Living in inner city 39 62     
Using ß agonist 56 89  53 84  
Using inhaled steroids 48 76  48 76  
Using oral steroids 0   4 6  
PEF   349L/min(123)   330L/min(129) 
FEV1   2.21L(0.85)   2.13L(0.83) 
AQLQ symptom score   4.78(1.41)   4.70(1.36) 
Q score   2.23(2.21)   2.66(2.33) 
HAD Anxiety   7.96(4.51)   7.68(4.65) 
HAD Depression   4.90(4.07)   4.11(3.35) 
Attends GP >1       
In 6 months    5 8  
 
 
Table 10b: Baseline Data and Twelve months Data for 
subjects in BTS Guidelines treatment step 3-5 
 
Variable 
Base 
Line 
N=32 
% Mean (SD) 
12 
months 
N=32 
% Mean (SD) 
Age   46(10)    
Gender (male) 14 44     
Current smokers 7 22     
Living in inner city 18 56     
Using ß agonist 32 100  31 97  
Using inhaled steroids 32 100  32 100  
Using oral steroids 6 19  7 22  
PEF   335L/min(149)   320L/min(140) 
FEV1   2.13L(1.02)   2.11L(1.00) 
AQLQ symptom score   4.10(1.59)   4.10(1.49) 
Q score   4.31(2.40)   3.43(2.86) 
HAD Anxiety   8.35(4.55)   8.12(4.38) 
HAD Depression   6.06(3.22)   5.40(3.57) 
Attends GP >1       
In 6 months    6 19  
 
At baseline no differences between groups were observed for 
spirometry and PEF. This observation was repeated at twelve 
months. Subjects in higher treatment steps were significantly 
more depressed (p<0.05) and recorded more symptoms (Q score 
p<0.001, AQLQ symptoms score p<0.01) at baseline but this 
observation was not repeated at twelve months. However, a trend 
of increased morbidity, anxiety and depression was evident at 
twelve months in the higher treatment steps (3-5). Which is 
illustrated in Figures 29 and 30.   
 
 Figure 29 – Mean AQLQ symptom score and Q score for BTS 
Guidelines treatment Steps 1-2 and 3-5 at twelve months. 
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 Figure 30 – Mean HAD Anxiety and Depression scores for BTS 
Guidelines treatment step 1-2 and 3-5 at twelve months. 
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4.2.4 Change at Twelve Months – the population subdivided by initial 
Psychological Status 
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The population was sub divided for depression at baseline (see 
Table 4a and b). Subjects with HAD depression scores of 7 or less 
were said to exhibit no sign of depression or anxiety while those 
with scores of 8 or greater were placed into the depressed group. 
The HAD scale delineates for borderline depression with scores 
of 8 or above.  At baseline 83% (25/30) of depressed subjects 
lived in the inner city and more depressed subjects smoked (33% 
v 25%), although there was no significant difference for inhaled 
therapy more depressed subjects were prescribed oral steroids as 
part of treatment (6% versus 10%). Subjects in the depressed 
group at baseline were significantly more anxious and depressed 
(both p<0.001) but no significant differences were found between 
groups for morbidity. At baseline 30/113 (27%) subjects were 
depressed, at twelve months 26/30 (87%) depressed subjects 
attended for review, 15 subjects depressed at baseline remained so 
at twelve months. At baseline 80/113 (73%) subjects were not 
depressed, at twelve months 69/80 (86%) non-depressed subjects 
assessed at baseline attended for review, 64 subjects not 
depressed at baseline remained so at twelve months. These data 
are shown in Tables 11a and b. 
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Table 11a: Baseline and Twelve Months data for Depressed 
subjects 
 
Variable 
Base 
Line 
N=26 
% Mean (SD) 
12 
months 
N=26 
% Mean (SD) 
Age   46 (9)    
Gender (male) 10 39     
Current smokers 9 35     
Living in inner city 21 80     
Using ß agonist 24 92  23 89  
Using inhaled steroids 22 85  22 85  
Using oral steroids 3 12  3 12  
Inhaled steroids 
increased at 12 months 
   4 15  
BTS Guidelines 
treatment step (3-5) 11 42  15 58  
PEF   316L/min(147)   301L/min(154) 
FEV1   2.12L(1.07)   1.96L(1.05) 
AQLQ symptom score   3.72(1.55)   3.86(1.58) 
Q score   4.30(2.54)   4.03(2.69) 
HAD Anxiety   11.88(4.18)   10.80(4.91) 
HAD Depression   10.23(2.65)   7.65(3.65) 
Attends GP >1       
In 6 months    7 27  
 
Table 11b: Baseline and Twelve Months data for Non-
Depressed subjects 
 
Variable 
Base 
Line 
N=69 
% Mean (SD) 
12 
months 
N=69 
% Mean (SD) 
Age   41(12)    
Gender (male) 24 35     
Current smokers 14 20     
Living in inner city 36 52     
Using ß agonist 64 93  61 88  
Using inhaled steroids 58 84  58 84  
Using oral steroids 3 4  8 12  
Inhaled steroids increased 
At 12 months    14 20  
BTS Guidelines treatment 
step (3-5) 21 30  33 48  
PEF       
FEV1   355L/min(124)   337L/min(123) 
AQLQ symptom score   2.20L(0.84)   2.18L(0.82) 
Q score   4.86(1.37)   2.40(2.28) 
HAD Anxiety   2.42(2.25)   2.40(2.28) 
HAD Depression   6.64(3.73)   6.71(3.87) 
Attends GP >1   3.39(2.17)   3.37(2.57) 
In 6 months    4 6  
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At twelve months 26/30 (87%) depressed subjects assessed at 
baseline attended for review while a similar proportion 69/80 
(86%) of non-depressed subjects also attended. At twelve months 
depressed subjects had attended their GP practice more often (on 
more than two occasions 27% versus 6%). There was an increase 
in both groups into the higher BTS treatment step (3-5) more 
depressed subjects (58%) received more therapy at twelve months 
than non-depressed subjects (48%) though not significantly so. It 
should be noted that more subjects (20%) in the non-depressed 
group reported their inhaled steroids increased at twelve months 
than depressed subjects (15%) did.  
 
The observation at baseline of depressed subjects recording 
significantly more depression and anxiety (both p<0.001) was 
repeated at twelve months. The trend of higher symptom 
reporting at baseline for the depressed subjects was significant at 
twelve months (Q score p<0.01, AQLQ symptom score p<0.05). 
Figure 31a and b illustrate higher symptom reporting in depressed 
subjects and Figure 32 illustrate that depressed subjects attended 
their GP practice more often than non-depressed subjects did. 
 
 Figure 31a – Mean AQLQ symptom score at baseline and twelve 
months for Depressed and Non-Depressed subjects. 
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 Figure 31b - Mean Q score at baseline and twelve months for 
Depressed and Non-Depressed subjects. 
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 Figure 32 – Bar chart of Depressed and Non-Depressed subjects 
who attended GP Practice once or less and twice or more over 
twelve months. 
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4.2.5 Changes at twelve months – subjects who had Inhaled Steroid 
medication increased  
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Subject prescriptions for inhaled asthma medication were 
reviewed at twelve months. The cohort was sub divided by 
subjects who had had their inhaled steroids prescription increased 
at the time of the twelve months assessment when compared to 
baseline prescription. Subjects were placed in the no change 
group if their inhaled steroid prescription remained as at baseline 
or their prescription altered in some other way from baseline 
(inhaled steroids reduced, other medication added or altered).  
 
Eighteen subjects (18/95,19%) reported their inhaled steroids 
increased at twelve months resulting in sixteen subjects situated 
in the higher BTS treatment steps (3-5).  Fourteen subjects (14/95, 
15%) reported an alteration in their medication that did not 
involve an increase in inhaled cortico steroids. Such alterations 
included the addition of long acting agonist, a change in 
agonist, the addition of oral steroids, or the addition of other 
non-steroid medication eg, anticholinergic, theophyllines or 
cromoglycate. No subject had his or her inhaled steroids reduced 
at twelve months. While 63/95 (66%) reported no change in 
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inhaled steroid therapy. The data are shown in Tables 12a and b. 
 
Table 12a: Baseline Data and Twelve Months Data for 
Subjects with Inhaled Steroids Increased 
 
Variable 
Base 
Line 
N = 18 
% Mean (SD) 
12 
months 
N=18 
% Mean (SD) 
Age   44(8)    
Gender (male) 5 28     
Current smokers 5 28     
Living in inner city 12 67     
Using ß agonist 17 94  17 83  
Using inhaled steroids 17 91  18 91  
Using oral steroids 2 11  8 27  
BTS Guidelines 
treatment step (3-5) 5 28  16 80  
PEF   316L/min(115)   327L/min(98) 
FEV1   1.84L(0.70)   1.94L(0.71) 
AQLQ symptom score   4.24(1.51)   4.14(1.64) 
Q score   2.94(2.64)   3.22(2.77) 
HAD Anxiety   8.17(4.20)   8.94(5.42) 
HAD Depression   5.52(3.00)   5.16(3.39) 
Attends GP >1       
In 6 months    3 17  
 
Table 12b: Baseline Data and Twelve Months Data for 
Subjects with Inhaled Steroids Reduced or No Change at 
Twelve Months 
 
Variable 
Base 
Line 
N=77 
% Mean (SD) 
12 
months 
N=77 
% Mean (SD) 
Age   42(12)    
Gender (male) 29 38     
Current smokers 18 23     
Living in inner city 45 58     
Using ß agonist 71 92  67 87  
Using inhaled steroids 63 82  62 80  
Using oral steroids 4 5  3 4  
BTS Guidelines 
treatment step (3-5) 27 35  32 42  
PEF   350L/min(135)   327L/min(139) 
FEV1   2.25L(0.93)   2.16L(0.92) 
AQLQ symptom score   4.62(1.50)   4.58(1.37) 
Q score   2.93(2.45)   2.85(2.49) 
HAD Anxiety   8.07(4.59)   7.57(4.31) 
HAD Depression   5.23(3.96)   4.40(3.48) 
Attends GP >1       
In 6 months    8 10  
An increase in subjects inhaled steroids at twelve months was not 
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linked to age, gender, smoking habit or place of residence. 
Subjects who had inhaled steroids increased did have poorer 
initial lung function but no difference in symptoms or 
psychological status was observed at baseline. 
 
At twelve months subjects whose inhaled steroids were increased 
had improved their FEV1 by 100mls but with no improvement in 
symptoms while subjects with no increase in inhaled steroids had 
dropped their FEV1 by 90mls. No change in psychological status 
was observed between groups at twelve months. 
   
4.3 Changes and Relationships within the Cohort of Subjects at Twenty-
four Months 
 
At twenty-four months one hundred and six subjects were left in the 
study. One subject had left the area without any forward address and 
fifteen subjects refused appointments, were unable to attend for review or 
did not attend despite repeated contact. Baseline data from twenty-four 
subjects who withdrew from the study can be found in Appendix XII. 
Ninety subjects attended for review at twenty-four months (90/114) 79% 
of the cohort. There were seventy-nine subjects who attended for review 
at baseline, twelve and twenty-four months. Their data can by viewed in 
Appendix XIII. 
 
4.3.1 Twenty-four month data for 90 subjects 
 
Table 13 illustrates the baseline data set and twenty-four month 
data set for ninety subjects who attended for review. Data will be 
explored against baseline for differences in order to note any 
changes in values. The relationships between morbidity, (as 
measured by AQLQ symptom score and Q score) psychological 
status, (as measured by HAD scores) FEV1 and PEF will be 
explored by Spearman rank order correlation coefficient in order 
to assess if relationships established at baseline persist at twenty-
four months. 
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Table 13: Data from 90 Subjects at Baseline and at Twenty-
Four Months  
 
Variable Base 
Line 
N=90 
% Mean (SD) 24 
months 
N=90 
% Mean (SD) 
Age   43 (11)    
Gender(Male) 35 39     
Living in inner city 55 61     
Current smokers 25 28     
Using  agonist 83 92  77 86  
Using inhaled steroids 75 83  75 83  
Using oral steroids 7 8  8 9  
Inhaled steroids       
Increased at 24 months    11 12  
BTS Guidelines 
treatment step (3-5) 28 31  44 49  
PEF   357L/min(130)   344L/min(127) 
FEV1   2.25L(0.89)   2.37L(0.91) 
AQLQ   4.73(1.22)   4.73(1.28) 
AQLQ symptom score   4.62(1.47)   4.69(1.55) 
Q score   2.78(2.41)   2.80(2.5) 
HAD Anxiety   7.93(4.22)   7.81(4.93) 
HAD Depression   4.95(3.63)   5.06(3.93) 
 
 
The observation at baseline and twelve months for the proportion 
of female subjects and subjects residing in inner city areas 
attending for review was repeated at twenty-four months. At 
twenty-four months 61%, (51/90) of subjects were female and 
61% (55 /90) were from the inner city subgroup. 
 
The decrease in the use of agonist observed at twelve months 
from baseline was maintained at twenty-four months (93% at 
baseline, 88% at twelve months and 86% at twenty-four months). 
The use of inhaled steroids was maintained throughout the study 
period (83% at baseline, 84% at twelve months dropping 1% at 
twenty-four months). The use of oral steroids rose slightly from 
7% at baseline to 12% at twelve months then down slightly to 9% 
at twenty-four months.  
The stability of the population observed at twelve months was 
repeated at two years with only 2% of the cohort admitted to 
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hospital in excess of 24 hours for exacerbation of their asthma. 
Similar observations occurred at two years for GP visits with 66% 
(59/90) of the population not visiting their GP for exacerbation of 
their asthma (75% at twelve months). Again similar observations 
were recorded for those who did attend their GP for exacerbation 
of their asthma at two years, 52% (16/31) received one or more 
courses of oral steroids with 54% (13/24) at twelve months. On 
their last visit to their GP for their asthma subjects were asked as 
to the purpose of their visit, 20% of subjects required better 
control of their asthma symptoms. 
 
The group observations at twelve months were repeated at two 
years. Within the group of ninety subjects no significant 
differences were found at twenty-four months from baseline for 
PEF, FEV1, AQLQ, AQLQ symptom score, Q score, HAD 
anxiety or depression. However, there was a significant increase 
in the number of subjects in BTS treatment steps 3-5 (31% versus 
49%, p<0.001) from baseline to twenty-four months (McNemar 
test). Figure 33b illustrates this. 
 
 
 Figure 33a - Subjects in BTS Guidelines treatment steps (1-2 and 
3-5) at baseline. 
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 Figure 33b - Subjects in BTS Guidelines treatment steps (1-2 and 
3-5) at twenty-four months follow up (p<0.01).   
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The Relationship of Quality of Life Measures to Lung Function 
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 151
and Psychological Status at twenty-four months. 
  
Cross sectional changes 
The exploration of the cross sectional relationships of QoL 
measures to lung function and psychological status at baseline 
(see Table 2) was repeated at twelve months (see Table 8) and 
two years (see Table 14). At baseline symptom scores (AQLQ 
symptom score and Q score) were used as a measure of QoL, 
subjects spirometry (FEV1) and PEF were also recorded as a test 
of lung function, anxiety and depression were noted to assess 
psychological status and BTS guidelines treatment step as a 
measure of severity.  
 
The same observations recorded at baseline, twelve and twenty-
four months for symptoms of morbidity, Q score and AQLQ 
symptom score correlated in the same manner (both p<0.01) (see 
Figures 34a and b). Symptoms correlated to lung function (FEV1 
and PEF) (both p<0.01) at baseline this observation was repeated 
throughout the two year study period (see Figures 35a and c) as 
did anxiety and depression (both p<0.01). Figures 35b and d show 
the relationship of recorded PEF expressed as a percentage of 
predicted values to morbidity scores at twenty-four months. Lung 
function (FEV1) and PEF did not correlate to psychological status 
at two years. This was a different observation to baseline, 
depression weakly correlated to PEF while at twelve months 
anxiety (p<0.05) and depression (p<0.01) correlated to FEV1 and 
PEF. 
 
Longitudinal changes 
Within the group of ninety subjects reviewed there were no 
significant differences at twenty-four months from baseline for 
PEF, FEV1, AQLQ, AQLQ symptom score, Q score, HAD 
anxiety or depression.  
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Table 14: Spearman Rank Order Correlation Coefficients for 
90 subjects at Twenty-four Months 
 
 Q 
Score 
24 
months 
AQLQ 
Symptom 
Score 
24 months 
HAD 
Anxiety 
24 
months 
HAD 
Depression 
24 months 
FEV1 
24 
months 
PEF 
24 
months 
Q Score 24 
months  -.748 .351 .473 -.469 -.454 
AQLQ 
symptom score 
24 months 
-.748  -.400 -.485 .285 .321 
HAD Anxiety 
24 months .351 -.400  .719 NS NS 
HAD 
Depression 24 
months 
.473 -.485 .719  NS NS 
FEV1 
24 months -.469 -.469 NS NS   
PEF 
24 months -.454 .321 NS NS   
 
All values were significant p<0.01 NS not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 34a - Baseline Q score correlated to Q score at twenty-
four months (p<0.01) 
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 Figure 34b - Baseline AQLQ symptom score correlated to AQLQ 
symptom score at twenty-four months (p<0.01). 
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 Figure 35a - Morbidity as measured by AQLQ symptom score 
correlated to poor lung function as measured by PEF at twenty-
four months (p<0.01). 
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 Figure 35b - Correlation of PEF at twenty four months as a 
percentage of predicted PEF to morbidity as measured by AQLQ 
symptom score (p<0.01) 
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 Figure 35c Morbidity as measured by Q score correlated 
inversely to poor lung function as measured by PEF at twenty-
four months (p<0.01). 
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 Figure 35d - correlation of PEF at twenty four months as a 
percentage of predicted PEF to morbidity as measured by Q score 
(p<0.01) 
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4.3.2 Changes at twenty-four months – the population sub divided by 
place of residence. 
 
The population was subdivided by their place of residence at 
baseline. Sixty-five percent (70/114) of subjects lived within the 
inner city area (see Table 4a and b). Similar proportions for 
groups’ inner city and suburban residents attended for review at 
two years (inner city residents, 61%, 55/90) these data are shown 
in Table 15a and b. This was a repartition of the baseline and 
twelve months observation (see Table 9a and b). 
 
Table 15a: Baseline Data and Twenty-Four Month Data for 
Inner city subjects  
 
Variable Base Line 
N=55 
% Mean (SD) 
24 
months 
N=55 
% Mean (SD) 
Age   41(12)    
Gender (male) 21 38     
Smoking 21 38     
Using ß agonist 50 91  48 87  
Using inhaled steroids 46 84  46 84  
Using oral steroids 4 7  7 13  
Inhaled steroids 
increased at 24 months    8 15  
BTS Guidelines 
treatment step (3-5) 15 27  24 44  
PEF   350L/min(137)   333L/min(137) 
FEV1   2.2L(0.95)   2.36L(0.97) 
AQLQ   4.47(1.35)   4.42(1.36) 
AQLQ symptom score   4.25(1.52)   4.29(1.62) 
Q score   3.25(2.67)   3.27(2.67) 
HAD Anxiety   9.22(4.00)   8.70(4.40) 
HAD Depression   5.83(3.97)   5.69(3.98) 
Attends GP >1       
In 6 months    11 20  
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Table 15b: Baseline Data and Twenty-Four Month Data for 
Suburban subjects  
 
Variable 
Base 
Line 
N=35 
% Mean (SD) 
24 
months 
N=35 
% Mean (SD) 
Age   45(11)    
Gender (male) 14 40     
Smoking 4 11     
Using ß agonist 33 94  29 83  
Using inhaled steroids 29 3  29 83  
Using oral steroids 3 9  1 3  
Inhaled steroids 
increased at 24 months    2 6  
BTS Guidelines 
treatment step (3-5) 13 37  20 57  
PEF   369L/min(117)   360L/min(110) 
FEV1   2.29L(0.78)   2.38L(.80) 
AQLQ   5.14(0.88)   5.21(.95) 
AQLQ symptom score   5.22(1.20)   5.30(1.22) 
Q score   2.05(1.71)   2.07(2.04) 
HAD Anxiety   5.94(3.81)   6.40(5.42) 
HAD Depression   3.60(2.51)   4.08(3.69) 
Attends GP >1       
In 6 months    2 6  
 
Fifty-five (61%) subjects resided and attended GP practices 
within the inner city. Little change occurred in the usage of 
agonist or inhaled steroids over the two-year period although 
there was an increase in the use of oral steroids (7% versus 13%). 
There was however, an increase in the number of subjects in the 
higher treatment group (BTS Guidelines treatment step 3-5) of 
17% (p<0.01), this was a repeated observation from baseline to 
twelve months. 
 
Thirty-five (39%) subjects resided and attended GP practices 
within the suburbs. There was little change in the use of 
medication over the two-year period in the suburban subjects. 
Although there was an increase in the dosage of inhaled steroids 
as noted by the 20% increase in the number of subjects in steps 3-
5 (p<0.01), this was a repeated observation from baseline to 
twelve months. 
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The observation of no significant difference for lung function 
(FEV1 and PEF) between groups at baseline was repeated at 
twelve and twenty-four months.  
 
At baseline there were no significant differences between groups 
for morbidity scores. However, at twelve months morbidity score 
were significantly higher in inner city subjects. This observation 
was repeated at two years where morbidity as measured by Q 
score and AQLQ symptom score were significantly higher in 
inner city subjects (p<0.05 and p<0.01 respectively). Levels of 
treatment for inner city subjects did increase more so than 
suburban subjects at twelve months and this was repeated at two 
years. Inner city subjects received more oral steroids (13% versus 
3%) and 15% versus 6% had their inhaled steroids increased.  
 
The relationship of psychological status between groups changed 
over the two-year period. At baseline inner city subjects were 
significantly more anxious and depressed this was repeated at two 
years although the relationships were not as strong (anxiety 
p<0.01 and depression p<0.05). At twelve months inner city 
subjects remained depressed but no more anxious than their 
suburban counterparts. Figures 36a and b illustrate inner city 
subjects were more depressed and had increased morbidity levels 
when measured by AQLQ symptom score and Q score 
 
 Figure 36a – Mean AQLQ symptom scores and HAD Depression 
scores for inner city and suburban subjects at twenty-four months. 
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 Figure 36b - Mean Q scores and HAD Depression scores for 
inner city and suburban subjects at twenty-four months. 
 
 
 
 159
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 HAD Depression score at 24 mths
14.00
12.00
10.00
8.00
6.00
4.00
2.00
M
ea
n 
To
t
8
6
4
2
0
 
 
 
 
 
4.3.3 Changes at twenty-four months - the population sub divided for 
al
 Q
 S
co
re
 a
t 2
4 
m
th
s
Inner city subjects
Suburban subjects
 
 160
severity (BTS Guidelines treatment step 1-2 versus 3-5) 
 
Subjects were sub divided at baseline into two groups according 
to asthma severity, BTS Guidelines treatment step 1-2 and 3-5  
(see Table 6a and b). The majority of the subjects recruited to the 
study were in the lower treatment step of 1-2, 70% (80/114) at 
baseline. At twelve months 79% (63/80) attended for 
reassessment and 78% (62/80) at two years. A high percentage of 
subjects in treatment steps 3-5 attended for review at twelve 
months (94%, 32/34) this was repeated at two years with 82% 
(28/34) of subjects attending.  At two-year follow up the majority 
of subjects (69%, 62/90) remained in the lower treatment group of 
BTS Guidelines treatment step 1-2.These data are shown in Table 
16a and b. 
 
Table 16a:Baseline Data and Twenty-Four Month Data for 
subjects in BTS Guidelines treatment step 1-2 
 
Variable 
Base 
Line 
N=62 
% Mean (SD) 
24 
months 
N=62 
% Mean (SD) 
Age   41(12)    
Gender (male) 21 34     
Smoking 19 31     
Inner city 40 65     
Using ß agonist 55 89  50 81  
Using inhaled 
steroids 47 76  47 76  
Using oral steroids 1 2  1 2  
PEF   362L/min(117)   343L/min(127) 
FEV1   2.30L(0.79)   2.39L(0.87) 
AQLQ symptom 
score   4.80(1.40)   4.88(1.48) 
Q score   2.19(2.09)   2.62(2.45) 
HAD Anxiety   8.11(4.25)   8.12(4.94) 
HAD Depression   4.50(3.68)   4.61(3.93) 
Attends GP >1       
In 6 months    6 10  
 
 
 
Table 16b:Baseline Data and Twenty-Four Month Data for 
subjects in BTS Guidelines treatment step 3-5 
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Variable 
Base 
Line 
N=28 
% Mean (SD) 
24 
months 
N=28 
% Mean (SD) 
Age   47(10)    
Gender (male) 14 50     
Smoking 6 21     
Inner city 15 54     
Using ß agonist 28 10  27 96  
Using inhaled steroids 28 0  28 100  
Using oral steroids 6 0  7 25  
PEF   344L/min(157)   345L/min(129) 
FEV1   2.13L(1.08)   2.32L(1.00) 
AQLQ symptom score   4.23(1.58)   4.26(1.64) 
Q score   4.25(2.45)   3.17(2.62) 
HAD Anxiety   7.51(4.20)   7.10(4.91) 
HAD Depression   6.00(3.33)   6.07(3.79) 
Attends GP >1       
In 6 months    7 25  
 
Sixty-nine percent (62/90) of subjects from baseline were in BTS 
Guidelines treatment step 1-2 requiring minimal medication to 
reduce asthma symptoms.  
 
Thirty-one percent (28/90) of subjects from baseline were in BTS 
Guidelines treatment step 3-5 requiring moderate medication to 
minimise asthma symptoms. At twenty-four months all subjects 
(100%) within BTS Guidelines treatment step 3-5 had remained 
in the same step from baseline. 
 
There were no significant differences between these groups at two 
years. However, the trend of increased morbidity associated with 
anxiety and depression in higher treatment steps noted at twelve 
months was repeated at two years. At twenty-four months 
subjects in high treatment steps also visited their GP practice 
more often (10% versus 25%) than their step 1-2 counter parts. 
Figures 37 and 38 illustrate subjects in high treatment step were 
more depressed and exhibited more symptoms of asthma than 
subjects in low treatment step. Figure 39 illustrates subjects in 
high treatment steps attended their GP practice more often than 
other subjects did. 
 
 Figure 37 - Mean HAD Anxiety and Depression scores for BTS 
Guidelines treatment steps 1-2 and 3-5 at twenty-four months.  
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4.3.4 Change at twenty-four months –the population subdivided by 
initial psychological status 
 
The population was subdivided for depression at baseline (see 
Table 5a and b). Subjects with HAD depression scores of 7 or less 
were said to exhibit no sign of depression or anxiety while those 
with scores of 8 or greater were placed in the depressed group. 
The proportion of depressed subjects was maintained throughout 
the two year study period with 27% (30/113) depressed at 
baseline, 27% (26/95) at twelve months and 24% (22/90) at two 
years. Three-quarters (76%, 83/113) of the cohort were not 
depressed at baseline. Leaving 24% (30/113) of subjects 
depressed, of those depressed subjects 86% (25/30) resided within 
the inner city and smoked (32% versus 27%) more than their non-
depressed counterparts. Twenty-four percent (22/90) of subjects 
were classed as depressed at outset with HAD depression scores 
of 8 or more.  At twenty-four months 14/22 (64%) subjects 
remained depressed. Seventy-six percent (68/90) of subjects were 
classed as non-depressed at outset with HAD depression scores 
below 8. At twenty-four months 58/68 (85%) subjects remained 
non-depressed. These data are shown in Table 17a and b. 
Table 17a: Baseline Data and Twenty-Four Months Data for 
Depressed subjects 
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Variable 
Base 
Line 
N=22 
% Mean (SD) 
24 
months 
N=22 
% Mean (SD) 
Age   48(8)    
Gender (male) 8 36     
Smoking 7 32     
Inner city 19 86     
Using ß agonist 19 86  19 86  
Using inhaled steroids 20 91  20 91  
Using oral steroids 3 14  3 14  
Inhaled steroids 
increased at 24 months    5 23  
BTS Guidelines 
treatment step (3-5) 9 41  16 73  
PEF   318L/min(147)   320L/min(139) 
FEV1   2.06L(.97)   2.17L(0.98) 
AQLQ symptom score   3.73(1.52)   3.85(1.80) 
Q score   4.13(2.47)   4.09(2.89) 
HAD Anxiety   11.68(4.24)   10.72(4.53) 
HAD Depression   10.04(2.21)   8.59(3.41) 
Attends GP >1       
In 6 months    5 23  
 
 
Table 17b: Baseline Data and Twenty-Four Months Data for 
Non-Depressed subjects 
 
Variable 
Base 
Line 
N=68 
% Mean (SD) 
24 
months 
N=68 
% Mean (SD) 
Age   41(12)    
Gender (male) 27 40     
Smoking 18 27     
Inner city 36 53     
Using ß agonist 64 94  58 85  
Using inhaled steroids 55 81  55 81  
Using oral steroids 4 6  5 7  
Inhaled steroids 
increased at 24 months 
      
BTS Guidelines 
treatment step (3-5) 19 28  29 43 
 
PEF   369L/min(123)   351L/min(123) 
FEV1   2.30L(0.86)   2.43L(0.88) 
AQLQ symptom score   4.91(1.34)   4.96(1.37) 
Q score   2.35(2.23)   2.38(2.23) 
HAD Anxiety   6.70(3.44)   6.86(4.70) 
HAD Depression   3.28(2.13)   3.92(3.38) 
Attends GP >1       
In 6 months    8 12  
 
There were more depressed subjects in the higher treatment step 
(3-5) at baseline and at twelve months this trend was maintained 
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at twenty-four months (73% versus 43% at twenty-four months). 
At the two-year assessment the increase in the number of subjects 
from both groups into the higher treatment step observed at 
twelve months was maintained. Seventy-three percent of 
depressed subjects were in steps 3-5 by twenty-four months, 
increase in the number of subjects in the higher treatment group 
with 23% having their inhaled steroids increased. Subjects were 
said to have inhaled steroids increased at two years if their initial 
inhaled steroid therapy prescription was increased at the time of 
the two-year review. It should be noted that more subjects in the 
depressed group (23%) reported their inhaled steroids increased at 
twenty-four months than non-depressed subjects (7%) did. This is 
directly opposite to the twelve-month increase.    
 
The initial and twelve-month observation that depressed subjects 
remained significantly more depressed and anxious was 
maintained at two years (both p<0.001). The twelve month 
observation regarding symptoms was also repeated at two years 
with depressed subjects reporting more symptoms of asthma (Q 
score p<0.05, AQLQ symptom score p<0.01) than their non-
depressed counterparts. The observation at twelve months of 
depressed subjects attending their GP practice more often than a 
non-depressed subject was maintained at two years. Depressed 
subjects attended their GP practice on more than two occasions 
23% versus 12% than non-depressed subjects (see Figures 40a 
and b and 41). 
 
 
 Figures 40a – Mean AQLQ symptom scores for depressed and 
non-depressed subjects at twenty-four months. 
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 Figure 40b - Mean Q scores for depressed and non-depressed 
subjects at twenty-four months. 
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 Figure 41  - Attendance at GP practice in last six months prior to 
twenty-four month review for depressed and non-depressed 
subjects.  
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4.3.5 Changes at twenty-four months – subjects with Inhaled Steroids 
medication increased  
 
Subject prescriptions for inhaled asthma medication were 
reviewed at twenty-four months. The cohort was sub divided by 
subjects who had their inhaled steroid prescription increased at 
the time of the two-year assessment (‘increased treatment’ group) 
when compared to baseline prescription. Subjects were placed 
into the ‘no change’ group if their inhaled steroid prescription 
remained as at baseline or their prescription altered in some other 
way from baseline (inhaled steroids reduced, other medication 
added or altered). Ten (11%) subjects recorded inhaled steroids 
increased at twenty-four months. Eighty (89%) subjects reported 
no change or a reduction in inhaled steroids at twenty-four 
months. These data are shown in Table 18a and b. 
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Table 18a: Baseline Data and Twenty-Four Months Data for 
Subjects with Inhaled Steroids Increased  
 
Variable 
Base 
Line 
N=10 
% Mean (SD) 
24 
months 
N=10 
% Mean (SD) 
Age   43 (8)    
Gender (male) 4 40     
Smoking 3 30     
Inner city 8 80  10 100  
Using ß agonist 9 90  10 100  
Using inhaled 
steroids 8 80  10 100  
Using oral steroids 0 0  3 30  
BTS Guidelines 
treatment step (3-5) 3 30  10 100  
PEF   365L/min(118)   323L/min(130) 
FEV1   2.46L(0.87)   2.40L(0.91) 
AQLQ symptom 
score   4.02(2.02)   4.15(1.59) 
Q score   3.60(2.95)   4.10(2.99) 
HAD Anxiety   10.40(4.35)   8.70(5.07) 
HAD Depression   6.70(4.00)   6.56(4.64) 
Attends GP >1       
In 6 months    4 40  
 
 
Table 18b: Baseline Data and Twenty-Four Months Data for 
Subjects with no change or a reduction in inhaled steroids 
 
 Variable 
Base 
Line 
N=80 
% Mean (SD) 
24 
months 
N=80 
% Mean (SD) 
Age   43(12)    
Gender (male) 31 39     
Smoking 22 28     
Inner city 47 59     
Using ß agonist 74 93  67 83  
Using inhaled 
steroids 
67 83  65 81  
Using oral steroids 7 9  5 6  
BTS Guidelines 
treatment step (3-5) 25 31  36 44  
PEF   356L/min(132)   346L/min(0.91) 
FEV1   2.25L(0.90)   2.35L(0.91) 
AQLQ symptom 
score 
  4.70(1.39)   4.75(1.55) 
Q score   2.68(2.33)   2.63(2.41) 
HAD Anxiety   7.62(4.13)   7.70(4.93) 
HAD Depression   4.73(3.54)   4.88(3.82) 
Attends GP >1       
In 6 months    9 11  
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Ten subjects (10/90, 11%) reported their inhaled steroids 
increased at twenty-four months. Twelve percent (11/90) of 
subjects reported an alteration in their medication that did not 
involve an increase in their inhaled steroids. Such alterations 
included the addition of oral steroids, or the addition of other non-
steroid medication eg, anticholinergic, theophylline or 
cromoglycate while one subject had their inhaled steroid stopped 
at two years. Sixty-nine subjects (69/90, 77%) recorded no 
change in inhaled steroids while. Overall seven subjects moved 
into the higher BTS treatment steps (3-5) over the two-year 
period. Figure 42 illustrates the limited increase in inhaled 
steroids in high and low treatment steps at two years. 
 
Any increases in subjects inhaled steroids at two years were not 
linked to age, gender, smoking habit, or place of residence. At 
baseline the ‘increased treatment’ group did have slightly better 
PEF, but also had a slight increase in morbidity and psychological 
status. Figure 43a and b illustrate little change in morbidity 
despite any increase in inhaled steroids at two years. 
 
At two years there was deterioration in PEF for both groups but 
spirometry had increased slightly in the ‘no change’ group.  The 
‘increased treatment’ exhibited a slight increase in morbidity and 
psychological status. It should be noted that subjects whose 
inhaled medication was increased attended their GP practice more 
often (40% versus 11%) than other subjects. 
 
 
 
 
 
 
 
 
 
 Figure 42 – Bar chart of subjects in BTS Guidelines treatment 
steps 1-2 and 3-5 with inhaled steroids increased, unchanged or 
reduced at twenty-four months 
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 Figures 43a – Mean Q score for BTS Guidelines treatment steps 
1-2 and 3-5 at baseline and twenty-four months. 
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 Figures 43b – Mean AQLQ symptom score for BTS Guidelines 
treatment steps 1-2 and 3-5 at baseline and twenty-four months  
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4.4 Discussion – Year One and Year Two Data 
 
The aim of this study was to observe the management of a cohort of 
known asthmatic subjects in their own primary health care setting over a 
two-year period. The results of that observational process are examined in 
this section. Year one and year two data are dealt with together.  
 
Objectives for the study were related to the observation of asthma 
management in primary care over the two-year period.  Assessing subjects 
from differing socio-economic groups and exploring the relationship of 
morbidity to lung function, asthma severity, psychological status and 
increase in asthma medication. 
 
Overview of the two year study 
The majority of asthmatic subjects are routinely managed in primary care 
(Neville et al, 1999); the results presented in this thesis were obtained 
from adult subjects whose asthma management was under the control of 
their GP. The strength of this study lies in its observation of routine 
clinical practice in its natural setting over a two-year period. At no time 
throughout the study period was there any interference by the researcher 
into routine clinical practice. Data were gathered from subjects separate to 
GP assessment or review and were recorded and stored separate to GP 
data. Data gathered are therefore reflective of conventional GP care 
within the community and the same variables were gathered repeatedly 
over time. Subjects recruited for this study were ordinary adult asthmatics 
that could be recruited from any GP practice and are therefore by nature 
different from highly selected or trained subjects that are commonly used 
in clinical trails.  
 
This study examined two groups of subjects from differing socio-
economic backgrounds (inner city and suburban areas). Whilst differing 
socio-economic background can be objectively assessed by Jarman scores 
(Jarman, 1983) this study cannot differentiate between the health service 
providers. All GP practices professed to manage asthma patients 
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according to published BTS Asthma Guidelines (Thorax, 1993 and 1997) 
so the same therapies were available to all subjects.  
 
One hundred and fourteen adult asthmatic subjects were recruited and had 
their treatment observed over a two-year period. Eighty three percent of 
subjects attended for review at one year while 79% attended for two-year 
review. Only one subject died and one subject moved away from the area 
during the study period. Although more female subjects and inner city 
residents were recruited to the study, the proportions attending from 
baseline to one and two-year recall remained constant (female subjects 
63%, 64% and 61% respectively, inner city residents 65%, 60% and 61% 
respectively). Twenty-four subjects did not complete the study, their data 
can be found in Appendix XII. There were no significant differences at 
baseline between the subjects who withdrew from the study and those 
who continued in regard of their spirometry, PEF, asthma severity, 
psychological status or QoL. 
 
Results obtained and conclusions drawn were based on a group of 
asthmatic patients that were randomly selected from their primary care 
base. The method of recruitment for this study was inclusive enough for 
conclusions to be applicable to other GP practices operating in similar 
circumstances. However, it should be noted difficulties were encountered 
when recruiting for suburban subjects. Within the cohort there would 
appear to be a recruitment bias towards subjects residing within the inner 
city (discussed in section 4.4.2). Subjects residing within the inner city 
had significantly increased psychological status at baseline (p<0.001 for 
HAD anxiety and p<0.01 for HAD depression) and this observation was 
present throughout the study period. At twelve months inner city subjects 
were more depressed (p<0.05) but not anxious while at two years they 
remained more depressed (p<0.05) and were again more anxious 
(p<0.01). Increased morbidity was also observed in this sub-group over 
the two years. At baseline no significant differences were noted but at 
twelve months morbidity scores were significantly increased (Q score 
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p<0.001 and AQLQ symptom score p<0.01) in the inner city sub-group 
and remained so at two years (Q score and AQLQ symptom score p<0.05 
and p<0.01 respectively). However, there were no other significant 
differences between groups.    
 
Overview of results - Cross-sectional analysis 
The subjects were assessed at baseline and over the two year study period 
for interactions between spirometry and PEF, morbidity and overall QoL, 
psychological status, asthma severity and inhaled steroid increase. This is 
the first observational study assessing subjective and objective markers of 
asthma to be carried out over two years. Objective markers of asthma 
were recorded as spirometry, PEF and asthma severity, while subjective 
markers were considered as subject’s HRQL including morbidity and 
psychological status (see Tables 1, 7 and 13 and 2, 8 and 14). The study 
explored the relationships between subjective and objective markers of 
asthma at baseline and over the two-year study period. Relationships 
were examined between subjects from differing socio-economic 
backgrounds, (see Tables 4a and b, 9a and b, 15a and b). Subjects with 
increased or reduced asthma severity (see Tables 6a and b, 10a and b, 16a 
and b). Differing psychological status (see Tables 5a and b, 11a and b, 
17a and b) and from subjects with differing medication again over the 
two-year period (see Tables 12a and b and 18a and b). The inter-
relationships of subjective and objective markers of asthma are discussed 
in section 4.4.1. 
 
Poor lung function (spirometry and PEF) was associated with increased 
symptoms  (AQLQ symptom score and Q score) and severity at baseline 
and observed throughout the study period (see Figures 6 and 7, 16 and 17, 
26a and c and 27a and c and 35a and c). Recorded values for PEF and 
FEV1 were both expressed as a percentage of the predicted values for 
each subject in order to control for age, height and gender (see Figures 6a 
and 7a, 16a and 17a, 26b and d and 27b and d and 35b and d).This did not 
improve the regression and findings must be due to other factors. 
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Depression was associated with these findings but the strength of the 
relationship varied throughout the study period (see Figures 10, 11 and 
12, 31 a and b and 40a and b). 
 
Overview of results - Longitudinal analysis 
Differences between groups of subjects were also explored over time. The 
responses of subjects from different socio-economic backgrounds were 
sort (see Tables 4a and b, 9a and b and 15a and b). Results obtained at 
one and two year review indicate that there was little difference in 
objective markers of asthma (spirometry and PEF) between subjects 
residing in the inner city and their suburban counterparts. However, the 
initial observation of subjects from more deprived areas with increased 
morbidity did not diminish over time (see Figure 13 and 15). 
Observational data recorded over the two year period for subjects residing 
in inner city and suburban areas are discussed section 4.4.2. 
  
In order to establish the cohort as representative of an asthma population 
the severity of subjects according to BTS treatment step was recorded at 
baseline (see Table 1). The majority of subjects recruited (70%) were in 
lower treatment steps and were reflective of a community based asthma 
population (Neville et al, 1999). Changes in asthma severity were 
observed over time in order to assess if reported changes in morbidity 
reflected severity. Subjects in higher treatment steps with more severe 
asthma reported more symptoms (see Figure 29 and 38) and were seen 
more often in the GP practice (see Figure 39). Thus subsequently 
received more treatment but reported no significant reduction in 
symptoms at one or two year review. The lack of improved outcome for 
subjects following an intervention by the GP practice is discussed in 
section 4.4.3. 
 
 
Psychological status is not routinely assessed in asthmatics yet the 
influence the patients psyche can exert over their asthma has been 
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documented (Harrison, 1998). The initial observation of subjects with 
increased psychological scores reporting more asthma symptoms and 
visiting their GP practice more often than their non-depressed 
counterparts was repeated over the two year period (see Figures31a and b, 
32, 40a and b and 41). It was noted that more subjects who were 
depressed came from inner city areas and this observation remained 
constant. It was unknown if subjects with increased psychological status 
were recognised and treated by the clinician but these subjects received 
more treatment for their asthma symptoms. Data gathered over the two-
year study period for subjects with differing psychological status are 
discussed in section 4.4.4. 
 
Current asthma management guidelines recommend increasing inhaled 
steroids to combat increased symptoms (Thorax, 1997). All GP practices 
recruited into the study operated using current guidelines. Any alteration 
in inhaled steroid medication was recorded at twelve and twenty-four 
months for all subjects against reported symptoms, anxiety and 
depression (see Tables 12a and b and 18a and b). If subjects were 
compliant then increasing inhaled anti-inflammatory medication would be 
expected to reduce symptoms and possibly alleviate anxiety and 
depression over time. Subjects with recorded increases in inhaled steroid 
medication did not note any significant reduction in symptoms, anxiety or 
depression following their treatment intervention. The lack of improved 
outcome for subjects following an intervention by the GP practice is 
discussed in section 4.4.5. 
 
4.4.1  The relationship of Quality of Life measures to lung function and 
psychological status throughout the two-year study period. 
 
  Relationships at baseline 
 
The relationship of asthma QoL, especially morbidity in 
association with lung function and psychological status at 
baseline were explored (see Tables 2, 8 and 14). Objective 
markers of asthma ie, lung function are the markers most 
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commonly used by clinicians to assess for improvement or 
deterioration in asthma status. Alteration in these objective 
markers can lead to an increase or reduction in asthma 
medication. However, the patient may be unaware of any changes 
in lung function but may be receptive to small changes in 
symptoms. Does the health professional managing the patient 
assess symptoms in a similar manner to lung function? It has been 
previously documented (Juniper, 1998) that symptom reporting is 
subjective, subjects matched for lung function can report different 
symptom scores. 
 
The problems associated with symptom reporting 
In the overall cohort depression was the best predictor of 
symptoms (see section 3.4.7). This relationship might have 
important implications if the management of asthma is based 
upon symptom reporting alone. This study observed a sub-group 
of subjects at baseline (see Table 5a) who recorded increased 
morbidity and depression and also received more therapy 
(treatment steps 3-5). This could indicate there was a small group 
of subjects with mild depression who were receiving more 
medication in response to increased symptoms. The symptoms 
may be due to asthma but the reporting of the same symptoms 
may well differ between subjects (Juniper, 1998).  If this 
hypothesis is correct then increasing asthma medication may 
therefore do little to alleviate asthma symptoms if they are 
associated with depression. 
 
Asthma guidelines recommend the use of serial PEF monitoring. 
The experience of this study (see section 3.4.1) concludes that 
such data may not be readily available for the clinician at 
consultation and treatment may therefore be based on symptom 
reporting alone. Baseline data from this study reveals increased 
symptoms, depression and asthma therapy associated with 
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subjects residing in inner city areas (see Tables 4a and b, Figures 
13, 14 and 15). Such symptom reporting in the inner city cohort 
may well be due to the stresses and strains of life under poor 
socio-economic conditions rather than any real increase in asthma 
symptoms. The implication of this finding is that little 
improvement can be expected if management is based upon 
symptom reporting accompanied by an increase in medication. 
Other possible causes for an increase in symptoms should be 
explored to ensure maximum improvement in these subjects. 
Does this observation reveal a sub-group of asthma patients in 
high treatment step (3-5) who are depressed by their long-term 
illness or does the increased awareness of symptoms result in 
depression? Therapy directed solely to asthma symptoms may not 
be always be appropriate, other factors such as increased 
psychological status may be worth considering (Rimington et al, 
2001). 
 
Relationships over the two year period 
The population of asthmatics recruited for the study changed little 
during the two year period with only one subjects dying and one 
subject moving away from the area. Few subjects were admitted 
to hospital for more than twenty-four hours for exacerbation of 
their asthma symptoms over the two-year study period (2% at 
baseline, twelve and twenty-four months). As asthma is by nature 
a variable disease individual patients may well have attended the 
study assessment sessions when symptoms were increased. Any 
individual variations could be reduced by using group data thus 
diminishing the impact on the overall nature of the data.  
 
It was to be expected there would be little significant change in 
symptom reporting by the more stable patients regardless of 
severity. A community-based population is by nature more stable 
that a hospital population requiring specialist care (Neville et al, 
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1999). However, there was a significant increase in the number of 
subjects into steps 3-5. The increased drug dosage may imply 
poor symptom control but it has been reported that symptom 
reporting can vary between subjects (Juniper, 1998). At the start 
of the study period there were 30% (34/114) of subjects in steps 
3-5, this increased to 51% (48/95) at twelve months and 49% 
(44/90) at twenty-four months. If the increase in morbidity had 
been tackled by increased therapy then a reduction in symptom 
reporting should have been evident at the end of the two-year 
period. Poor control of symptoms persisted despite increased 
therapy. Also in the high treatment group (treatment steps 3-5) 
were subjects reporting increased psychological status (anxiety 
and depression) (see Figures 30 and 37). This increased 
psychological status would appear to be a problem not always 
associated with asthma and not necessarily recognised or tacked 
by a GP practice (Centanni et al 2000).  
 
Objective markers of asthma (spirometry and PEF) along with 
morbidity and psychological status were assessed over the two-
year period for differences. Table 7 illustrates twelve month data 
while Table 13 displays twenty-four month data. Morbidity scores 
changed little throughout the study period (see Figures 23a and b 
for twelve months and Figures 34a and b for twenty-four months). 
It is disappointing to note that morbidity did not decrease in line 
with increased therapy. Although both spirometry and PEF are 
known to decline with age (Cotes, 1993), there were no 
significant differences at twelve or twenty-four months. Lung 
function correlated to morbidity throughout the study period, as 
did anxiety and depression, patients with poor lung function 
complained of more asthma symptoms. Observations at baseline 
for lung function, morbidity and psychological status remained 
constant over time; patients did not deteriorate neither did they 
improve. However, severity of asthma did change over time. At 
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baseline and twenty-four months subjects with more severe 
asthma (steps 3-5) reported increased morbidity with poorer 
spirometry and PEF (see Figures 23a and b, 26a and b, 35a and 
b). Psychological scores responded in the same manner. The 
number of subjects in the higher treatment steps (3-5) increased 
significantly at twelve and twenty-four months (both p<0.001). It 
is however disappointing to note that in the cohort as a whole 
symptom reporting did not diminish in response to the increase in 
asthma treatment. 
 
Guidelines for asthma management were reviewed in 1995 
(Thorax, 1997) part way through this study. It would appear that 
the recommendations included within these and previously 
published guidelines (BMJ 1990 and Thorax 1993) to use the 
‘step wise approach’ to care may have been adhered to by the GP 
practices. The number of subjects receiving inhaled asthma 
therapy rose over the two-year period (see sections 4.2.5 and 
4.3.5).   
 
The majority of subjects who visited their GP did so in order to 
achieve a reduction in their asthma morbidity. Some subjects did 
receive increased asthma medication as recommended by 
guidelines but all subjects did not record reduced asthma 
symptoms (see Tables 12a and 18a). The lack of a significant 
reduction in symptom reporting may be due to a variety of 
reasons. This may well have been due to a lack of structured care 
either by the GP practice or the patients themselves.  Subjects 
may not have been asked to return to the GP practice following a 
suitable period in order to report their symptoms or subjects may 
not have bothered to report improvements to their GP or there 
may well have been a lack of compliance with prescribed 
medication. Poor compliance is a common feature for many 
patients receiving long term medication for chronic disease (Dales 
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et al 1989, Horn et al, 1990, Cochrane, 1993, Bosley et al, 1994, 
Yeung et al, 1994, Cochrane, 1996). Monitoring of symptoms is a 
crucial component of structured asthma care (Thorax 1997). A 
patient focused morbidity index such as the Q score (Rimington et 
al, 1997) or Jones score (Jones et al, 1992b) if used in the primary 
care setting could highlight subjects with increased medication 
and no subsequent reduction in morbidity.  
 
Neville et al, (1997) in their UK study compared the management 
of acute asthma attacks by GPs in 1991/92 to 1992/93. Neville 
acknowledges the uptake of the invitation to participate in the 
study signals an interest in asthma so is not therefore 
representative of all UK GP practices. Similarly this study group 
mirrors that same interest and willingness to participate. Bearing 
in mind the first set of asthma guidelines were published in the 
UK in 1990 Neville and colleagues noted the gap between the 
management of acute attacks that occurred in GP practice and the 
recommendations for management that were given in the newly 
published guidelines. They did however comment on the 
increased use of inhaled steroids in the follow-up year (1992/93) 
as compared to the initial survey of 1991/92. UK asthma 
guidelines have been reviewed, published and distributed to all 
UK GP practices since 1990. GP practices participating in this 
study some three to four years later also reflect the same increase 
in the use of inhaled steroids following the 1995 review of asthma 
guidelines (published in 1997).  As guidelines were reviewed and 
published part way through the study, has this re-enforced the 
goals of asthma management to participating practices? 
According to Hoskins et al, 1998, 2000 and Osman et al, 1996 GP 
practices could benefit from continued input and support with 
asthma management in addition to published guidelines  
The publication of guidelines has brought about a change in the 
management of asthma in the primary care setting (Neville et al, 
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1997) but to maximise the desired outcome for patients 
publication of guidelines alone may not be enough. It has 
previously been documented that many practitioners freely 
interpret guidelines (Legorreta et al, 1998). Input by local 
specialist (be they consultant physician or GP with special 
interest) on a regular basis may be what is required to bring about 
consistency in the use and interpretation of guidelines. The 
difficulty remains not only in recruiting GP practices unwilling to 
participate but also in the amount of time required to achieve and 
maintain change. Some subjects in the present study did receive 
an increase in therapy, as a response to increased symptom 
reporting (see Tables 12a and b, 18a and b). What they may not 
have received or decided not to participate in was structured 
follow-up. Lack of structured care could lead to little 
improvement in outcome for patients. Could input by local 
specialist re-enforce guidelines or would audit of asthma 
management by individual GP practices highlight gaps in their 
implementation? Further study is required to answer such 
questions locally but others have already carried out further 
investigations. 
 
The Tayside Asthma Management Initiative was set up with the 
aim of providing a regional led asthma management programme 
for use in primary care (Hoskins et al, 1998). The Tayside group 
wished to improve the management of asthma in primary care in 
order to reduce the number of acute asthma admissions, thus 
relieving pressure on acute services in their region and across 
Scotland (Hoskins et al, 2000). They offered to local practices a 
distance learning package related to asthma and detailed feedback 
regarding the asthma management of a number of selected cases. 
Subjects participating in the study were assessed by means of the 
Tayside Asthma Stamp which evaluates symptoms similar to the 
Q score but also records PEF, inhaler technique and compliance 
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with days lost from work. GP practices recruited to this study did 
not receive any additional support from local specialist or GPs 
with a special interest in asthma management assistance was 
available only by referral to specialist hospital clinic. Asthma 
management was based on a combination of clinical skills and 
their interpretation of published guidelines. The present study did 
not observe routine GP assessment of asthma patients so the role 
of PEF monitoring remains unclear in each practice, whether 
inhaler technique was checked on a regular basis or how 
accurately guidelines were implemented. The Tayside stamp 
incorporates elements of the Q score and elements of BTS 
Guidelines essential items for objective management. Such tools 
could easily have been incorporated into asthma care at GP 
practices used in this study ensuring appropriate questions for 
successful management were asked and answered at each 
intervention. Clinicians may well be unaware such simple tool are 
available and easy to use. The support of specialist input could 
assist with the introduction of such objective tools thus improving 
care for asthmatics in a similar manner to the Tayside project.  
 
The GP practices participating in the current study may have 
exhibited some of the “enthusiast bias” reported in the Tayside 
initiative although no incentives were offered to take part in the 
current study. GP practices were however interested and keen to 
participate although their management of asthma patients may 
well adhere to published guidelines more so than practices that 
did not take part in the study. This phenomena has previously 
been reported by Neville et al, (1996) when the Tayside group 
carried out a study similar to their Tayside Asthma Management 
Initiative but recruiting GP practice’s from across the UK. GP 
practice performance may well be improved if they receive 
structured feedback and support from specialist groups.   
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Other groups within the UK have looked at different ways to 
support GP practices in the management of asthma care following 
the publication of guidelines. Osman et al (1996) developed and 
studied a package of integrated care for asthmatics (GRASSIC, 
1994). Recognising the vast majority of asthma patients were 
managed in primary care Osman et al and GRASSIC offered a 
service similar to the Tayside group. Difficult to manage patients 
could be referred to a specialist for feedback, the majority of 
stable patients continued to be managed by the practice. 
According to Osman et al this type of support can lead to better 
outcome for patients and a more cost-effective service for primary 
and secondary care. A package of integrated care has not been 
adopted by the local hospital and GP practices where the present 
study took place. Whether this approach could have improved the 
outcome for subjects with sustained symptoms remains 
speculative. 
 
Inner city subjects who reported increased morbidity and 
depression persisting over the two-year study period despite 
increased inhaled steroids are a vulnerable group of patients who 
require identification and particular care (see Figures 28a and b, 
36a and b). Specific patient sub-groups have been targeted, 
Dickinson et al, (1998) had implemented asthma guidelines in 
their practice but wanted to monitor closely patient’s outcome. 
Subjects taking part in the study were assessed using the Jones 
morbidity index (somewhat similar to the Q score, (Jones et al, 
1992b). Their medication was then reviewed in line with asthma 
guidelines and patients were monitored by use of the Jones index. 
Subject’s asthma therapy was assessed and revised as necessary 
throughout the study period. At the end of the study subjects who 
had participated in the study all had inhaled steroids added to 
their therapy with symptom reporting decreased. This active input 
by interested health professionals again illustrates that 
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improvements can be made in line with guidelines but may rely 
on  “enthusiast bias”. If such a policy had been implemented 
would subjects in the present study with increased symptoms and 
depression have benefited from intervention rather than 
observation? Certainly using the Q score over the two-year period 
did highlight symptom reporting but this information was not 
available to the GP practice and therefore they were unable to act 
upon this information. Further follow up using the Q score by the 
GP practice for their information may well draw such patients to 
the attention of the health professional but remains speculative.   
 
4.4.2 The Population by Place of Residence – Who Fairs Best, Inner 
City or Suburban Asthmatics? 
 
Recruitment bias for subjects from differing areas of residence 
has been acknowledged (see section 4.4) More subjects from 
inner city areas were recruited in this study (65%, see Table 1) 
although all practices approached were very willing for 
recruitment to take place.  Recruitment to the study proved 
difficult (see section 2.2.5) subjects from suburban practices 
found it more difficult to attend the GP practice during working 
hours (see section 3.3.2). Sessions at the practice for study 
purpose finished before 6.00 pm and many subjects found it 
impossible to attend before then and were reluctant for the 
researcher to secure a home visit. Subjects from a suburban 
background reported to be in higher social classes (70% versus 
24% groups I and II) and an unwillingness to allow the researcher 
to intrude into the home environment was evident. This sub-group 
may well have preferred more privacy with regard to their disease 
process than the inner city sub-group. This may well have 
influenced their poor recruitment to the study.  
 
Little difference in objective markers of asthma (spirometry and 
PEF) was observed from outset to twelve and twenty-four 
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months, (see Tables 1, 7 and 13) a trend reflected in the study 
group as a whole. There was also a trend of increased medication 
and a subsequent rise in the number of subjects in higher 
treatment steps over the two-year period and again this was 
reflected in the cohort as a whole. Inner city subjects consistently 
reported significantly more symptoms and higher depression 
scores over the two-year period than suburban subjects, yet only 
at twenty-four months did they reportedly attend their GP twice as 
often as suburban subjects (20% versus 6%) (see Tables 9a and b, 
15a and b). This would indicate suburban subjects were more self-
reliant and coped better with their asthma symptoms than inner 
city subjects who were more dependent on health professionals 
for support. 
 
Differences in socio-economic background based upon Jarman 
scores (Jarman, 1983) as used in this study rely upon the weighted 
values for percentages of the number of elderly persons living 
alone, children under five years, single parent families, social 
class V, unemployed overcrowding and ethnic minorities. A 
number of studies now suggest an association between increased 
reporting of morbidity and social deprivation (von Schlegell et al, 
1999). Subjects living in areas of social deprivation may on 
account of the geographical location be exposed to higher levels 
of outdoor pollutants such as ozone and sulphur dioxide.  While 
subjects indoor environment may be polluted by cigarette smoke, 
damp and overcrowding. This increased risk of exposure to 
trigger factors may go some way to account for some of the 
increased reporting of asthma symptoms (Hajat et al, 1999). This 
study did not seek information from subjects regarding their 
personal circumstances but inner city residents record more 
subjects in lower social classes, (95% of inner city residents in 
social class III, IV and V) and significantly (p<0.01) more inner 
city subjects smoked. This would go some way to re-enforce the 
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inner city population residing in areas of social deprivation 
according to Jarman scores. 
 
In the UK asthma is not commonly associated with poverty 
(Rona, 2000) but there are many reports where asthma is 
associated with higher social class especially in children 
(Littlejohns and Macdonald, 1993).  Do adults in higher social 
class prefer not to “bother” their GP practice with their own 
respiratory problems but are willing to report episodes and 
symptoms of their children, or are the suburban residents reluctant 
to attend their GP?. No significant difference was observed at 
twelve months with 11% suburban subjects attending GP on two 
or more occasions at twelve months versus 12% of inner city 
residents. At the two-year assessment suburban residents were 
somewhat more reluctant (6% versus 20%) than they had been 
previously. Respiratory disease can however be found more 
commonly in areas of socio-economic deprivation. Inner city 
subjects from this study attended their GP practice more often 
than their suburban counterparts. This phenomena has also been 
reported by the Lung and Asthma Agency, (2000). The Lung and 
Asthma Agency also note that these subjects come mainly from 
social class III, IV and V, 95% of the inner city sub-group were 
found to be in those social classes. Subjects from deprived areas 
are also known to attend Accident and Emergency Departments 
more often than other asthmatics of similar severity (Kolbe et al, 
1997) yet over the two-year period only four subjects (all inner 
city residents) were admitted to hospital in excess of twenty-four 
hours. This would indicate a more stable population that that 
recruited by Kolbe et al. It may also appear that subjects from 
differing social classes respond differently to increases in 
morbidity. This observation may account for the number of inner 
city subjects attending the GP practice more often than suburban 
subjects. 
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Inner city subjects from the current study reported more asthma 
symptoms than their suburban counterparts (see tables 9a and b, 
15a and b). Leidy and Coughlin (1998) comment that subjects 
from areas of socio-economic deprivation often reported more 
severe asthma and record lower educational standards. Inner city 
subjects also smoked more (p<0.01) and smoke inhalation is a 
well-documented trigger factor for increased morbidity (Martinez 
et al, 1992). Certainly in children increased morbidity is said to 
be higher in low socio-economic groups (Mielck et al, 1996). 
Education programmes for asthma usually involve guidance as to 
the benefits of smoking cessation alongside the recognition of 
triggers that increase symptoms and the reduction via self-
management of such symptoms. Studies have previously 
examined the efficacy of education programmes for asthma 
subjects with low socio-economic status (Gibson et al, 1998). 
Although many of these studies related to poverty were carried 
out in the USA their finding may be applied to this cohort of inner 
city subjects. The majority of the inner city subjects were in social 
classes III, IV and V, which would indicate poorer educational 
standards. Subjects from areas of deprivation may have lower 
educational standards experiencing difficulty in the appreciation 
of the benefits of smoking cessation and the interpretation of 
guidelines for the management of asthma symptoms. This may go 
some way to account for the increased visits to the GP practice for 
the inner city subjects and the repeated observation of increased 
symptom reporting. These subjects may have been unable to 
successfully interpret self-management plans and appreciate the 
benefits of smoking cessation.  
 
All GP practices participating in the study agreed that they 
followed current published guidelines for the management of 
asthma (Thorax, 1997). Current guidelines advocate the use of 
self-management plans for patients wishing to have an active role 
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in the management of their asthma. The results of this study 
would suggest that suburban subjects have risen to the challenge 
of self-management plans for asthma. GP practices in inner city 
areas – areas of social deprivation and poverty, may therefore 
need to spend more time educating their asthma sufferers if they 
wish to achieve a better outcome for their patients (Nsouli, 1999). 
 
4.4.3 Asthma Severity – BTS Guidelines Treatment Step Group 1-2 
versus 3-5. 
 
A community based asthmatic population was observed over a 
two-year period, the majority of subjects (80/114 at baseline, 
63/95 at twelve months and 62/90 at twenty-four months) 
required little inhaled medication to control their asthma 
symptoms (BTS Guidelines treatment step 1-2). See Tables 6a 
and b, 10a and b, 16a and b. This spread of severity is an expected 
feature of a GP based asthma population (Neville et al, 1999). In 
Neville and colleagues 1999 study they wished to assess the 
proportion of adult asthmatics at each step of BTS Guidelines to 
provide a cost analysis of asthma prescribing in the UK. Over 
17,000 adult asthma patients were recruited from GP practices 
across the UK. Almost half of the subjects recruited were in BTS 
Guidelines treatment step 1-2. 
 
There was however a noticeable shift at twelve months that was 
maintained at twenty-four months of subjects moving into the 
higher treatment step (3-5)(see Tables 10b and 16b). Such an 
increase in therapy could possibly be associated with the 
publication and dissemination of the review of national guidelines 
for the management of asthma carried out in 1995 and published 
in 1997 (see section 4.4.1) (Neville at al, 1997).  It is to be hoped 
that the publication, dissemination and repeated review of asthma 
guidelines within the UK has been recognised and acted upon by 
GPs resulting in the increase in prescribed asthma therapy for 
subjects over the two year study period. 
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Subjects in higher treatment steps 3-5 had greater morbidity and 
depression at twelve and twenty-four months than subjects with 
less severe asthma (see Figures 29, 30, 37 and 38). It might be 
expected that subjects with more severe symptoms of asthma, 
(cough, wheeze or dyspnoea) would require more therapy to 
reduce their symptoms, placing them in treatment steps 3-5. This 
could also go some way to account for patients in the higher 
treatment step visiting their GP more often (see Figure 39). If 
symptoms are troublesome this can lead to depression (Dales et 
al, 1989) and subjects in the higher treatment steps did record 
slightly higher depression scores than subjects with less severs 
asthma (HAD depression scores of 4.11.versus 5.90 at twelve 
months and 4.61 versus 6.07 at twenty-four months for steps 1-2 
and 3-5 respectively). 
 
Previous studies published before the production and 
dissemination of national guidelines (Horn and Cochrane, 1989) 
report the use of sub-optimal therapy when dealing with more 
severe asthma. Despite subjects with more severe asthma 
(treatment step 3-5) receiving more therapy, usually an increase in 
inhaled steroids or the addition of a long acting agonist their 
symptom reporting did not reduce over the study period. Subjects 
were unable to stabilise symptoms adequately in order to reduce 
medication and move down into a lower treatment step. This 
phenomenon could be due to non-compliance but subjects with 
high morbidity scores require regular review (Jones, 1989). If the 
subjects with increased morbidity had received regular 
monitoring of symptoms or if offered, had participated in the 
review then morbidity may well have been reduced in a number 
of subjects thus a reduction in therapy and appropriate treatment 
step may also have been achieved.  
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Dickinson et al, (1997) used a GP based asthma population 
similar to the present study and is one of the few studies that 
notes and monitors changes in severity of asthma over time. 
Dickinson noted and targeted subjects with more severe 
symptoms of asthma (as measured by the Jones Morbidity Index, 
1992b) by checking inhaler technique, altering medication as 
necessary and encouraging use of PFM as a means of monitoring 
airways hyper responsiveness. Subjects with higher morbidity 
scores who attended regular clinics over the twelve months period 
did report lower scores following practice intervention. It would 
appear that GP practices used in our study either did not offer 
regular review for subjects with increased symptoms or may have 
done so and subjects did not avail themselves of this service. In 
the present study the majority of subjects attended their GP on 
one (or less) occasions throughout the study period (75% at 
twelve months and 60% at twenty-four months). This study was 
unaware of any systems in place for objectively evaluating and 
recording symptoms at any GP practices used in this study. It 
would seem health care professionals remained unaware of 
persistently high symptoms, managing subjects only when they 
attended clinic.  
 
Hoskins et al, (1997) commented that GP practices participating 
in an audit cycle combined with an asthma related distance 
learning package did at the end of the study period change their 
management of acute asthma attacks in accordance with 
published guidelines (see also section 4.4.1). Neville et al, (1996) 
also reported improvements in the overall management of asthma 
patients when GP practices participated in an audit cycle. 
Participating GPs in the Hoskins study were members of the 
General Practitioners in Asthma Group (GPIAG). This is a 
specialist interest group for the UK and was therefore 
representative of those practitioners who were interested in 
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improving their asthma management skills, a comment raised by 
the authors. The problem remains whether practice was altered 
due to the publication and dissemination of guidelines or the 
atypical GP population participating in asthma audit. If subjects 
are to benefit from guideline publication and dissemination and 
subsequent adherence to them (for the reduction of reported 
symptoms by patients) they should be supported by the GP with 
regular attempts to follow up and review patients. The GP 
practice may also benefit from specialist input by groups such as 
GPIAG and respiratory physicians. If the offer of review for the 
patient is perceived as unnecessary and the input from specialist 
for GPs viewed as unwelcome little progress can be made. Indeed 
published guidelines (Thorax, 1997) recommend that successful 
implementation is more likely with education of health 
professionals and patients alike accompanied by feedback from 
locally based asthma task forces. 
 
GPs are at the forefront of asthma management but there 
continues to be a “missing link” between theoretical guidelines 
and practical implementation (Collins et al, 1998). It was 
unknown if GP practices used in this study participated in a 
regular audit cycle as suggested by Hoskins (et al, 1997). The 
researcher was unaware if any GP was a member of GPIAG or 
supported by a local asthma task force. Although the number of 
subjects in higher treatment steps (3-5) increased morbidity was 
not noticeably reduced (see Figures 22a and b, 3a and b, 29 and 
38). Participating in an audit cycles may well have lead to the 
observation of long standing increased morbidity, once 
highlighted problem patients could be reviewed. Such actions 
would not address the problems of non-compliance but it appears 
GPs in this study were implementing published guidelines but 
without actively monitoring treatment as suggested. 
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4.4.4 Psychological Status – Why do Depressed Subjects Remain So? 
 
According to Zigmond and Snaith (1983) signs of depression may 
be exhibited by subjects if they have a HAD score at either the 
upper (11) or lower (8) end of the borderline range. This study 
chose to include those subjects with “borderline” anxiety and 
depression whose scores were of eight points or greater on the 
HAD scale. Subjects taking part in the study had three 
questionnaires to complete at the same time (AQLQ, Q score and 
HAD scale). The AQLQ asks the subjects to reflect on their 
asthma status over the past two weeks while the Q score asks 
them to reflect over the past week. The HAD scale also asks the 
subjects to reflect how they have felt over the past week so the 
psychological status of these asthma subjects closely mirrors 
morbidity. 
 
Only a small proportion of the study cohort could be classed with 
borderline depression throughout the two year period (30/114 at 
outset, 15/22 remained depressed at twelve months while 14/22 
remained depressed at twenty-four months) (see Tables 11a and b, 
17a and b). What is note worthy is that these depressed subjects 
reported their asthma symptoms by attending their GP practice 
more often that their non-depressed counterparts (see Figure 43). 
The relationship of asthma to psychological status has a long 
history and was initially reported some years ago (Harrison, 1998 
cites Osler from 1903). Since the introduction of inhaled steroids 
as first line management for symptoms the association of 
psychological status and the influence it can exert upon the 
asthmatic patient seems to have been forgotten. Yet only at the 
twenty-four month review did depressed subjects report their 
inhaled steroids increased more than non-depressed subjects (23% 
versus 7%). Current management relates to patients’ symptoms 
rather than psyche but as recently as 2000 Centanni et al reaffirms 
the relationship of asthma morbidity to psychological status and 
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states that prior to therapy the clinician should consider the 
subjects’ psychological status. Published guidelines (Thorax, 
1997) do acknowledge the influence psychological factors can 
exert over symptoms and state that if asthma proves difficult to 
control then other factors should be investigated. If subjects are 
repeatedly reporting symptoms, as in the depressed subjects from 
this study health care professional may need to consider 
reviewing the subject’s psychological status along with regular 
asthma management.   
 
Harrison, (1998) postulated that within an asthmatic population as 
a whole there would appear to be a small sub-group of patients 
being either non-compliant with their medication, have very 
poorly controlled asthma (brittle asthma), suffer near fatal asthma 
attacks or patients who do actually die following an asthma 
attack. Superimposed upon this sub-set of an asthma population 
psychological influences can be found. The sub-group of 
depressed asthma patients in the current study who remained 
depressed throughout might well have exhibited any of the traits 
noted by Harrison (1998). However, only one subject died during 
the study period (though not due to asthma), subjects did not 
suffer near fatal asthma attacks nor were any subjects within the 
study cohort brittle asthmatics.  
 
Problems with patient compliance have previously been noted in 
section 3.3.3. Some of the depressed subjects in this study may 
well have been non-compliant with their asthma therapy, resulting 
in poor symptom control. As previously stated by Dales et al, 
(1989) chronic symptoms can lead to depression. This circle of 
depression, non-compliance, increased morbidity and depression 
may go some way to account for some of  the subjects who 
remain depressed. Such subjects can actively ignore warning 
signs of deteriorating asthma. Yet these subjects did visit their GP 
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practice complaining of increased morbidity, which may well 
have been assessed by the subject and GP as warranting further 
therapy. Indeed Bosley et al, (1995) noted that subjects with 
increased HAD scores were more likely to be non-compliant with 
asthma medication. Bosley comments that the reasons for 
asthmatic non-compliance can be complex but how patients feel 
about their disease can affect how they comply with therapy. 
Subjects who may be depressed may well perceive symptoms of 
asthma and report them but simply be too depressed to comply 
with treatment. Campbell et al, (1994) also thought that greater 
emphasis should be placed on psychological issues in subjects 
who were thought to be non-compliant. As psychological overlay 
has been largely ignored in recent years the health professional 
may no longer consider the role poor psychological status could 
play in symptom reporting. Treatment is not likely to be 
successful unless such influences are recognised and tackled as 
part of a structured management plan. 
 
The majority of the depressed subjects were located in the inner 
city sub-group, (83%, 25/30) with 11/30 (37%) having depression 
scores of eleven or over, indicating significant depression (see 
Table 5a). Profound emotional stress related to poor housing and 
finances can be common and residents can be exposed to high 
pollutant levels which are known factors associated with 
deprivation (Jarman, 1983). Emotional stress and pollution are 
also associated with asthma morbidity. A previously reported 
strong association between asthma, depression and high Jarman 
scores in a similar inner city area to the ones used in this study 
was noted by Payne et al, (1993). Areas of high deprivation such 
as the inner cities can leave a patient exposed to pollution, 
poverty, over crowding and the stresses and strains of modern day 
living on a reduced income. The recording of continued 
depression by these inner city subjects (see Figures 28a and b, 36a 
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and b) over the two year study period could be due more to their 
area of residence rather than their asthma morbidity (Rimington et 
al, 2001). Indeed life events may exert an indirect effect on 
asthma morbidity if the subject has few psychological resources 
left to draw upon (De Araujo et al, 1973). Repeated visits to the 
GP reporting asthma symptoms that have not responded to 
increased medication may well suggest a need for attention other 
than for asthma. 
 
4.4.5 Changes to Inhaled Asthma Medication over the Two-year Period 
– Increasing Inhaled Steroids Reduces Morbidity? 
 
Asthma guidelines have been the world-wide response to under 
diagnosis and under treatment of asthma. Published guidelines 
advise an increase in medication in response to symptom increase 
and PEF variability (Thorax, 1997). Horn et al, (1990) state that 
morbidity can be significantly reduced in asthma patients who 
receive high doses of inhaled steroids as in treatment steps 3-5 of 
BTS Guidelines. Guidelines actively encourage the monitoring of 
symptoms with corresponding adjustment to therapy. 
Recommended therapy by the BTS for increased symptom 
reporting is given by providing a “step wise approach” to 
management. 
 
The subjects in the present study received an increase in 
medication including oral steroids, inhaled steroids and long 
acting agonist as a response to increased symptom reporting (see 
tables 12a and b, 18a and b). Despite what was observed to be the 
adherence to guidelines by the GP practices participating in this 
study little was achieved as an improved outcome measure for 
these patients. There were eighteen subjects (18/95, 19%) who 
reported an increase in their inhaled steroid medication from 
baseline to twelve months and ten subjects (10/90, 11%) who 
reported inhaled steroids increased from baseline to twenty-four 
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months. Symptoms were not significantly reduced for these 
subjects when group data was explored. However Juniper et al 
(1997) notes that when using the AQLQ for group data 
statistically significant changes in QoL scores may not be 
detected. When using the AQLQ for individual subject a change 
of 0.5 in domain and overall AQLQ score may well denote what 
the patient would consider to be an improvement or a decline in 
their health status. This study analysed only group data and 
cannot therefore comment on individual cases. As the numbers 
for the sub-group ‘inhaled steroids increased’ remained small this 
may go some way to account for the lack of significant 
improvement from baseline. What is also important to note and as 
Juniper (1998) states symptom reporting is subjective. Patients 
can be matched for age, gender and lung function but when 
morbidity is assessed AQLQ scores may vary considerably, as 
patients perceive the same symptoms with differing severity.  
The overall lack of improvement in symptoms may however be 
due to a variety of factors. Rona (2000) comments that subjects in 
lower socio-economic groups may well report symptoms of 
wheeze and remain under treated for such symptoms. This may be 
due to health care professionals considering other factors 
associated with low socio-economic status influencing subjects 
more so than symptoms associated purely with asthma (eg, 
cigarette smoke). Inner city residents smoked significantly more 
cigarettes (p<0.01) at baseline than suburban subjects did. 
Subjects in higher socio-economic groups may well report 
increased symptoms such as wheeze and receive appropriate 
therapy in response. Indeed some subjects may operate their own 
self-management plans and increase therapy immediately. 
Management of symptoms by health care professionals may 
therefore be influenced by the patient’s socio-economic status. 
 
It is well documented that subjects undervalue the influence that 
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anti-inflammatory therapy can have on their condition (Gottlieb et 
al, 1995). Inhaled steroids do not offer immediate relief of 
symptoms and may well be viewed as a poorer choice in the relief 
of symptoms in comparison to quick acting agonists (Horn et al, 
1990). Compliance with inhaled steroids would therefore appear 
to be more problematic than that of a agonists (Bosley et al, 
1994). The difficulties estimating patient compliance of inhaled 
medication has previously been discussed (see section 3.3.3). In 
many asthma studies less than half the study population at any 
one time are thought to be compliant with their medication 
(Yeung et al 1994). Also the severity of asthma seems to have 
little effect of rates of compliance, as subjects with severe asthma 
are just as likely to be non-compliant as those subjects with less 
severe symptoms. Subjects with their inhaled steroid increased 
may well have been advised to increase inhaled steroid intake but 
may have decided not to comply with recommendations resulting 
in little reduction in morbidity. Indeed poor compliance is a well-
documented cause of persistent symptoms in asthma patients 
(Horn et al, 1990). Not only does poor compliance with therapy 
lead to poor symptom control but the overall cost of non-
compliance with therapy leads to days lost from work (Costello, 
1991). 
 
Compliance can also be the result of poor knowledge of the 
disease process (Boulet, 1998). Subjects with poor standards of 
education can have difficulty understanding the concept of self-
management and fail to grasp the different effects of their 
medication, (Bosley et al, 1994, Yeung et al 1994, Apter et al, 
1998 and Boulet, 1998) though other studies relating to 
compliance had earlier refuted this (Hayes-Baulista, 1976). 
Clinicians looking after asthma patients should try to allay fears 
related to the use of inhaled steroids and need to question their 
patient carefully in order to assess if patients understand treatment 
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processes (Boulet, 1998). Poor compliance can be associated not 
only with poor educational standards but also with poor 
communication skills. Many patients have difficulty asking 
questions at consultation and this may result in the patient 
developing a lack of responsibility for the management of their 
disease being unable to respond to their own health needs. 
However, clinical time available for patient consultation is often 
limited and clinicians may not always ask the right questions nor 
seek to reassure patients (Keeley 1999). Such problems are more 
commonly associated with subjects from poor socio-economic 
background though not exclusively so (Cochrane, 1996). 
 
4.4.6 Summary 
 
This study set out to observe the asthma management of a group 
of adult asthmatics over a two-year period. During the study 
period the researcher did not advise or comment on GP 
management during the follow up period. Asthma guidelines 
(BMJ 1990, Thorax 1993) were observed by all practices taking 
part in the study, although there was a lack of regular asthma 
specific clinics organised and managed by accredited asthma 
nurse available to the patients. Asthma guidelines were reviewed 
part way through the study, 1995 and published in 1997 (Thorax 
1997). 
 
Most subjects attended their GP on only one occasion during each 
of the twelve month periods (11/95, 12% of subjects attended 
more than once within the first twelve months while 11/90, 12% 
attended more than once in the second twelve month period). This 
is reflective of a community based asthma population. There was 
however, a significant increase in the number of asthmatic 
subjects in the higher treatment steps from baseline to twelve and 
twenty-four months (34% of subjects in BTS guideline treatment 
step at baseline, 51% at twelve months and 49% at twenty-four 
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months). This may well indicate that practices were adhering to 
guidelines by increasing inhaled therapy. However, there was 
within the study cohort a small population of subjects in high 
treatment steps (3-5) who required more therapy yet did not have 
an improved outcome following practice intervention. Also there 
remained a small group of subjects who were depressed at outset 
and remained depressed over the two-year period. Many of those 
depressed subjects came from the inner city sub-group (80% at 
twelve months and 86% at twenty-four months) who visited the 
GP practice more often, smoking more and reported more 
symptoms of asthma. These subjects who showed little 
improvement over the two-year study period in terms on 
symptoms or psychological status were not identified by the GP 
practice. The problems of patient compliance with treatment have 
already been discussed, subjects may have been advised to alter 
treatment and be in receipt of self-management plans but have not 
acted accordingly, resulting in poor outcome. If practices are not 
auditing their asthma management programmes then it is more 
likely that these subjects have been overlooked. Audit has been 
shown to improve clinical outcomes for patients (Bryce et al, 
1995). 
 
GP practices taking part in the study all had GPs with a specific 
interest in asthma though who was a member of the GPIAG was 
not established. All practices did not have an asthma nurse and 
none that had completed any post registration-training specific to 
the management of asthma. Asthma specific clinics were run at 
each GP practice though only one ran them on a regular basis all 
others were ad hoc. It was uncertain if asthma audit been 
completed or contemplated to assess how asthma guidelines were 
being implemented. There may therefore appear to be a lack of 
structure in the overall management of asthma patients within the 
primary care setting. With an absence of asthma dedicated staff 
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and none specific clinics, guidelines are administered but it is 
uncertain if assessment has been routinely carried out as to their 
efficacy. There may also appear to be poor symptom monitoring 
with health care professionals failing to ask the right questions. 
The Q score is a simple patient focused morbidity index that can 
be used by any member of the health care team.  Using the Q 
score in the absence of any “gold standard” (as stated by 
Dickinson et al, 1997) might well have alerted clinicians to the 
evidence that increased therapy over the two-year period did not 
effectively reduce morbidity.  
 
Some inner city subjects faced problems associated with their 
economic status. These subjects were more depressed, had poorer 
symptom control, smoked more, took more medication and visited 
their GP more often than others. This sub-group may well require 
sustained monitoring and input from health professionals if 
improvements in subjective markers of asthma are to be observed. 
Clear and consistent advice from all health care professionals 
involved asthma education and the development of good patient 
clinician relationship along with genuine two way communication 
could go some way to improving patient compliance with 
management (Dickinson et al 1998).  Subjects who remained 
depressed reported symptoms of asthma that did not improve with 
therapy. Psychological status can exert a considerable influence 
on asthma symptoms, a small proportion of subjects may be 
receiving excess therapy when their reported symptoms are not 
caused by asthma alone (Rimington et al, 2001). 
 
Extra input to GP practices by specialists in asthma may well be 
the answer to improve outcome for patients as proposed by the 
Tayside Asthma Management Initiative, its Scottish counterpart 
(Hoskins et al 1997, 1998, 2000) and the work by GRASSIC  
(1994). GP practices can audit asthma management and review 
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practice and most importantly ensure that they use questions such 
as those found in the Q score that are relevant to patients’ asthma 
status. 
 
4.5 Study Limitations 
 
Problems associated with the recruitment of GP practices and subjects to 
the study must be acknowledged. GP practices participating in the study 
agreed they adhered to published guidelines for the management of 
asthma (BMJ, 1990, Thorax, 1993 and Thorax, 1997) but the researcher 
did not observe any health care professionals in consultation with 
individual patients. Therefore the accuracy of guideline interpretation has 
not been assessed. Legorreta et al, (1998) and Picken et al, (1998) both 
comment on the admission by clinicians as to differences in interpretation 
of guidelines at local level.  How clinicians interpreted the “stepwise 
approach” to assist in the reduction of symptoms, the use of self-
management plans and interpretation of PEF remains speculative.  
 
It has already been stated (see section 3.3.1) that the diagnosis of asthma 
was taken from GP practice asthma registers. Verification of the 
diagnosis by the use of PFM and recording peak flow variability over a 
two-week period was attempted as stated in section 2.4.1. Unfortunately 
so few subjects returned peak flow diaries that is was impossible to use 
this data. The diagnosis of asthma from the GP was therefore accepted. 
Section 3.3.1 explores the diagnosis of asthma subjects used in this study. 
It must be must concluded that subjects participating in this two-year 
follow up study did have a true diagnosis of asthma but acknowledge 
some subjects may exhibit components of other respiratory disease. 
However, the subjects used for this study are reflective of a primary care 
based asthma population. 
 
GP practices recruited to the study had an established interest in the 
management of respiratory disease and may therefore exhibit practice 
bias. All practices regularly referred patients to the local chest unit and 
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had participated in previous studies with the chest unit.  This would 
indicate a willingness to participate in respiratory-based studies with a 
population of subjects who may previously also have been recruited. 
However, it must be stressed that no health professionals from any of the 
participating primary care settings took part in the selection of subjects 
for the inclusion into the study or in the collection of data. 
 
More female subjects were recruited (63%) and more subjects came from 
inner city practices (65%) (see section 3.3.2). Moreover, the gender ratio 
is typical of a GP based asthma population (Neville et al, 1999). The 
original study aim was to recruit forty subjects from each of the four 
practices participating in the study (see section 2.2.5). Only one hundred 
and fourteen subjects were recruited and the reduced sample size is 
accepted. Due to a number of confounding factors (as stated in section 
2.2.5) the population included fewer subjects from suburban practices. In 
order to prevent the bias towards an inner city population it may have 
been pertinent to have continued to recruit from the existing suburban 
practice or have included another suburban based GP practice into the 
study. However, time and resources were limiting factors in extending 
recruitment to ensure a larger sample or reduce inner city bias. 
 
The study design was observational in nature used as “an appropriate 
technique for getting at ‘real life’ in the ‘real world’” (Robson, 1993 
pg.191). Therefore the study did not control for any factors; subjects were 
assessed on an annual basis independently from any asthma assessment 
carried out by the GP practices. This study did not report data to any 
participating practice until after the study was complete. The study 
process itself was therefore ‘blind’ to any treatment interventions by the 
clinician other than the recording of prescription up take by subjects. 
Observer bias was a possibility but all data using questionnaires was 
recorded without unnecessary assistance from the researcher taking part 
in the study. This problem could have been resolved by the use of ‘blind’ 
collection of data but resources were not available. Extraneous variables 
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were not control for. Subjects were assessed in different seasons of the 
year, on different days and at different time. Often subjects were 
reviewed in the GP practice but subsequently reviewed in their own 
home. Subjects on long term steroids may also be subject to mood swings 
(Costello, 1991) this was avoided in the present study by observing the 
population over a two year period.  
 
4.6 Clinical Implications of the Study 
 
The findings of this study relate to the validation of the Q score as a tool 
for monitoring patient symptoms and the management of asthma in 
primary care. The Q score was designed as a simple patient focused 
morbidity index and as such it is accepted that it is less complex and not 
as sensitive as the AQLQ. Nevertheless the Q score correlates to the 
AQLQ symptom score and is responsive to changes in the AQLQ 
symptom domain. In the absence of any “gold standard” for morbidity 
assessment the Q score would appear to be an acceptable outcome 
measure to use in any busy health care setting. 
 
The Q score has been evaluated using a cohort of asthma subjects with 
varying degrees of severity as measured by BTS guidelines treatment 
step. The Q score reflects symptom activity at all levels of asthma 
severity. BTS guidelines recommend a “stepwise” approach to the 
management of symptoms. If therapy is increased as recommended by the 
“stepwise” approach and patients symptoms of asthma subsequently 
diminish a lower Q score should be achieved, regardless of the level of 
severity. The Q score will reflect any change in symptoms over a one-
week period. The aim of current asthma management is to reduce patient 
symptoms to a minimum with minimum use of therapy. The Q score can 
be administered by any member of the health care team in order to assess 
current patient symptoms. If a high Q score is obtained this would 
indicate poor control of asthma symptoms and patients may therefore be 
invited to attend the GP practice for consultation in order to reduce 
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symptoms. Conversely, if a low Q score is observed this would indicate 
asthma symptoms were well-controlled at that point in time and therapy 
has been optimised. The Q score is not a diagnostic tool but a patient 
focused morbidity index and could therefore be used as single symptoms 
score for screening patients in the wider health care setting. For example 
NHS Direct could employ the Q score as a simple screening tool thus 
advising patients with high Q scores (increased symptoms) to seek early 
medical advice. 
 
The Q score could be used as part of an ongoing asthma audit in any 
health care setting, either on a regular basis (annual or biannual) or when 
patients attend for any consultation. It can also be used to monitor change 
in therapy. Any increase or decrease in therapy may alter symptoms. The 
Q score can reflect changes in symptoms in response to alteration in 
therapy. The Q score could prove to be a simple evaluative tool in this 
area. 
 
The Q score is a suitable tool for use with all adult asthma patients, the 
questions used being asthma specific. The Q score contains questions that 
the health practitioner should ask asthma patients at each consultation. 
Questions relating to nights waking, wheeze and interference with daily 
activities are incorporated into the Q score as the findings of the Royal 
College of Physicians recommend (Pearson and Bucknall, 1999). Using 
the Q score as an audit tool or to evaluate treatment change would not 
detract from valuable clinical contact time. Indeed, using the Q score at 
every contact would not adversely affect the consultation.  Although the 
majority of asthma patients are managed in the primary care setting the Q 
score is an appropriate tool for use either there or in secondary care. It 
can ensure the clinician asks the patient the right questions every time 
(Keeley 1993).  
 
Although it would appear asthma guidelines are adhered to in primary 
care as previously noted they are open to interpretation (Legorreta et al, 
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1998 and Picken et al, 1998). This study has drawn attention to the lack 
of routine monitoring in asthma management. As a regular procedure 
following an alteration in medication patients taking part in this study it is 
unknown if subjects were asked to attend for review. Any changes in 
subject morbidity should be assessed following an alteration in therapy. 
Poor monitoring can lead to subjects with increased symptoms over the 
two-year study period.  Although problems with patient compliance to 
therapy have been noted subjects studied  attend their GP practice only 
once or less in any twelve-month period nor where they supported by 
external experts in the field. Access to asthma specialists be they GPs, 
specialist physicians or other health professionals especially when dealing 
with problem patients has been shown to improve outcome for patients. 
Such action and support mechanisms should be incorporated into routine 
care in the primary setting. 
 
This study observed a small sub-group who were depressed at outset and 
remained depressed over the two-year period. It remains unknown if the 
psychological status of these subjects was not noted and assessed by any 
member of the GP practice over the study period. These subjects 
complained of increased symptoms and visited their GP practice more 
often than others in the cohort. More of these subjects resided in inner 
city areas. These subjects may well have felt the stresses and strains of 
inner city life (reflected in social deprivation and poverty) giving rise to 
increased psychological status. Such subjects with a heightened 
psychological state may well be more aware of their asthma symptoms. It 
is well documented that symptom reporting is subjective (Juniper et al, 
1998). Subjects with increased symptoms who do not respond to therapy 
may well have psychological problems that cannot be expected to 
respond to changes in asthma medication. If asthma subjects are 
monitored and reviewed as part of an audit cycle health care professionals 
may become aware of the influence of psychological status over 
morbidity.  
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4.7 Areas for Future Study 
 
Other asthma specific questionnaires are available to assess morbidity but 
many are too long to be of practical use in the busy health care setting. 
The Q score was designed as a pragmatic instrument for use in every day 
asthma management and is by design less complex than other out come 
measures. The Q score was evaluated against a reliable and validated 
asthma specific QoL questionnaire (AQLQ) that uses four domains 
relating to asthma specific problems (activity limitation, emotional and 
environmental factors and symptoms). The symptom domain of the 
AQLQ was used to assess the sensitivity of the Q score over the two-year 
period. The Q score correlated to the AQLQ symptom domain throughout 
the assessment period. The Q score was only assessed with the AQLQ but 
as stated there are other asthma specific questionnaires available that also 
record symptoms. Further studies are advisable to assess the Q score 
against such tools eg, the Jones morbidity index (Jones et al, 1992b) and 
St George’s short form questionnaire (White and Jones, 1997). 
 
It is proposed and supported by the RCP (London) that data in relation to 
morbidity should be collected at each patient visit. While it is recognised 
that all asthma subjects do not visit their GP on a regular basis, certainly 
in the cohort in the present study 88% visited their GP only once or not 
even at all in a twelve-month period. Indeed, studies have shown that up 
to two thirds of patients with asthma fail to attend for review (Barritt and 
Staples, 1991, Gruffydd-Jones et al, 1999). Over five years the majority 
of subjects will probably have incurred at least one visit. Data collected at 
routine visits should be recorded separately to emergency visits, as 
symptom reporting will certainly be higher on such occasions. Data may 
also be recorded following postal or telephone contact and can be 
collected by any member of the health care team  (Pearson and Bucknall, 
1999). It is recommended that further studies use the Q score to collect 
data with regards to morbidity on each visit to the GP practice for all 
asthma subjects. This should form part of a regular asthma audit. 
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The GPIAG are in the process (personal communication) of conducting a 
randomised controlled trial comparing the clinical and cost effectiveness 
of telephone consultations with face to face consultations for the 
management of adult asthmatics in primary care. It is intended to recruit 
two hundred and twenty-five adult asthmatics from five GP practices 
within the UK.  The study proposes to use the Q score  and the AQLQ as 
part of their evaluation tools. All consenting patients will be sent postal 
questionnaires at baseline, patients will then be randomised to a face to 
face consultation or telephone consultation for their asthma. Twelve 
weeks following consultation subjects will be sent the two questionnaires 
(Q score and AQLQ) again. The study hopes to establish that telephone 
consultations can be as successful an intervention as face to face 
consultation, measured by a reduction in symptoms (Q score) and 
improvement in QoL (AQLQ). 
 
It is the intention of the author to submit for publication further work 
from this thesis. The present study aimed to observe the management of 
asthma subjects in their own primary care environment over a two-year 
period. The author intends to comment on the observed management of 
the subjects in relation to published guidelines (Thorax, 1997) over that 
two-year period. As the GP practice is at the forefront of asthma 
management the implementation and interpretation of guidelines requires 
evaluation and deserves comment. The problem of compliance by adult 
asthma patients with the regular use of inhaled medication is well 
documented and has been addressed in 3.4.3. The author also intends to 
explore the relationship of compliance to social class. Data were collected 
from all subjects taking part in the study pertaining to their social class 
and asthma severity (as measured by BTS guidelines treatment step). 
Although compliance was not formally monitored actual prescription 
uptake by patients was noted over the two-year period and can be 
compared to medication prescribed. It is intended to examine how 
subjects from differing social classes comply with their prescribed asthma 
medication. 
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4.8 Conclusion 
 
The aim of this study was to observe the management of a cohort of adult 
asthma patients in the primary care setting over a two-year period. Also to 
assess a newly devised patient focused morbidity index (Q score) for 
validity, reliability, sensitivity and specificity by comparison to an 
established asthma-based QoL questionnaire (AQLQ). This study accepts 
the hypothesis that the Q score is as reliable as the AQLQ symptom score 
when used to monitor symptoms as part of the management of asthma 
patients in primary care. 
 
The Asthma Outcomes Seminar held at the RCP (London) in 1998 
published their report the following year (Pearson and Bucknall, 1999). 
The aim of the seminar was to “investigate the feasibility of reaching a 
consensus across a national spectrum for a simple patient focused tool for 
measuring clinical outcome in chronic persistent asthma”.  The author was 
invited to present the baseline results of this current study and introduce 
the Q score at the seminar. 
 
The main conclusions from the seminar were:- 
 
 Outcome measures should be patient focused and based upon 
asthma related symptoms. 
 The assessment tool should consist of three questions that are 
relevant to the clinician and the patient. 
 The three questions should cover night-time disturbance, day-time 
symptoms and interference with daily activities.  
 Each question should cover a short time span either a week or a 
month and have a response that can be quickly and easily 
recorded. 
 
The Q score complies with the RCP seminar conclusions. It is a short 
patient focused morbidity index devised in consolation with a variety of 
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health care professionals. It is suitable for use with adult asthmatics of any 
severity. It asks questions that are important and relevant to the patient 
and is short enough to be used during any asthma intervention. The 
questions asked should routinely be asked but are often overlooked by 
patient and clinician. However, the Q score does contain four as opposed 
to three questions, the fourth question relates to the use of agonist 
inhalers. The rationale for the inclusion of this question in the Q score was 
as a means of indicating the patient’s asthma control. Thus the Q score 
must be envisaged as a reliable asthma specific tool that can be used 
quickly, simply and effectively for better patient management and 
outcome. 
 
The study also set out to observe asthma management in primary care. 
Guidelines for the management of adult asthma have been published, 
disseminated and embraced by many GP practices with improved 
outcome for patients. The success of the guidelines following 
implementation may be attributed to the manner in which they were 
disseminated. Success can only be maintained by repeated educational 
activities focused on improving the health professionals’ knowledge and 
understanding of the guidelines. Such activity needs to be carried out in 
conjunction with practice audit assessing the process of care. 
 
The GP practice remains at the forefront of asthma care and should 
therefore be offering appropriate treatment and regular review of patient’s 
asthma control. Altering medication as per BTS Guidelines can give the 
impression of treating asthma, but without short-term reassessment the 
same levels of morbidity can persist. Relying upon reported symptoms of 
asthma alone as a guide for any alteration in treatment may be misleading. 
The relationship between morbidity and non-asthma related factors can be 
complex. When assessing reported asthma symptoms psychological and 
socio-economic factors should always be considered by the health 
professional. 
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ASTHMA OUTCOMES PROJECT – GP PRACTICE AGREEMENT 
 
Aims of the Study 
To follow cohorts of asthmatic patients from differing primary health care settings over a 
two-year period.  To assess a newly devised short answer morbidity index relating to 
asthma for validity, reliability, sensitivity and specificity by comparison to an established 
asthma based quality of life questionnaire (Juniper et al, 1993). 
 
The Practice 
Subjects for the study will be recruited from four different practices within South Sefton 
area. 
 
The practice is asked to supply a list of asthma patients.  This will require scrutiny 
by practice members for rogue patients.  (Reade Code (five characters) H33.) 
 
Following that members of the project team will take over the collection of data, subjects 
suitable to take part in the study will be chosen randomly from the supplied list 
(maximum 40 patients per practice). 
 
Suitable subjects will be aged 16 - 60 years.  They should have been receiving treatment 
for their asthma for the past 6 months.  Such treatment may include any prophylactic 
inhaler or 2 or more prescriptions for a Beta2agonist inhaler. 
 
Each subject must present evidence of asthma either at entry to the study or 
retrospectively. 
 
It is anticipated project staff will initially require assistance from the Practice Manager 
and clerical staff in order to familiarise themselves with practice record keeping and 
administration.  The practice is asked to supply project staff with accommodation to 
assess patients within the practice itself.  A few patients may require home visits, project 
staff will be free to do so if required. 
 
Exclusion from the Study 
Subjects will be excluded from the study if they present with a smoking history of >20 
pack years. If they have existing bronchiectasis, other lung pathology or cardiac disease. 
 
Subjects will be free to exclude themselves from the study at any time. 
 
Method of Assessment 
Data will be collected for the cohort by members of the University of Salford.  Such data 
will include the administration of various questionnaires monitoring the patients use of 
prescribed medication, PEF and noting any hospital admissions for asthma.  This will 
take place over the 2-year period at 12 monthly intervals. 
 
Copies of the full protocol are available from Lesley Rimington on request. 
This project has received approval from South Sefton Research Ethics Committee - 
25.06.96. 
Practice assistance with this project will be acknowledged. 
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PATIENT INFORMED CONSENT 
 
ASTHMA MANAGEMENT IN THE PRIMARY HEALTH CARE 
SETTING 
 
 
Aintree Chest Centre along with your GP Practice proposes to follow up over two 
years a group of patients with asthma.  Over that two year period we would 
monitor your asthma management by looking at your lung function (eg, peak 
flow readings), noting down your medication and asking you to complete one or 
two questionnaires at regular 12 monthly intervals.  At the assessments three 
questionnaires will be used along with the lung function assessments and the 
medication identification.  All information collected during this study will be 
dealt with in confidence and anonymously. 
 
This study does not involve any tests, which are not normally undertaken by 
patients with asthma, and therefore there are no risks to me if I enter this study. 
 
I understand that I am free to withdraw from this study at any time and this will 
in no way prejudice my subsequent treatment. 
 
 
 
I hereby agree to take part in the study 
 
 
Signed:        Date: 
 
 
I have explained the purpose and procedures of the study to the above named 
patient and have answered any questions that have arisen. 
 
 
Investigators’ signature:      Date: 
 
 
 
If at any time you have any questions relating to the study then please contact: 
 
Dr MG Pearson, Aintree Chest Centre, Aintree Hospitals, Fazakerley, Liverpool. 
Telephone: 0151 529 3857 
or, 
Lesley Rimington, Department of Rehabilitation, Faculty of Health Care and 
Social Work Studies, University of Salford. 
Telephone: 0161 295 2418. 
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British Thoracic Society Guidelines Treatment Step
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APPENDIX IV 
 
Patient Data Sheet - Baseline
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ASTHMA MANAGEMENT IN THE PRIMARY HEALTH CARE 
SETTING 
BASELINE PATIENT DATA SHEET 
 
 
 
Patient No: 
 
Date of interview: 
 
 
Practice: (circle) 
 
N S W R Y 
 
 
Patient Name: 
 
 
Patient address/phone: 
 
 
 
 
 
 
Date of birth:        M/F 
 
 
Smoking history: 
 
 Yes 
 
 No 
 
 
 
Pack years 
 
 
 
Allergy: 
 
 
 Yes 
 
 No 
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Occupation/previous occupation: 
 
 
Patient Medication (list ALL - oral and inhaled): 
 
 
DOSAGE 
(amount and how many times per day) 
MEDICATION 
(name) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Self-management plan for asthma? 
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Severity (as per BTS Treatment Step): 
 
In the past 6 months note: 
 
 
Number of hospital admissions (in excess of 24 hours) 
 
 
 
Number of exacerbations (visits to GP for deteriorating 
asthma) 
 
 
 
Number of oral steroid prescriptions 
 
 
 
Number of repeat prescriptions for INHALED steroids 
medication 
 
 
 
Number of repeat prescriptions for INHALED 
bronchodilators 
 
 
 
 
Spirometry: Recorded 
 
 
PEF 
 
 
 
FEVI 
 
 
 
FVC 
 
 
 
Spirometry: Predicted 
 
 
PEF 
 
 
 
FEVI 
 
 
 
FVC 
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SHORT ANSWER QUESTIONNAIRE (Q SCORE) 
 
 
In the past week: 
 
(please circle) 
 
 
1 On how many days have you wheezed or been breathless? 
0-1 2-4 5-7 
 
 
 
2 On now many nights have you been woken because of asthma? 
0-1 2-4 5-7 
 
 
 
3 On how many days has asthma prevented you doing your normal 
activities?  
0-1 2-4 5-7 
 
 
 
4 How many times are you using your reliever inhaler each day? 
0-1 2-4 5+ 
 
 
 
 
SCORE 
 
0 = left 
1 = middle 
2 = right column (total score out of 8) 
 
0 = well controlled 
8 = poor control 
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PATIENT EXPECTATION OF TREATMENT 
 
 
When you last came to the GP practice (for your asthma) what did you want 
to achieve from your visit? 
 
 
a) I wanted my asthma to be better controlled 
 
b) I wanted to check my medication 
 
c) I wanted to discuss the side effects of my medication 
 
d) I wanted to know what to avoid so my asthma would go away 
 
e) I wanted to stop my sleep from being disturbed by my chest 
 
f) Other ………………………………………………………………….. 
 
 ………………………………………………………………………….. 
 
 
Write below the first and second most important things you expected to 
achieve following your visit to the GP practice. 
 
 
First  …………………………………………………………………… 
 
 
Second …………………………………………………………………… 
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PRACTICE QUESTIONNAIRE 
 
 
Name of GP Practice: 
 
 
Date: 
 
 
1 Does the practice have a designated Asthma Nurse and/or GP? 
 
Asthma Nurse 
 
 Yes 
 
 No 
 
 
Designated Asthma GP 
 
 
 Yes 
 
 No 
 
 
2 Does the practice have any specific asthma clinics? 
 
 
 Yes 
 
 No 
 
 
If YES, how often are they run eg, weekly, fortnightly, monthly? 
 
 
 
3 Does the practice follow the recommendations of the BTS Asthma 
guidelines (eg, prescribe PF metres regularly, issue self-management 
plans, ask patients to keep PFM charts, use inhaled steroids etc)? 
 
 
 Yes 
 
 No 
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APPENDIX V 
 
Twelve/Twenty Four Months Patient Data Sheet
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ASTHMA MANAGEMENT IN THE PRIMARY HEALTH CARE 
SETTING 
TWELVE AND TWENTY FOUR MONTHS PATIENT DATA SHEET 
 
 
Patient No: 
 
 
Date of interview: 
 
 
Practice: (circle) 
 
N S W R Y 
 
Patient Name: 
 
 
Patient address/phone: 
 
 
 
 
Has the patient’s medication changed since last seen in study? 
Yes No 
 
If YES, what has changed? 
 
 
Patient Medication (list ALL - oral and inhaled) 
 
DOSAGE 
(amount and how many times per day) 
MEDICATION 
(name) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Severity (as per BTS Treatment Step): 
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In the past 12 months note: 
 
 
Number of hospital admissions (in excess of 24 hours) 
 
 
 
Number of exacerbations (visits to GP for deteriorating 
asthma) 
 
 
 
Number of oral steroid prescriptions 
 
 
 
Number of repeat prescriptions for INHALED steroids 
medication 
 
 
 
Number of repeat prescriptions for INHALED 
bronchodilators 
 
 
 
 
Spirometry: Recorded 
 
 
PEF 
 
 
 
FEVI 
 
 
 
FVC 
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SHORT ANSWER QUESTIONNAIRE (Q SCORE ) 
 
 
In the past week: 
 
(please circle) 
 
 
1 On how many days have you wheezed or been breathless? 
 
0-1 2-4 5-7 
 
 
2 On now many nights have you been woken because of asthma? 
 
0-1 2-4 5-7 
 
 
3 On how many days has asthma prevented you doing your normal 
activities?  
 
0-1 2-4 5-7 
 
 
4 How many times are you using your reliever inhaler each day? 
 
0-1 2-4 5+ 
 
 
 
 
SCORE 
 
0 = left 
1 = middle 
2 = right column (total score out of 8)  
 
0 = well controlled 
8 = poor control 
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PATIENT EXPECTATION OF TREATMENT 
 
 
When you last came to the GP practice (for your asthma) what did you want 
to achieve from your visit? 
 
 
a) I wanted my asthma to be better controlled 
 
 
b) I wanted to check my medication 
 
 
c) I wanted to discuss the side effects of my medication 
 
 
d) I wanted to know what to avoid so my asthma would go away 
 
 
e) I wanted to stop my sleep from being disturbed by my chest 
 
 
f) Other ...................................................................................................... 
 
.................................................................................................................. 
 
 
 
Write below the first and second most important things you expected to 
achieve following your visit to the GP practice. 
 
 
First  ......................................................................................................  
 
 
Second ......................................................................................................
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APPENDIX VI 
 
Asthma Quality of Life Questionnaire
 
 243
 
ASTHMA QUALITY OF LIFE QUESTIONNAIRE - (AQLQ) 
(JUNIPER ET AL, 1993) 
 
Patient No: 
 
Date:       0/12/24 months review 
 
You should identify 5 activities that are limited by your asthma. 
If more than 5 activities are identified then choose the 5 most important. 
To ensure all possible activities are included use the following list as a prompt. 
 
Bicycling 
Dancing 
Doing home maintenance 
Doing housework 
Gardening 
Hurrying 
Jogging, exercising or running 
Laughing 
Mopping or scrubbing the floor 
Mowing the lawn 
Playing with pets 
Playing with children 
Playing sports 
Singing 
Doing regular social activities 
Having sexual intercourse 
Talking 
Running upstairs or uphill 
Vacuuming 
Visiting friends or relatives 
Walking upstairs or uphill 
Woodworking or carpentry 
Carrying out your activities at work 
 
When 5 activities have been identified please ask the patient to what extent they 
have been limited by each of the activities they have chosen.  List the activities 1-5. 
 
Then for each activity - please indicate how much you have been limited by your 
asthma in (insert activity) during the last two weeks by choosing one of the 
following options.  (Green card) 
Activity Score 
1  
2  
3  
4  
5  
The remaining 27 questions are the same for all patients. 
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6 How much discomfort or distress have you felt over the last two 
weeks as a result of chest tightness?  (Red card) 
 
7 In general, how often during the last two weeks have you felt 
concerned about having asthma?  (Blue card) 
 
8 How often during the past two weeks did you feel short of breath 
as a result of your asthma?  (Blue card) 
 
9 How often during the past two weeks did you experience asthma in 
your chest?  (Blue card) 
 
10 How often during the past two weeks did you experience a wheeze 
in your chest?  (Blue card) 
 
11 How often during the past two weeks did you feel you have to 
avoid a situation or environment because of cigarette smoke? (Blue 
card) 
 
12 How much discomfort or distress have you felt over the past two 
weeks as a result of coughing?  (Red card) 
 
13 How often during the past two weeks did you feel frustrated as a 
result of your asthma? (Blue card) 
 
14 How often during the past two weeks did you experience a feeling 
of chest heaviness? 
 
15 How often during the past two weeks did you feel concerned about 
the need to take medication for your asthma?  (Blue card) 
 
16 How often during the past two weeks did you feel the need to clear 
your throat? 
 
17 How often during the past two weeks did you experience asthma 
symptoms as a result of being exposed to dust?  (Blue card) 
 
18 How often during the past two weeks did you experience difficulty 
breathing out as a result of your asthma?  (Blue card) 
 
19 How often during the past two weeks did you feel you had to avoid 
a situation or environment because of dust?  (Blue card) 
 
20 How often during the past two weeks did you wake up in the 
morning with asthma symptoms?  (Blue card) 
 
21 How often during the past two weeks did you feel afraid of not 
having your asthma medication available?  (Blue card) 
 
22 How often during the past two weeks were you bothered by 
heaving breathing?  (Blue card) 
 
23 How often during the past two weeks did you experience asthma 
symptoms as a result of the weather or air pollution outside?  (Blue 
card) 
 
 
 

 

 

 

 
 
 
 
 

 

 

 
 
 

 

 
 
 
 
 

 

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24 How often during the past two weeks have you been woken at 
night by your asthma?  (Blue card) 
 
25 How often during the past two weeks have you had to avoid going 
outside because of the weather or air pollution?  (Blue card) 
 
26 How often during the past two weeks did you experience asthma 
symptoms as a result of being exposed to strong smells or 
perfume? (Blue card) 
 
27 How often during the past two weeks did you feel afraid of getting 
out of breath?  (Blue card) 
 
28 How often during the past two weeks did you feel you had to avoid 
a situation or environment because of strong smells or perfume? 
 
29 How often during the past two weeks has your asthma interfered 
with getting a good night’s sleep?  (Blue card) 
 
30 How often during the past two weeks have you had the feeling of 
fighting for air? (Blue card) 
 
31 Think of the overall range of activities that you would have liked to 
have done during the past two weeks?  How much has your range 
of activities been limited by your asthma?  (Yellow card) 
 
32 Overall, among all the activities that you have done during the past 
two weeks, how limited have you been by your asthma?  (Green 
card) 
 

 

 
 
 
 
 

 

 

 
 


 
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HOW TO SCORE THE AQLQ QUESTIONNAIRE 
 
 
Domains 
 
The items are grouped into 4 domains:- 
 
1 Activity limitations 
(Items 1-5, 11, 19, 25, 28, 31, 32) 
 
2 Symptoms 
(Items 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 29, 30) 
 
3 Emotional function 
(Items 7, 13, 15, 21, 27) 
 
4 Exposure to environmental stimuli 
(Items 9, 17, 23, 26) 
 
 
Scoring 
 
Calculate the mean scores for the items within each domain for each subject. 
 
The overall QoL score may be estimated from the mean score for all items. 
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AQLQ RESPONSE OPTIONS 
 
 
Green Card 
 
1 Totally limited, couldn’t do activity at all 
2 Extremely limited 
3 Very limited 
4 Moderate limitation 
5 Some limitation 
6 A little limitation 
7 Not at all limited 
 
Red Card 
 
1 A very great deal of discomfort or distress 
2 A great deal of discomfort or distress 
3 A good deal of discomfort or distress 
4 A moderate amount of discomfort or distress 
5 Little discomfort or distress 
6 Very little discomfort or distress 
7 No discomfort or distress 
 
Blue Card 
 
1 All of the time 
2 Most of the time 
3 A good bit of the time 
4 Some of the time 
5 A little bit of the time 
6 Hardly any of the time 
7 None of the time 
 
 
Yellow Card 
 
1 Severely limited - most activity not done 
2 Very limited 
3 Moderately limited - several activities not done 
4 Slightly limited 
5 Very slightly limited - very few activities not done 
6 Hardly limited at all - have done all activities that I wanted to do 
7 Not limited at all - have done all activities that I wanted to do 
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Hospital Anxiety and Depression Scale
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HOSPITAL ANXIETY AND DEPRESSION SCALE 
 (ZIGMOND AND SNAITH, 1983) 
 
 
Patient No: 
 
 
Date:          0/12/24 months review 
 
Doctors are aware that emotions play an important part in most illnesses.  If we know 
about these feelings we will be able to help more. 
 
This questionnaire is designed to help us know how you feel.  Read each item and 
underline the reply which comes closest to how you have been feeling in the past week. 
 
Don’t take too long over your replies; your immediate reaction to each item will 
probably be more accurate than a long thought out response. 
 
1a I feel tense or “wound up”: 
most of the time 
a lot of the time 
from time to time, occasionally 
not at all 
 
2d I still enjoy the things I used to enjoy: 
definitely as much 
not quite as much 
only a little 
hardly at all 
 
3a I get a sort of frightened feeling as if something awful is about to happen: 
very definitely and quite badly 
yes, but not too badly 
a little, but it doesn’t worry me 
not at all 
 
4d I can laugh and see the funny side of things: 
as much as I always could 
not quite so much now 
definitely not so much now 
not at all 
 
 
5a Worrying thoughts go through my mind: 
a great deal of the time 
a lot of the time 
from time to time but not too often 
only occasionally 
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6d I feel cheerful: 
not at all 
not often 
sometimes 
most of the time 
 
7a I can sit as ease and feel relaxed: 
definitely 
usually 
not often 
not at all 
 
8d I feel as if I am slowed down: 
nearly all the time 
very often 
sometimes 
not at all 
 
9a I get a sort of frightened feeling like “butterflies” in the stomach: 
not at all 
occasionally 
quite often 
very often 
 
10d I have lost interest in my appearance: 
definitely 
I don’t take so much care as I should 
I may not take quite as much care 
I take just as much care as ever 
 
11a I feel restless as if I have to be on the move: 
very much indeed 
quite a lot 
not very much 
not at all 
 
12d I look forward with enjoyment to things: 
as much as ever I did 
rather less than I used to 
definitely less than I used to 
hardly at all 
 
13a I get sudden feelings of panic: 
very often indeed 
quite often 
not very often 
not at all 
 
14d I enjoy a good book or radio or TV programme: 
often 
sometimes 
not often 
very seldom
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HOW TO SCORE THE HAD SCALE 
 
 
The HAD scale scores for both depression and anxiety.  The even numbers refer 
to depression (i.e., 2, 4, 6 ..) and the odd numbers to anxiety.  The rating is based 
on a 4-point scale. 
 
 
Score nos.:  1, 3, 5, 6, 8, 10, 11, 13 as 
 
Top scores - 3 
Next scores - 2 
Next scores - 1 
Bottom scores - 0 
 
Score nos.:  2, 4, 7, 9, 12, 14 as 
 
Top scores - 0 
Next scores - 1 
Next scores - 2 
Bottom scores - 3 
 
Anxiety score nos.: 1a, 3a, 5a, 7a, 9a, 11a, 13a 
 
Depression score nos.: 2d, 4d, 6d, 8d, 10d, 12d, 14d 
 
A score of 0 - 7 is indicative of no depression or anxiety. 
 
A score of 8 - 10 indicated a possible or “borderline” depression or anxiety. 
 
A score of 11 - 21 indicates probable significant depression or anxiety. 
 
 
Remember, for the depression total score add up the scores for all the even 
questions. 
 
For the anxiety total score add up the scores for all the odd questions. 
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Letter to Patient Confirming Date/Time of Appointment 
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APPENDIX IX 
 
Peak Flow Chart
 
 255
 
 256
 
 
 
 
 
 
 
 
 
 
 
APPENDIX X 
 
Letter to Patient if Did Not Attend for Appointment
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APPENDIX XI 
 
Local Ethical Approval 
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APPENDIX XII 
 
Base-line Data for Twenty-Four Subjects who did not 
complete the Study 
 
 261
 
The following table illustrates the baseline data for twenty-four subjects who did 
not complete the two-year study. Subjects withdrew of their own free will. 
 
There were no significant differences at baseline between subjects who withdrew 
from the study and those who continued with the study for lung function, PEF, 
morbidity or psychological status. 
 
 
Variable N=24 % Mean (SD) 
Age   40(13) 
Gender (male) 7 29  
Inner city subjects 19 79  
Still smoking 6 25  
Pack years   2.7(5.8) 
Using agonist 24 100  
Using inhaled steroids 19 79  
Using oral steroids 1 4  
BTS Guidelines Treatment Step (3-5) 6 25  
PEF   338L/min(110) 
Predicted PEF   449L/min(88) 
FEV1   2.15L(0.90) 
Predicted FEV1   2.97L(0.58) 
FVC   2.93L(0.93) 
Predicted FVC   3.74L(0.65) 
FEV1/FVC  72  
AQLQ score   4.80(1.27) 
AQLQ Symptom score   4.80(1.50) 
Q score   2.50(2.53) 
HAD Anxiety   9.66(4.49) 
HAD Depression   5.95(4.93) 
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APPENDIX XIII 
 
Data for Seventy-Nine Subjects Assessed at Baseline, 
Twelve and Twenty-four Months 
 
263
 
 
 
The following table illustrates data for seventy-nine subjects who participated in the study at baseline, twelve and twenty-four month. 
There were no significant differences between subjects who attend attended on all three occasions and those who did not. 
 
Baseline 12 months 24 months Variable N=79 % Mean(SD) N=79 % Mean(SD) N=79 % Mean(SD) 
Age (years)   43(11)       
Gender (male) 30 38        
Inner city residents 45 57        
Current smokers 19 24        
Pack Years   2.75(5.79)       
Using agonist 73 92  69 87  68 68  
Using Inhaled Steroids 65 82  68 86  69 87  
Using Oral Steroids 6 8  10 13  7 9  
BTS Guidelines Treatment 
Step (3-5) 28 35  39 49  41 52  
Inhaled Steroids increased     14 18  8 10  
PEF   352L/min(135)   331L/min(137)   344L/min(128) 
Predicted PEF   463L/min(89)       
FEV1   2.20L(0.91)   2.18L(0.90)   2.35L(0.91) 
Predicted FEV1   2.98L(0.62)       
FVC   2.82L(0.98)       
Predicted FVC   3.79L(0.73)       
FEV1/FVC  77        
AQLQ score   4.65(1.24)   4.35(1.39)   4.71(1.31) 
AQLQ Symptom score   4.54(1.51)   4.51(1.45)   4.67(1.60) 
Q score   3.0(2.44)   2.94(2.54)   2.82(2.62) 
HAD Anxiety   7.73(4.27)   7.82(4.56)   7.51(4.85) 
HAD Depression   5.12(3.61)   4.74(3.60)   5.20(3.97) 
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Published Papers and Abstracts from Conference 
Presentations Associated with this Thesis 
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http://thorax.bmj.com/cgi/content/abstract/56/4/266 
 
 
 
http://www3.interscience.wiley.com/cgi-bin/fulltext/119423635/PDFSTART 
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LD Rimington, D Furphy, R Nissen, A Patel, C White and MG Pearson (2000).  
 
CHANGES IN DEPRESSION OVER TWO YEARS – A FOLLOW-UP STUDY 
OF ASTHMA PATIENTS IN PRIMARY CARE. Am J Crit Care Med 161; 3: 
A315. 
 
 
 
 
Published asthma guidelines focus on the control and reduction of symptoms, 
they do not take into account psychological status. We studied 71 subjects (mean 
(SD)) age 42 (12) range 16-60, 27 males, FEV1 2.2L (0.95), FEV1 predicted 3.0L 
(0.62) and PEF 352L/min (140) over two years from four health care practices, 
two inner city,  two suburban. We recorded Juniper AQLQ and Q Score 
(Rimington et al, 1997), HAD Scale, UK Asthma Guidelines treatment step and 
inhaled medication at outset and at 24 months. 30% of patients recorded HAD 
depression scores of 8 denoting depression (10.14(2.2) v 3.0(2.0)). 90% of 
these subjects were from inner city GP practices. Depressed patients were of 
similar asthma severity (proportion of treatment step 3-5, 38% v 20%, mean 
FEV1 2.01L (0.97)  v 2.32L (0.94) and PEF 313L/min (149) v 369L/min 
(134), inhaled steroids 91% v 80%). Over the two year period depressed 
patients visited their GP more often (on two occasions or more 24% v 18%) with 
no significant reduction in morbidity as measured by AQLQ and Q score. 
Anxiety and depression were slightly reduced but again not significantly so, 
12.91 (3.6) v 10.95 (4.5) and 10.14 (2.2) v 8.6 (3.4) respectively. We have 
previously reported the relationship between morbidity and psychological status 
(Rimington et al, 1998) this follow-up data continues to support the rationale that 
using morbidity to monitor asthma may be misleading, psychological factors may 
influence reporting. 
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LD Rimington, D Furphy, R Nissen, A Patel, C White and MG Pearson (2000).  
 
TWO YEAR FOLLOW-UP STUDY OF ASTHMA MANAGEMENT IN 
PRIMARY HEALTH CARE. Am J Crit Care Med 161; 3: A319. 
 
 
 
 
Asthma remains a high profile disease with pressure to improve outcomes for 
patients (Neville and Higgins, 1999). We studied 71 subjects (mean (SD)) age 42 
(12) range 16-60, 27 males, FEV1 2.2L (0.95), FEV1 predicted 3.0L (0.62) and 
PEF 352L/min (140) over two years from four health care practices. We recorded 
Juniper AQLQ and Q Score (Rimington et al, 1997), HAD Scale, UK Asthma 
Guidelines treatment step and inhaled medication at outset and at 24 months. No 
specific advice was given to clinics regarding asthma management over the study 
period. 82% of subjects were taking inhaled steroids at 2 years, 14% had inhaled 
steroids increased while 63% had no change in inhaled steroids at the end of the 
study period. Subjects taking inhaled steroids v reduced or no steroids (82% v 
18%) had no significant difference in morbidity as measured by AQLQ 4.3(1.6) v 
4.8(1.1) or Q score 3.1(2.7) v 2.5(1.8) at two years. Subjects with increased 
inhaled steroids were slightly more depressed, HAD anxiety 8.4(4.7) v 7.0(4.7) 
and HAD depression 5.7(3.8) v 3.5(3.5) (p<0.01). 53% of subjects taking inhaled 
steroids were in BTS treatment step 3-5. Despite the increase in inhaled steroids, 
these subjects (14%) had no significant reduction in morbidity over 2 years, 
AQLQ 4.0(2.0) v 4.1(1.5), and Q Score 3.6(2.9) v 4.1 (2.9). In subjects with 
unchanged inhaled medication (68%), morbidity also remained unchanged. 
AQLQ 4.4(1.4) v 4.3(1.7), Q Score 3.1(2.5) v 2.9(2.7). Anxiety and depression 
did not change significantly in either group. Despite the publication of asthma 
guidelines, this observation of clinical practice reveals levels of persistent 
morbidity with no improvement  in outcome for patients. 
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LD Rimington, A Fisk, S Hannah, G Midgeley, S Whitehall, I Ryland and MG 
Pearson (1999).  
 
DOES CHANGE IN MEDICATION OVER 12 MONTHS AFFECT ANXIETY 
AND DEPRESSION IN ASTHMA PATIENTS IN PRIMARY CARE ERJ 14; 
Suppl 30: 106. 
 
 
 
 
Emotional disorders are commonplace in patients exhibiting longstanding 
disability and depression can be associated with increasing morbidity. A random 
sample of 75 patients were studied (mean (SD)) age 42 (12) range 16-60 years, 
26 male, FEV1 2.14L (0.97), FEV1 70% predicted. Subjects were assessed using 
Juniper AQLQ and Q Score (Rimington et al, ERJ 1997 ; 10:194) HAD Scale 
and UK Asthma Guidelines Treatment Step. Measurements were recorded before 
and after 12 months of routine care and no advice was given to the treating 
physician. Over 12 months 26 subjects had their inhaled medication increased (11 
no increase in inhaled steroids) 49 did not. There were no other differences 
between the two groups. Change over 12 months in 49 subjects were Juniper 
Symptom score 4.4 (1.5) v 4.4 (1.4), Q Score 3.04 (2.6) v 3.3 (2.4), HAD Anxiety 
8.9 (4.4) v 8.4 (4.4), HAD Depression5.2 (4.0) v 4.7 (3.6). In the 26 subjects, 
Juniper Symptom score 4.2 (1.45) v 4.2 (1.5), Q Score 3.4 (2.4) v 3.1 (2.5), HAD 
Anxiety 7.9 (4.7) v 7.6 (4.5), HAD Depression 6.2 (4.1) v 4.9 (2.9). Depression 
decreased (p=0.03) amongst those who’s treatment increased. Over 12 months 
treatment symptoms remained unchanged in both groups. Depressed patients 
received more treatment without affecting asthma symptoms. 
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LD Rimington A Fisk S Hannah G Midgeley S Whitehall I Ryland and MG 
Pearson (1999). 
 
AN AUDIT OF ASTHMA MANAGEMENT IN PRIMARY CARE. ERJ 14; 
Suppl 30: 106. 
 
 
 
 
The impact of asthma specific clinics in Primary Health care is said to reduce 
morbidity. We assessed a random sample of patients from 4 GP Practices, (2 
inner city, 2 suburban) claiming to adhere to BTS Treatment Guidelines and 
providing Nurse led asthma clinics although only 1 practice ran clinics on a 
regularly monthly basis. 75 patient attendance and prescribing records were 
examined over a 12-month period. Mean (SD) data, age 42 (12), range 16-60 
years, 26 male FEV1 2.4L (0.97), FEV1 71% predicted, 81% were prescribed 
regular inhaled corticsteroids. We recorded Juniper AQLQ, Q Score (Rimington 
et al, ERJ 1997; 10:194) and BTS Treatment Step at outset and 12 months. 73% 
of patients did not attend asthma specific clinics over the 12-month period, 12% 
attended on 2 or more occasions. Non attenders had no change in symptoms over 
12 months, Juniper symptoms scores 4.4 (1.5) v 4.5 (1.3), Q Score 2.9 (2.6) v 3.0 
(2.4) despite 32% of subjects having inhaled medication increased. Clinic 
attenders had increased symptom scores (p=0.042) but no change over 12 
months, Juniper symptom scores 3.4 (1.5) v 3.3 (1.4), Q Score 4.7 (1.7) v 5.3 
(2.0) although 56% had their treatment increased. A minority of asthma patients 
with higher symptom scores used the formal asthma clinics though neither group 
had fewer symptoms at 12 months. 
 
 275
LDRimington A Fisk S Hannah G Midgeley D McKearney I Ryland and MG 
Pearson (1999) 
 
THE RELATIONSHIP OF ANXIETY, DEPRESSION AND ASTHMA 
SYMPTOMS IN DIFFERING SOCIO ECONOMIC PRIMARY HEALTH 
CARE SETTINGS. Am J Crit Care Med 159; 3: A654. 
 
 
 
 
The relationship between social deprivation and increased asthma morbidity is 
well-documented (Watson and Lewis, 1995). We studied 114 subjects (mean 
(SD)) age 42 (12) years (range 16-60), 42 male, FEV1 2.23L (0.89); FEV1 
predicted 3.00L (0.62), PEF 353L/min. (126) from 4 primary health care 
practices. Jarman scores (Jarman, 1983) were used as an index of community 
wide social deprivation. The 2 inner city practices had worse Jarman sores (more 
deprived) than the two suburban practices (+18.7 and +13.45 versus -19.58 and -
18.27 respectively). Subjects were assessed using Juniper AQLQ and Q Score 
(Rimington et al, 1997) the HAD Scale and BTS Asthma Guidelines Treatment 
Step. Smoking was also recorded. Inner city patients were of similar asthma 
severity (proportion of treatment step 3-5, 26% vs. 29%, mean FEV1 2.2L vs. 
2.3L and PEF 348 vs. 363L/min) as suburban patients but were more depressed 
(5.95 vs. 3.72 p<0.05) significantly more anxious (9.5vs 6.17, p<0.001) and were 
more likely to be current smokers (36% vs. 10% p<0.001). Within the whole 
group anxiety correlated strongly with lower AQLQ, higher Q Score and with 
increased treatment level (all p<0.01) and was the greatest difference between 
asthma patients in different socio economic areas. Some of the increased asthma 
morbidity in deprived areas may be manifestation of anxiety rather than of 
difference in disease. 
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LD Rimington A Fisk S Hannah G Midgeley I Ryland and MG Pearson (1999).  
 
CHANGES IN TREATMENT AND MORBIDITY OF ASTHMA OVER ONE 
YEAR IN PRIMARY HEALTH CARE CLINICS Am J Crit Care Med 159; 3: 
A759.  
 
 
 
 
Primary health care clinics should expect to decrease asthma symptoms over time 
(Jones et al 1992). We studied 75 subjects (mean (SD)) age 42(12) range 16-60 
years, 26 male, FEV1 2.14L (0.97) PEF 338L/min (141) 81% were on regular 
inhaled corticsteroids. We recorded the Juniper AQLQ, Q Score (Rimington et al, 
1997) the HAD Scale and UK Asthma Guidelines treatment step at out set and at 
12 months. No specific advice was given to clinics regarding asthma 
management. Initial cross sectional data showed that Juniper AQLQ and Q Score 
correlated with worsening levels of FEV1, PEF, increased treatment step (all 
p<0.01) and increased HAD scores for depression (p<0.01) (Rimington et al, 
1998). 34% of patients had their treatment modified during the year. These 
patients had similar lung function, levels of treatment and age as those who’s 
treatment was unchanged. There was a trend to a lower initial symptom level 
(AQLQ 17.2 Vs 18.5, Q Score 3.4 Vs 3.0) and an improvement over 12 months 
(AQLQ 17.7, Q Score 3.15) against no change in those with unaltered therapy 
(AQLQ 18.3, Q score 3.36) but none of these trends were statistically significant. 
Initial and 12 month AQLQ and Q scores remained closely correlated (both p< 
0.001). The sub group with the highest Q Scores4, 75%) were in treatment step 
3-5 continued to be symptomatic. A similar pattern was shown in those subjects 
with fewer symptoms.  Observation of routine primary care practice shows that 
decisions to alter treatment are independent of the level of morbidity and resulted 
in no significant improvements. We conclude that altering medication may give 
an impression of treating asthma, but without short-term reassessment the same 
levels of morbidity can persist.    
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LD Rimington L Aronoffsky A Mowatt E Warburton and MG Pearson (1997).  
 
THE RELATIONSHIP BETWEEN ASTHMA SYMPTOMS, ANXIETY AND 
DEPRESSION. Thorax 52; Suppl 6: A47. 
 
 
 
 
The prime aim of asthma management is to reduce symptoms but symptom 
reporting depends on both disease severity and on the threshold for perception of 
symptoms which is linked to psychological state (Janson-Bjerklie, 1993). We 
studied 90 patients, age 43(12), 32 male, FEV1 2.21L(0.94), by selecting every 
8th patient from the asthma register of 4 GP practices. Each subject completed an 
Asthma Quality of Life Questionnaire (AQLQ, Juniper et al, 1993) the Hospital 
Anxiety and Depression scale (Zigmond and Snaith, 1983), spirometry and 
details of current treatment. 73 (81%) were on regular inhaled steroids of which 
19 (21%) were on high dose (steps 3-5 of BTS guidelines). Mean PEF 
347L/min.(137), 74% predicted, was significantly correlated with the AQLQ 
(p<0.001) and negatively correlated with increasing treatment step (p<0.001). 
HAD scores for the depression (p<0.001) but not anxiety correlated with the 
worse functioning in both the symptom domain and overall AQLQ but were not 
related to the level of PEF. Despite the expected univariate relationship between 
increasing symptoms and lower PEF, multiple regression analysis showed that 
symptom levels were most sharply linked to depression scores of the HAD rather 
than the level of treatment or to the level of PEF. These data suggest that using 
reported symptoms as a measure of asthma control may be misleading, because 
non asthma factors may be even more important in individuals. 
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LD Rimington L Aronoffsky A Mowatt E Warburton and MG Pearson (1997).  
 
USE OF A SIMPLE PATIENT FOCUSED ASTHMA MORBIDITY SCORE.  
ERJ 10; Suppl 25: 194. 
 
 
 
 
Established and validated questionnaires have been shown to be useful research 
tools with which to assess  asthma morbidity (Juniper et al, 1993) but they are too 
time consuming for routine clinical practice. We have used 4 questions that a 
doctor would usually ask in each consultation (covering nights waking, reliever 
inhaler use, daytime wheezing and disruption of activities) to produce an 8 point 
score  that requires no extra time from the clinician. We have assessed this short 
questionnaire (Q score) with the Juniper morbidity score (total score and 
symptom score), with levels of PEF and with the UK Asthma Guidelines 
Treatment Step in 81 patients randomly selected  from 3 general practices (mean 
(SD) age 43 (12) 26 male, PEF 345 (138) FEV1 1.2 (0.9) and repeated the 
observations two weeks later in subset of 21 patients. The paired observations 
showed  that both Juniper (r=0.87) and Q score (r=0.79) were repeatable with 
similar variability. The Q score was negatively correlated with the Juniper 
symptom score (r=0.79, p<0.01) and total score (r=0.73, p<0.01) and both Q 
score and Juniper correlated with levels  of resting FEV1 (Q:r=0.44, J:r=0.42) and 
with the severity of asthma as indicated by the treatment step (Q:r=0.47, J:r=-
0.36. all<0.01) although there was considerable scatter for the latter. The Q score 
correlates well with both the established longer questionnaire and also shows 
similar relationships to lung function and to levels of severity . If it also shows 
sensitivity to changes in asthma status over the next year it may provide a 
practical tool with which to estimate asthma morbidity in routine practice. 
 
 
